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1.1 Macromolecular assemblies from proteinaceous materials 
Proteins are essential structural materials in life. The proper 
structures and functions of our skin, bones, and connective tissue largely 
depend on the assembly of proteinaceous materials. Collagen and elastin 
are major components of this structural and connective tissue. Collagen 
is rich in glycine and proline and is formed from a precursor by post-
translational modifications such as hydroxylation, glycosylation and 
cleavage.[1] It forms fibrils consisting of crosslinked triple-helixes. Elastin 
is made from tropoelastin, which coacervates due to the presence of 
hydrophobic regions and is cross-linked into an elastic material.[2] These 
coacervating, hydrophobic regions are rich in valine, glycine, proline and 
alanine while the cross-linked, hydrophilic regions consist mainly of 
lysine residues separated by alanine stretches.[3] Silk is another notable 
structural protein material consisting of mainly sericin and fibroin that 
is produced by e.g. silkworms to provide protection during complete 
metamorphosis.[4] Fibroin is a hydrophobic protein containing repeats of 
alanine, serine and glycine that form antiparallel β sheets giving silk its 
rigid structure and tensile strength.[5] The behavior of these materials – 
macromolecular assembly – can be exploited by identifying, modifying 
and engineering the underlying functional sequences. This allows for 
their assembly properties to be controlled, resulting in various 
macromolecular structures such as rods, fibrils, sheets, hollow and 
dense particles. Their stability, stiffness and surface properties can be 
tuned as well, making them ideal candidates for functional 
supramolecular materials. For example, sheets and gels can give 
structural rigidity and stability during wound healing, while 
nanoparticles can act as macromolecular carriers of a multitude of 
functional cargoes. Here we will focus on the derivatives of elastin, 
elastin-like peptides and their biomedical applications requiring 
macromolecular carriers in the form of nanoparticles. 
1.2 Elastin-like polypeptides 
Elastin-like polypeptides are derived from the hydrophobic 
regions found in natural elastin.[6] Studying its coacervation mechanism, 
Urry et al. discovered that reversible coacervation could also be observed 
in polymers of a small consensus sequence, GVGVP.[7] These polymers 
are soluble below their lower critical solution temperature (LCST), also 
called transition temperature (Tt). Above their transition temperature, the 
structure of elastin-like polypeptides (ELPs) changes from a disordered 
secondary structure to primarily type II β-turns, and to a lesser extent 
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type-I β-turns and β-strands (Figure 1.1).[8–11] The structural change 
exposes the hydrophobic side chains on the surface of the spiral, leading 
to coacervation.  
 
Figure 1.1. Side and front view of the simulated structure of (GVGVP)18 above its 
transition temperature. The structure consists of β-spirals, exposing the hydrophobic 
valine side chains (blue). The proline side chains (yellow) together with glycine (purple) 
are the driving force for the formation of type II β-turns, determining the structure of 
the peptide backbone (green). Reprinted with permission from reference[8]. 
This behavior is thermodynamically driven: at the transition 
temperature, solvation of the protein backbone and side chains becomes 
entropically unfavorable. The conformational change and exposure of 
hydrophobic residues followed by aggregation results in liberated water 
molecules, lowering the total energy of the system. Further increases in 
temperature enhance this effect. Remarkably, while retaining other 
properties, the second residue may be replaced by any proteinogenic 
amino acid[9,12,13], changing only the transition temperature. Efficient 
incorporation of unnatural amino acids as the guest residue was reported 
as well.[14]  
The transition temperature changes linearly with the fractional 
exchange of a given guest residue for another; historically, valine is taken 
as the reference guest residue (Figure 1.2). Based on these data, 
hydrophobicity coefficients were calculated that allow predictions about 
changes in transition temperature upon guest residue exchange in a 
given polymer.[7] The transition temperature of poly(GXGVP) depends 
however not only on the nature of the guest residue X, but also on length 
and concentration of the polymer. With increasing length, the transition 
temperature decreases (Figure 1.3A). A given ELP sequence converges 
onto a sequence-specific transition temperature at infinite length. More 
hydrophobic sequences approach this critical transition temperature 
relatively earlier and show less transition temperature variation for a 
given difference in ELP length than more hydrophilic sequences. 
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Figure 1.2. Transition temperature plotted against the mole fraction of different guest 
residues replacing valine. Circles indicate data points, dotted lines represent linear fits. 
The zero, plus, and minus superscripts stand for the uncharged, positively, and 
negatively charged states of the side chains; Ser(PO-4) indicates phosphorylated serine; 
the "m" superscript on E represents the methyl ester of the glutamic acid residue, HyP 
stands for hydroxyproline, and the other letters are the standard single-letter codes for 
the naturally occurring amino acids. Reprinted with permission from reference[7]. 
This behavior was described by fitting the slope of the transition 
temperature variation, which was defined by dividing a sequence-specific 
parameter k (°C) by the chain length L (number of pentapeptides). The 
change in transition temperature depending on ELP concentration C is 
logarithmic (Figure 1.3B). Combining this information yielded two 
additional parameters; the critical transition temperature Tt,c (°C) which 
is the derived transition temperature of an ELP sequence at infinite 
length, and a critical concentration Cc (µM) at which the transition 
temperature converges to Tt,c independent of length. Once these 
parameters are determined, the transition temperature can be 
approximated according to 
  , 


ln


.   (1) 
This means that for more hydrophobic ELP sequences, length becomes 
less and less a determining factor of the transition temperature. This is 
also the case for the effect of concentration on transition temperature. 
This is important to consider in the design of ELP sequences: different 
sequences and lengths can display the same transition temperatures 
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under different conditions, but more hydrophilic sequences will be much 
more influenced by changing concentration, polymer length and 
assumingly also by conjugation to other proteins.[16,17] 
 
Figure 1.3. Changes in transition temperature depending on ELP sequence, polymer 
length and concentration. In brackets is the overall guest residue composition and 
length given as [AXBYCZ-n], where A, B and C denote the guest residues, X:Y:Z their ratio 
within the ELP block, and n the number of pentapeptide repeats. A) ELP length plotted 
against transition temperatures. All ELP sequences diverge toward a sequence-specific 
transition temperature at infinite polymer length. More hydrophobic sequences 
approach this critical transition temperature relatively earlier and show less transition 
temperature variation for a given difference in ELP length than more hydrophilic 
sequences. B) ELP concentration plotted against transition temperature. The transition 
temperature follows a logarithmic relation to the protein concentration. The more 
hydrophilic a given sequence is, the larger the slope of the change in transition 
temperature. Reprinted with permission from reference[15]. 
Lastly, the presence and concentration of electrolytes affects the 
transition temperature as well, with kosmotropic salts having a larger Tt-
reducing effect in agreement with the Hofmeister series.[18] Unfortunately, 
the parameters for a specific sequence have to be determined first before 
an accurate transition temperature can be calculated. For alanine and 
valine, guest residue-specific parameters were calculated to allow the 
design of ELPs with desired properties de novo.[18] For other guest 
residues, particularly hydrophobic ones, the hydrophobicity scale 
developed by Urry et al. still remains an important reference.[7]  
While the first ELPs made by Urry et al. were made by chemical 
synthesis, with the increasing capabilities of genetic engineering it was 
realized that ELPs may also be produced recombinantly. While cloning 
repetitive DNA sequences can be taxing due to difficulties in oligo 
synthesis, incompatibility with polymerase chain reactions (PCR) and 
plasmid instability, techniques have been developed to deal with these 
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issues such as recursive directional ligation.[19] After expression and lysis, 
ELPs can be purified by inverse-transition cycling (ITC): heating or adding 
salt precipitates ELPs, which may then be collected by centrifugation or 
filtration (step 1). Solubilization by cooling or low-salt buffers allows the 
removal of irreversibly aggregated contaminants (step 2). Repeating steps 
1 and 2 yield purified ELPs. High yields have been reported in shaking 
cultures and in fermentation reactors. For industrial applications, flow 
purifications by microfiltration have been reported as well.[20] The general 
principle of purification is shown in Figure 1.4, which also applies to ELP 
fusion proteins. 
 
Figure 1.4. Elastin-like peptide (-fusion protein) purification by inverse transition cycling. 
A) After cell lysis, the ELP (-fusion protein) is aggregated by the addition of salt and/or 
heating. The resulting coacervate is precipitated by centrifugation and the supernatant 
removed. B) The pellet containing the ELP (-fusion protein) is re-dissolved and insoluble 
contaminants removed by cold centrifugation. This cycle is repeated until C) the protein 
reaches sufficient purity. Adapted with permission from reference[28]. 
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1.3 Fusion proteins with elastin-like polypeptides for purification 
and application 
By using ELPs as a purification tag (Figure 1.4),[21] numerous 
recombinant proteins have been purified from multiple organisms such 
as plants, mammalian and bacterial cells. Generally, ELP fusions show 
better solubility when expressed, preventing the protein of interest to 
become localized in inclusion bodies. Thioredoxin produced in E.coli and 
purified with an ELP tag resulted in better purity and similar yield in 
comparison to using an affinity tag, polyhistidine.[22,23] Additionally, the 
recovery of low concentrations of ELP-fusion protein could be enhanced 
by co-aggregation with ELP added during the purification protocol.[22] 
Many other functional proteins were successfully produced in E.coli, e.g 
levansucrase, catalyzing the synthesis of the fructose homopolymer 
levan[24]; interleukin-1 receptor antagonist, decreasing the inflammatory 
mechanisms of stimulated monocytes[25]; the antimicrobial peptide 
Halocidin18 with a 2.3 fold increase in yield compared to expression 
without an ELP tag[26]; and the stimulatory peptide glucagon-like peptide 
1 (GLP-1) for human insulin release[27]. In mammalian and plant cells, 
mini-glycoprotein 130, which blocks signaling factors involved in the 
development of autoimmune diseases such as Crohn and rheumatoid 
arthritis, was successfully expressed with an ELP tag in tobacco 
plants[29], which is claimed to be 10-50 times cheaper than an E.coli 
expression system[30].  
Anti-HIV-1 antibodies 2F5 and 2G23 were purified with ELP after 
expression in Chinese hamster ovary cells and tobacco plants[31,32]. 
Mycobacterial antigens against tuberculosis Ag85B and ESAT-6 showed 
immune activation after recombinant purification with ELP tags in 
tobacco plants.[33] Similarly, two antigens for the H5N1 flu were made 
without disturbing their biological activity.[34] A (self-) cleavage tag, also 
called intein, may be introduced to obtain the native protein of interest.[35–
37] After purification, the intein can be cleaved to obtain the pure protein 
after separation from the ELP precipitate (Figure 1.5).  
In general, ELPs seem to have favorable effects on both yields and 
purity of recombinant proteins by protecting the protein of interest from 
proteolytic degradation.[38] In the case of toxins, the formation of ELP 
coacervates within cells may limit the toxicity during expression. Tagging 
proteins with ELPs can also be beneficial for their in vivo properties[39]; 
e.g. GLP-1 has a longer circulation time if its hydrodynamic radius is 
enhanced by adding a disordered ELP structure, and a reservoir of GLP-
1-ELP may be injected subcutaneously that forms a gel upon injection.[27] 
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There are numerous examples of gels and other tissue engineering 
applications that (partly) consist of ELPs (see e.g. these reviews[40–44]) that 
show great potential for biomedical engineering. The focus of this 
introduction will be on the creation of ELP nanoparticles for biomedical 
applications. 
 
 
Figure 1.5. Protein purification by using a self-cleavage tag. A) The protein of interest 
(POI) is fused to an intein and ELP block. B) The POI is then purified by using the 
coacervation behavior of the ELP. C) After intein cleavage, which can be e.g. induced by 
changing the pH of the solution, the purified protein simply needs to be separated from 
the ELP precipitate. Adapted with permission from reference[37]. 
1.4 Creation of ELP nanoparticles for biomedical applications 
By creating ELP diblock copolymers with different guest residues 
in each respective block, supramolecular structures may be created. The 
first example was shown by Lee et al.[45]; by genetically fusing two ELP 
blocks with different transition temperatures, a micellar structure was 
formed in-between both transition temperatures (Figure 1.6). When the 
transition temperature of one block is reached, its coacervation is 
restricted by the presence of the other block, which is still soluble. Most 
common are micellar structures, either as ELP diblocks[45–50] or ELP 
conjugates[51–53], but vesicles[48,54] and rod-like structures[55,56] have been 
created (partly) based on ELPs as well. These nanoparticles are excellent 
carriers for small molecules and macromolecular agents for drug delivery 
and diagnostic applications, and have been investigated in numerous in 
vitro studies (see reviews[57–60]).  
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Figure 1.6. Schematic representation of a micelle formed by an ELP diblock copolymer. 
The respective blocks have different transition temperatures due to their guest residues. 
In the temperature regime between the two transition temperatures, the ELP block with 
a lower Tt is coacervating. Its assembly is restricted by the ELP block with a high Tt, which 
stays soluble, to a micellar structure. This assembly can be dissolved again by cooling 
the micelle. 
In order to judge the full biomedical potential of ELP 
nanoparticles, it is important to gather data about their in vivo behavior 
as well. Here we will give an overview of the supramolecular assemblies 
that solely consist of ELPs and have been investigated in vivo; these are 
mainly micellar assemblies. ELPs are typically noted as [AXBYCZ-n], where 
A, B and C denote the guest residues, X:Y:Z their ratio within the ELP 
block, and n the number of pentapeptide repeats. For example, [A3G2-
60]-[I-60] denotes an ELP diblock that consists of one block with 60 
pentapeptide  repeats containing alanine and glycine in a ratio of 3 to 2 
as guest residues, and one part with 60 pentapeptide repeats containing 
only isoleucine as a guest residue, resulting in a protein with 600 amino 
acids total. Note that this notation does not define the exact position of 
each guest residue within a sequence when multiple guest residues are 
used. This notation will be adapted where necessary for structures which 
cannot be fully described by it.  
 
1.4.1 ELPs in cancer research and therapy 
ELPs have been used to target and treat different kinds of cancers. 
MacKay et al. conjugated doxorubicin via a hydrazone linker to the 
Chapter 1 
22 
cysteine groups of the ELP [VG7A8-160]-(GGC)8 to form ELP-Dox 
micelles.[61] The resulting particles had a CMC below 3 µM and radii of 
19.3 and 21.1 nm as determined by dynamic light scattering (DLS) and 
freeze-fracture transmission electron microscopy (TEM), respectively. In 
vivo, plasma retention and total drug exposure (area under the curve; 
AUC) was significantly improved when compared to free doxorubicin (716 
+ 139 µMh vs 4.7 µMh). In mice bearing C28 tumors, ELP-Dox micelles 
significantly reduced tumor size and extended the mean survival from 27 
days with free Dox to the survival of 8 out of 9 mice for up to 66 days, 
after which the study was stopped. 
Simnick et al.[62] fused the NGR tripeptide to [V1G7A8-64]-[V-90] to 
target the aminopeptidase-N receptor overexpressed on endothelial cells 
in certain cancerous tissues[63]. In comparison with unmodified control 
particles, NGR-ELP particles showed accumulation in endothelial and 
perivascular regions of human squamous cell carcinoma derived tumors 
in female BALB/c nude mice. 45 minutes after injection, around 80 % of 
NGR-ELP was retained in the vascular region of tumors, significantly 
more than in normal tissue. There also was a significant accumulation in 
extravascular regions when compared to normal tissues. However, these 
results did not significantly differ from ELP particles not displaying NGR. 
Cancerous tissue often shows a decreased extracellular pH due to 
aerobic glycolysis (Warburg effect)[64], ranging from 6.2 to 6.9. Callahan 
et al. created a pH-sensitive ELP diblock, [VG7A8-80]-[VH4-100], which 
forms a nanoparticle at physiological conditions with the addition of 
physiological concentrations of ZnCl2[65] and disassembles into 
monomers upon reaching a pH of 6.4.[49] This pH-sensitivity stems from 
using histidine, with its pKa of around 6, as a guest residue; it becomes 
protonated in slightly acidic conditions, increasing the transition 
temperature of the ELP.[7] The resulting particle showed a CMC of 8.9 + 
3 µM (measured by pyrene fluorescence), a hydrodynamic radius of 29.5 
nm and was on average composed of 73 ELP diblocks (measured by static 
light scattering). Injection of particles into nude mice bearing human 
colorectal adenocarcinoma-derived tumors showed a more homogenous 
distribution within tumor sections 4 h after injection than pH insensitive 
control ELP particles, but faster clearance from the tumor site 24 h and 
48 h after injection. In this study, the system was not tested in 
combination with a therapeutic agent. 
Sarangthem et al. used the construct (AP1-[V-12])6-(KLAK)4 to 
target tumor models in mice.[66] AP1 is a 7 amino acid peptide (RKRLDRN) 
that binds to the interleukin-4 (IL-4) receptor, which is implicated in the 
drug resistance of various cancers by amplifying the expression of anti-
Elastin-like polypeptide nanoparticles for biomedical applications 
 
23 
apoptotic proteins. The same group had previously shown that (AP1-[V-
12])6 accumulates in human breast cancer MDA-MB-231 xenografts in 
mice with increased affinity and uptake into IL-4 receptor expressing 
cells. KLAK-repeats destabilize eukaryotic membranes and induce 
apoptosis. The combined construct (AP1-[V-12])6-(KLAK)4 showed a 
micellar structure at physiological conditions with a hydrodynamic 
radius between 300 + 61 nm (measured by DLS) and ~ 60 nm (measured 
by TEM). Particles induced an 80-85 % decrease in tumor growth in MDA-
MB-231 xenografts in BALB/c female nude mice and in murine B16F10 
tumors of C57BL/6 black female mice after intraperitoneal injection. All 
parameters tested to ensure liver, heart and kidney function as well as 
hematological markers indicated no systemic toxicity after two weeks of 
daily injection of 150 mg kg-1. The material had a terminal half-life of 14.4 
+ 1.2 h and plasma clearance of 4.5 + 0.7 10-3 L hr-1 kg-1. 
Schaal et al. created stable depots for brachytherapy of prostate 
and pancreatic tumor models by inducing micelle-to-gel transition of [V-
120]-(GY)7, followed by 131I induced  β-irradiation mediated crosslinking 
(Figure 1.7).[67]  
 
  
Figure 1.7. Brachytherapy design using ELPs modified with 131I by iodogen oxidation[68]. 
After micelle formation, nanoparticles are injected into the tumor site, where they form 
both thermally and crosslinked-stabilized hydrogels. Adapted with permission from 
reference[67]. 
Radiolabeled ELPs formed micellar structures around ambient 
temperature with a hydrodynamic radius of 41.2 nm and an average 
radius of gyration of 50.3 nm, measured by DLS and SLS, respectively. 
These micelles formed crosslinked gels at 37 °C that retained 131I with 
very little off-target accumulation. In a mouse model, prostate tumor 
regression was larger than 95 % with a median survival rate five-fold 
higher than with free 131I, 60 versus 12 days, respectively. 
Aluri et al. fused a single-chain variable antibody fragment (scFV), 
derived from anti CD-20 rituximab, to the ELP [A-192].[56] The resulting 
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conjugate formed particles with hydrodynamic radii of 85.7 nm and 24.1 
nm as determined by DLS and cryoTEM, respectively. According to size-
exclusion chromatography coupled to multi-angle light scattering (SEC-
MALS), the particles possessed an average molecular weight of 25.5 MDa, 
resulting in an aggregation number of about 250 monomers per particle. 
However, after renaturation, a major population was observed with rod-
like morphologies (length 56.2 nm and width 17.9 nm). The molecular 
weight of these dropped significantly to an average of 8.4 MDa and an 
aggregation number of around 84. In a Raji xenograft mouse model, the 
scFV-ELP particles significantly reduced tumor growth when compared 
to Rituximab administered alone. 
Zhao et al. [69] created a fusion of the ELP di-block (GAGVPG)70-
(GVLPGVP)56-(GC)4 and scFV of the antibody αPD-1, which suppresses 
the programmed cell death protein 1 (PD-1). This protein prevents both 
desirable immune reaction against various types of cancers as well as 
autoimmune reactions. The resulting scFv-ELP formed cross-linked 
micelles with a radius of 21.5 nm as determined by DLS. In vitro, the 
resulting particles showed an avidity effect towards binding PD-1 positive 
EL4 cells when compared to free scFv or scFv-ELP in a monomeric state. 
This effect was also seen in a competitive binding assay. In vivo, no 
significant difference in PD-1 inhibition could be seen in monobese 
diabetic female NOD/ShiLtJ mice between the scFv-ELP nanoparticle 
and its non-crosslinked counterpart.  
The same group used the sequence (GAGVPG)70(GGGGGGGGC)8 
to deliver salinomycin and paclitaxel to orthotopic breast cancer.[70,71] 
Salinomycin was modified with 4-(aminomethyl)benzaldehyde and 4-(4-
N-maleimidophenyl)butyric acid hydrazide to obtain a maleimide-
functionalized drug that could be conjugated to the polymer but would 
be released after particle uptake due to acidification and hydrolysis of the 
hydrazone bond. Paclitaxel was non-covalently encapsulated together 
with α-tocopherol. The resulting particles had hydrodynamic radii of 25.6 
and 42.6 nm at 25 µm in phosphate-buffer saline (PBS) without and with 
paclitaxel, respectively. Tumor growth, metastasis and survival were 
monitored in Balb/c mice bearing 4T1 metastatic breast tumors. 
Salinomycin loaded particles decreased tumor growth and increased 
survival when compared to salinomycin alone. The combination of 
paclitaxel and salinomycin loaded particles further decreased tumor 
growth and increased metastasis-free survival and overall survival 
significantly than either particle alone. 
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1.4.2 ELPs in wound healing 
Koria et al. developed nanoparticles by fusing the keratinocyte 
growth factor (KGF) to the ELP [V-50].[72] The formed nanoparticles had 
radii of about 250 nm and 255 nm, as determined by TEM and DLS. In 
vitro, proliferation of keratinocytes was enhanced, albeit with a lower 
downstream phosphorylation of ERK1 and ERK2 when compared to free 
KGF. Proliferation of fibroblasts was increased for both free KGF and 
KGF-ELP particles, 4.9-fold and 1.6-fold compared to negative controls, 
respectively. In vivo, wounds of diabetic B6.BKS(D)-Leprdb/J mice showed 
increased granulation and reepithelization when treated with KGF-ELP 
nanoparticles embedded in fibrin gels. Although granulation was even 
higher for either free ELP or KGF and ELP given simultaneously, the 
reepithelization was highest for KGF-ELP and the granulation to 
reepithelization ratio was most favorable for KGF-ELP. 
In a follow-up study, Yeboah et al. fused stromal cell-derived 
growth factor-1 (SDF1) to the same ELP (Figure 1.8).[73] They obtained 
nanoparticle sizes with radii of 300 and 280 nm as measured by TEM 
and DLS, respectively. Binding of the fusion protein to the SDF1 receptor, 
CXCR4, was comparable with free SDF1 with dissociation constants of 
1.14 nM and 0.3 nM, respectively, as measured by surface plasmon 
resonance (SPR). Intracellular calcium release of SDF1-ELP 
nanoparticles in CXCR4-positive HL60 cells was lower at low 
concentrations when compared to free SDF1, but significantly higher at 
therapeutic relevant doses. In vivo, wound closure of diabetic mice was 
significantly accelerated when treated with SDF1-ELP particles 
embedded in fibrin gels, with wounds being completely closed after 28 
days compared to 42 days when treated with free SDF. Additionally, a 
thicker epidermis and dermis was observed after 42 days in the case of 
SDF1-ELP treated wounds. 
 
1.4.3 ELPs in vaccination 
García-Arévalo et al. fused a 20 amino acid antigen from M. 
tuberculosis to [E-50]-[I-60].[74] The resulting particles had a zeta potential 
-12.1 mV in PBS, and radii of 26.7, 27.7 and 33.2 nm, measured by static 
light scattering (SLS), cryo-TEM and atomic force microscopy (AFM), 
respectively. They had an average mass of 13.6 MDa, resulting in an 
aggregation number of 277. Curiously, the ρ ratio (radius of gyration 
divided by hydrodynamic radius) was 0.93, indicating a vesicular 
structure rather than a micellar one.[75,76] After immunization of 
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BALB/cByJ female mice with antigen-ELP, an initial immune response 
was observed, characterized by increased levels of IL-1β, IFN-γ and IL-5. 
Although isotype switching from IgM to IgG specific for the antigen-ELP 
fusion protein was observed, this strategy did not lead to IgGs specific to 
the antigen alone.  
 
Figure 1.8. Comparison of stromal cell-derived growth factor-1 (SDF1)-ELP nanoparticles 
with the free SDF1 protein for its wound healing capabilities. Wound healing was 
significantly accelerated when using ELP nanoparticles. Adapted with permission from 
reference[73]. 
Cho et al. used elastin-like peptide micelles as a carrier material 
for stimulating the response of cytotoxic T lymphocytes (CTLs) to an eight 
amino peptide epitope (SIINFEKL) derived from ovalbumin.[77] The 
polymeric di-block did not correspond to the canonical ELP sequence. 
Sequences were chosen by comparing mouse tropoelastin and human 
elastin and selecting regions resembling hydrophobic and hydrophilic 
ELP motifs, GVLPGVG and GAGVPG, respectively. These sequences were 
termed immune-tolerant elastin-like polypeptides (iTEPs) due to the 
hypothesis that they would be less immunogenic due to their natural 
occurrence. The resulting construct had the sequence 
G(GAGVPG)70G(GVLPGVG)28G(ESIINFEKLT)2GG and formed particles 
with hydrodynamic radii of 40.6 nm and 36.0 nm in PBS, depending on 
concentration. After immunization of C57BL/6 mice, these particles 
induced increased secretion of IFN-γ from splenocytes in response to the 
ovalbumin epitope, suggesting an increase in CTL activation. The 
stimulation was higher than with ovalbumin or the epitope alone. 
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1.4.4 ELPs in eye-related diseases (including eye cancer) 
Shah et al. developed rapamycin retaining nanoparticles by fusing the 
protein FKBP12, which binds rapamycin, to the ELP diblock [S-48]-[I-
48].[78] The resulting particles had hydrodynamic radii of about 24 nm as 
determined by DLS. In male NOD mice, an animal model for Sjoegren’s 
syndrome, the resulting particles positively influenced the 
pharmacokinetic parameters of rapamycin when compared to monomeric 
rapamycin-FKBP12-[S-48] or free drug alone (Figure 1.9).  
  
Figure 1.9. Immunomodulation by using ELP nanoparticles. The active agent, rapamycin, 
was non-covalently incorporated into micelles by two-phase solvent evaporation. 
Additionally, a rapamycin-binding domain, FKBP, was displayed on the surface of the 
particles to slow rapamycin release. Encapsulation reduced the nephrotoxicity and 
inflammation/necrosis due to tail vain injection and decreased the auto-immune 
symptoms of Sjoegren’s syndrome. Adapted with permission from reference[78]. 
Plasma concentration of rapamycin declined according to a two-phase 
decay model with an initial half-life time of 0.36 + 0.1 h-1 and terminal 
half-life of 8.8 + 2.6 h-1 when administered in the nanoparticle 
formulation, compared to a single-phase decay with terminal half-lives of 
5.1 + 0.4 h-1 and 5.6 + 0.8 h-1 for free drug and drug bound by the 
monomeric ELP fusion protein.  
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Both free drug and rapamycin-containing micelles decreased 
lymphocytic infiltration of the lacrimal glands (LGs) significantly when 
compared to controls, albeit with no significant difference between the 
two. Both altered the RNA expression profiles of cytokine and chemokine 
genes as well as mTOR-related genes. Notably, the rapamycin-containing 
nanoparticles reduced both the gene expression and activity of a 
biomarker, CATS, associated with dacryoadenitis in the LGs of NOD mice. 
The particles also showed reduced nephrotoxicity and 
inflammation/necrosis around the injection site. Of note, and showing 
the synergy of studying one nanoparticle system for multiple diseases, 
Shi et al.[79] used the same particles on MDA-MB-468 tumors grown in 
the fat pads of female nude mice. Tumor volume stagnated over the 
course of 60 days, while treatment with rapamycin alone had to be 
abandoned due to severe toxicity of the free drug. 
Hsueh et al. used ELP [S-48]-[I-48] fused to the terminal domain 
of the fiber capsid protein of adenovirus serotype 5.[80] This protein 
fragment with a molecular size of ~20 kDa is known to target the 
coxsackievirus and adenovirus receptor,[81] present at high levels on the 
basolateral side of cells composing the lacrimal glands.[82] The resulting 
particle had a zeta potential of – 7.9 mV and radii of 16.0 and 21.6 nm, 
measured by TEM and DLS, respectively. After intra-lacrimal injection in 
male BALB/c mice, particles showed basolateral to apical transcytosis by 
acinar epithelial cells to the lumen of laminar glands in vivo. It was 
proposed to use these particles as a delivery system for therapeutics to 
the ocular surface from within the body. 
In summary, elastin-like peptides are excellent tools to create 
nanometer-sized assemblies for biomedical applications. Their 
biocompatibility and ease of modification, either by genetic fusions or 
chemical modifications, makes them excellent materials for 
macromolecular carriers.  
 
1.5 Aim of this thesis 
The aim of this thesis is to expand the repertoire, complexity and 
understanding of ELP-based nanoparticles for biomedical applications. 
In Chapter 2, we created mixed micelles displaying controlled surface 
densities of a cell-penetrating peptide, octa-arginine (R8). We investigated 
uptake mechanisms and kinetics in mammalian cells and showed that 
uptake could be controlled by altering the density of R8 on the particles’ 
surface. Using 3D cultures of glioblastoma cells, we showed that 
nanoparticle penetration can be described by a binding-site barrier 
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model. Penetration depth could be modulated by altering the composition 
of the particles. 
In Chapter 3, we used the dual function of ELPs as a purification 
tag and structural unit of self-assembly to create micelles that display 
single-domain antibodies. These nanoparticles target tumor cells that 
express the epidermal growth factor receptor (EGFR). In combination with 
photodynamic therapy, we showed that ELP micelles showed selective 
toxicity towards EGFR expressing cells in in vitro co-cultures. 
In order to treat mitochondrial and other neurodegenerative 
diseases, it is important to deliver small molecules effectively across the 
blood-brain barrier by transcytosis of a suitable carrier. In Chapter 4, we 
created ELP nanoparticles that carried antioxidative compounds and 
showed that they can rescue patient cells from oxidative stress. By 
displaying a ganglioside binding peptide, G23, we showed that ELP 
micelles can cross the blood-brain barrier in vitro and we investigated 
their in vivo properties. 
Going to more complex assemblies, we describe in Chapter 5 
mono and diblock ELPs that show pathway-dependent co-assembly. We 
demonstrate that this property is reversible and solely depends on the 
assembly pathway taken. Particle size could be controlled within a 5-fold 
dynamic range. Exploiting this newly found behavior, we encapsulated 
macromolecular cargo in the form of fluorescent proteins into co-
assembled particles with high efficiency. 
In Chapter 6, the obtained results are put into the broader 
perspective of using macromolecular assemblies for biomedical 
applications, with the focus on future developments of ELP-based 
nanoparticles and delivery systems. 
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2.1 Introduction 
Nanoparticles as drug carriers are increasingly being used in 
targeted drug delivery for achieving higher drug doses at the site of action 
and for increasing the bioavailability of drugs with poor water solubility. 
At this point, liposomes are still the most widely used drug carriers.[1,2] 
However, liposomes are expensive to manufacture and have limited 
stability. Alternatively, nanoparticles can be made from polymers;[2–4] 
polymeric systems offer better control over size, surface charge, topology 
and responsiveness to external stimuli.[5,6] For biomedical applications, 
the used materials should be biocompatible with low immunogenic 
responses and low toxic degradation products. As a consequence, a major 
focus has been on polyester-based polymers such as the polylactic acid 
co-glycolides (PLGAs) or polycaprolactones.[7] Amino acid-based polymers 
or polypeptides combine complete sequential control with bio-
compatibility. Using natural and unnatural amino acids, a wide range of 
nanoparticles can be created that have a programmable size, shape, 
surface structure and targeting moieties.[8,9]  
One of the challenges of nanoparticles in medical applications is 
their modification to facilitate cell-uptake and tissue penetration. For the 
eradication of cancerous, solid tissue it is crucial to ensure sufficient 
particle uptake as well as penetration.[10] A high-affinity ligand may be 
confined to the periphery without the ability to penetrate further until a 
certain ligand concentration is reached. This is known as the binding-
site barrier, often encountered when using e.g. antibodies to target solid 
tumors.[11,12] Nanoparticles functionalized with targeting ligands that 
have intermediate affinities may be optimal for both cell uptake and 
tissue penetration. Therefore, control over surface density is critical to 
study the relation between ligand display and penetration depth. Here we 
use elastin-like peptides as a biopolymer for macromolecular assembly, 
combined with cell-penetrating peptides for cell binding and and uptake. 
 
2.1.1 Elastin-like polypeptide based nanoparticles 
Elastin-like polypeptide (ELP)-based nanoparticles hold great 
potential for drug delivery.[13–18] ELP diblocks can be designed that 
assemble into micellar structures at physiological conditions (Figure 
1.6). As described in Chapter 1, drugs can be coupled to the hydrophilic 
corona or encapsulated into the hydrophobic coacervate core. In addition, 
ELPs can be extended by functional peptides to achieve cell-specific 
targeting or enhance their cellular uptake.[19]  
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2.1.2 The cell-penetrating peptide octa-arginine 
Cell-penetrating peptides (CPPs) are widely employed to enhance 
cellular uptake. CPPs are mostly cationic peptides of 8 to 30 amino acids 
in length that induce the cellular uptake of (macro-) molecules that 
otherwise poorly enter cells.[20] This capacity also extends to 
nanoparticles.[21] Arginine-rich peptides are a prominent class of CPPs. 
Oligoarginines between 6 and 12 arginine residues show optimal activity 
as a CPP.[22] Interestingly, multivalency afforded by coupling  many 
individual arginine peptides to the surface of nanoparticles shows less 
activity than coupling an equivalent number of arginine residues in the 
form of oligopeptides.[23] Clearly, the structural arrangement of arginine 
residues/peptides plays a role in uptake and toxicity.[24] For 
nanoparticles it has been shown that CPP density has a positive impact 
on uptake.[25] However, the major part of CPP research has been 
performed with two dimensional tissue cultures. This bears little 
resemblance with the in vivo situation, where drug delivery systems need 
to penetrate tissues in three dimensions.  
In 3D, particle size is a critical parameter, as a nanoparticle 
carrier ideally should be smaller than 100 nm for effective penetration 
into tumor tissues. Particle binding and the permeability of tumor tissue 
are other parameters in effective nanomedicine-based treatment.[26,27] For 
drug delivery systems that employ active targeting through incorporation 
of receptor ligands, the binding site barrier (BSB) effect can compromise 
penetration.[28,29] High-affinity binding leads to capture of ligand-
functionalized particles in the periphery of the cell mass. Further entry 
is a function of successive saturation of binding sites from the periphery, 
as demonstrated in vivo.[30] Arginine-rich CPPs interact with the heparan 
sulfate proteoglycans of the glycocalyx. While each individual CPP binds 
with affinities in the lower micromolar to higher nanomolar range, a 
polyvalent presentation may strongly increase interactions due to avidity 
effects.[31]  
In this chapter we investigate the impact of CPP density on the 
penetration of ELP particles in 3D cancer cell spheroids. Spheroids are 
excellent models for avascular regions of tumor tissue, as they can be 
generated with a highly reproducible morphology, thus enabling a reliable 
determination of particle penetration depth.[27] In particular, we were 
interested to learn whether a higher CPP density, which should yield 
more efficient uptake in 2D, would compromise penetration in 3D due to 
sequestration of particles in the outer cell layer.  
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2.2 Results & discussion 
2.2.1 Rationale of design for elastin-like polypeptide nanoparticles 
The first step in the creation of self-assembled and functionalized 
ELP-based nanoparticles was the choice or design of suitable sequences. 
On the one hand, a monomer to micelle transition temperature well below 
37 °C had to be chosen to gain stable particles at physiological conditions. 
This transition temperature had to, on the other hand, be above 4 °C in 
order to allow disassembly for purification and modification. A micelle to 
aggregate transition temperature above 37 °C was necessary to avoid 
aggregation during formulation and application. However, it should be 
low enough to allow purification by selective precipitation upon addition 
of electrolytes and/or increase in temperature. Amino acids were chosen 
that did not contain side chains that react with commonly used moieties 
such as maleimides, succinimidyl esters or isothiocyanates to allow 
selective modifications of the N- and C-terminus.  
Based on this and other reports of micellar systems composed of 
ELPs[32–36], we selected isoleucine as the guest residue for the 
‘hydrophobic’, core-forming block. A length of 60 pentapeptides was 
chosen to ensure a transition temperature well below 37 °C down to low 
micromolar concentrations at experimental ‘physiological’ conditions, id 
est phosphate buffered saline pH 7.2 – 7.4. The transition temperature 
was expected to be above 4 °C up to millimolar concentrations, such as 
during formulation and aqueous modification protocols. As guest 
residues for the micelle corona or ‘hydrophilic’ block, we chose a ratio of 
alanine and glycine of 3 to 2 with a length of 60 pentapeptides. This 
should yield micelles that are stable up to 50 °C, therefore being 
hydrophilic enough to prevent undesired aggregation without prohibiting 
purification protocols that rely on the aggregation of micelles. The 1:1 
ratio of ELP block lengths was expected to lead to the formation of 
micelles with radii around 20-40 nm. As in literature the correlation 
between theoretically predicted and actually measured  aggregation 
numbers was not very straightforward,[37,38] no clear estimate could be 
given beforehand on this value.  
 
2.2.2 Cloning of (R8)-[A3G2-60]-[I-60] and [I-60]-[A3G2-60]-(R8) 
For cloning the repetitive ELP sequences, we chose a method 
called recursive directional ligation (Figure 2.1A).[39] This technique is 
based on the scar-free addition of sequences by utilizing type II restriction 
enzymes that cut outside of their recognition sequence.  
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Figure 2.1. Overview of recursive directional ligation (RDL) and used ELP sequences. A) 
RDL extends a given sequence by digestion with either AcuI or BseRI, both type II 
restriction enzymes, which generate the same overhang, and BglI (step 1 and 2). 
Combining parts generated in step 1 and 2 (step 3) results in the seamless fusion of both 
reading frames. Adapted with  permission from reference[40]. B)-D) Multiple cloning site 
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of B) the modified pET-24a(+) vector, C) the vector containing one penta-repeat of [I-n] 
and  D) [A3G2-n], respectively. Recognition sites of AcuI and BseRI are marked in color, 
the cutting sites with resulting overhangs are marked with black lines. 
A pET-24a(+) vector was modified to include cutting sides for AcuI and 
BseRI and a C-terminal tyrosine for spectrometric protein detection at 
280 nm (Figure 2.1B). A double-stranded DNA oligonucleotide (dsDNA) 
was designed to encode 5 ELP pentamers compatible with overhangs 
created by BseRI. After annealing, oligomers were ligated into the 
modified pET-24a(+) vector and transformed into E. coli XL1-Blue cells 
(Figure 2.1C, D). Colonies were selected based on the number of inserts 
and sequenced.  In the case of isoleucine, a clone with 15 pentapeptides 
([I-15]) and for alanine/glycine a clone with 10 ([A3G2-10)] pentapeptides 
was successfully selected. Care was taken to ensure full sequencing of 
the initial inserts (data not shown), since G/C rich sequences often limit 
the sequencing depth obtained for longer constructs. This was evident in 
the sequential cloning steps towards the final constructs, [A3G2-60]-[I-60] 
and [I-60]-[A3G2-60], where successful cloning was confirmed by test-
digestion and partial sequencing of the plasmid (Figure 2.2).  
 
Figure 2.2. Visualization of plasmids digested with XbaI and BamHI on a 1.5 % agarose 
gel. Arrows indicate the DNA length in base pairs as visualized with a marker. Both 
excised fragments coding for the ELP monoblocks have a length of 966 bp, while the 
diblocks have a length of 1866 bp and 1893 bp without and with R8, respectively. The 
digested modified pET24a(+) vector has a length of 5232 bp. 
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Sequences for octa-arginine were first inserted into the modified pET-
24a(+) plasmid and added to either the N- or C-terminus of ELP diblocks, 
resulting in R8-[A3G2-60]-[I-60] and [I-60]-[A3G2-60]-R8. 
2.2.3 Expression and purification 
After sequence design and cloning, a suitable expression host, 
culture conditions and purification protocols had to be chosen. Bacterial 
hosts such as E. coli are easily grown in shaken liquid cultures at various 
conditions.[41] Strains exist that are deficient in recombination factors, 
RNAses and/or proteases to enhance plasmid, RNA and protein stability. 
Expression can be either externally induced or auto-induced by co-
activation of transcription factors during metabolic shift.[42] E. coli 
BL21(DE3), BLR(DE3) or BL21Star(DE3) strains were used. BL21(DE3) is 
a strain deficient in Lon and OmpT proteases.[43] It carries a phage 
construct that expresses T7 RNA polymerase under the control of a 
lacUV5 operon.[44] A derivative of BL21(DE3) is BLR(DE3); it is 
recombinase A deficient[45] and should therefore ensure better stability of 
repetitive plasmids during culturing. BL21Star(DE3) has reduced levels 
of RNaseE when compared to BL21(DE3). As plasmids become unstable 
once transcription is initiated, enhanced RNA stability is expected to 
increase recombinant protein yield. After optimization, the most 
reproducible and effective culture conditions were: shaken cultures of 
600-1000 mL in baffled 2.5 L flasks with membrane seals, 250-350 rpm 
at 30-37 °C for 24-30 hours in terrific broth (TB) medium containing 5-8 
g/L glycerol, 150 mg/L kanamycin, 0.5 g/L D-glucose and 2 g/L alpha-
lactose. This medium is auto-inducing: glucose is the preferred carbon 
source of E. coli and its use inhibits lactose-related genes and 
transcription factors. Once glucose is depleted, the metabolic shift to 
lactose consumption[42] induces T7 RNA polymerase expression, 
transcription and translation of the ELP coding sequence within the 
pET24a(+) vector.  
Table 2.1 shows the yield of various constructs in the different E. 
coli strains, as far as tested, under the same expression conditions. For 
historical reasons, most expressions were done with the BLR(DE3) strain, 
however more recent results for BL21(DE3) and BL21Star(DE3) indicate 
the superiority of these strains even for repetitive biopolymers like ELPs. 
For cell lysis, different methods were compared: enzymatic lysis with hen 
egg lysozyme, mechanical disruption by sonication and mechanical 
disruption by cell-homogenizers. While the combination of enzymatic 
lysis and sonication yielded comparable results to high pressure 
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homogenization (data now shown), the latter technique was more suitable 
for larger culture volumes. After cell lysis and DNA precipitation, ELP 
aggregation was induced by i) changes in temperature or ii) adding salts 
in solid form or as solution.  
Table 2.1. Average expression yields of ELPs in different E.coli strains after purification. 
Reported values are averages of at least three independent expressions, unless 
indicated otherwise. 
Construct 
expressed 
Yield in 
BLR(DE3) 
Yield in BL21(DE3)  Yield in 
BL21Star(DE3)  
[I-60] 20 + 10 mg/L 60 + 13 mg/L  70 + 7 mg/L 
[A3G2-60] 12 + 6 20 mg/L (n =1) NA 
[A3G2-60]-[I-60] 24 + 7 44 mg/L (n=1) NA 
[I-60]-[A3G2-60] 34 + 9 75 mg/L (n=1) NA 
R8-[A3G2-60]-[I-60] 65 + 15 NA NA 
[I-60]-[A3G2-60]-R8 34 + 6 NA NA 
 
While most protocols report using solid sodium chloride to 
precipitate ELPs, a saturated solution of more kosmotropic ammonium 
sulfate, according to the Hofmeister series (Figure 2.3), proved to be more 
effective. When comparing the effect of various salts on the change in 
transition temperature, it became evident that ammonium sulfate has a 
stronger influence on lowering the transition temperature than sodium 
chloride.[46] Additionally, ammonium sulfate precipitation is a known 
method for the purification and storage of various proteins and is 
therefore expected to improve protein stability and to preserve function. 
While this should be inconsequential in the case of ELPs and their 
disordered secondary structure, it is important when purifying fusion 
proteins linked to ELPs as e.g. in Chapter 3 and 5. 
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Figure 2.3. Hofmeister series of selected ions. Generally, ions on the left side are more 
kosmotropic, facilitating protein aggregation and stability, while ions on the right side 
are chaotropic, facilitating protein solubility. 
Octa-arginine displaying elastin-like polypeptide nanoparticles for binding-site barrier 
analysis in glioblastoma spheroids 
43 
Figure 2.4. Analysis of purified 
ELP diblocks by sodium dodecyl 
sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE). As 
ELPs don’t contain any 
coomassie binding residues 
(left), they are silver-stained for 
better contrast. 
 
 
 
 
 
 
 
Typically, adding 4-20 vol% of a saturated ammonium sulfate solution 
was sufficient to precipitate the used ELPs even at 4 °C. This is well below 
the concentration of ammonium sulfate that is typically used for protein 
precipitation, thereby minimizing impurities. This yielded pure ELPs after 
2-4 ITC cycles. Figure 2.4 shows the purity of [A3G2-60]-[I-60], [I-60]-
[A3G2-60], R8-[A3G2-60]-[I-60] and [I-60]-[A3G2-60]-R8 after three 
purification cycles by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE). Size-exclusion chromatography of the 
purified ELPs ensured removal of other large or small contaminants still 
present before lyophilization; Figure 2.5 shows chromatograms of 
purified ELPs and bovine serum albumin (BSA) for comparison. 
Electrospray ionization – time of flight (ESI-ToF) mass spectrometry 
confirmed the molecular masses (Figure A2.1, Table 2.2). 
2.2.4 Analysis of micelle formation  
To determine the transition temperature of the ELPs, 
spectrophotometry was used to probe the state of aggregation by light 
absorption. Figure 2.6A shows the absorption at 350 nm of [A3G2-60]-[I-
60] at various concentrations in phosphate buffered saline pH 7.4 during 
a temperature ramping experiment from 10 °C to 60 °C.  
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Figure 2.5. Size-exclusion chromatography of different purified ELP constructs. Bovine 
serum albumin is included as a reference. The apparent hydrodynamic radius of [A3G2-
60]-[I-60] is larger than expected for a globular protein of 48 kDa. This is due to the 
unfolded structure of ELPs in solution. 
Two transition temperatures were observed; when micelles were 
formed, the turbidity increased slightly and scaled with concentration. 
When these micelles aggregated, a sharp transition was observed and the 
solution turned visibly turbid. [I-60] showed only one sharp increase in 
turbidity (Figure 2.6B), indicating monomer to aggregate transition. For 
[A3G2-60], no change in turbidity was observed over the full temperature 
range (data not shown) owing to the hydrophilicity of its guest residues. 
The transition temperature was defined as the maximum of the first 
derivative of the absorbance (Table 2.2). While the transition from 
monomer to aggregate or particle to aggregate was sharp and well defined 
at various protein concentrations (Figure 2.6A, B), the transition from 
monomer to particle could better be probed by a technique more sensitive 
to the presence of particles in solution, namely dynamic light scattering 
(DLS).  
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Figure 2.6. Determination of the transition temperatures of [A3G2-60]-[I-60] and [I-60] 
at different protein concentrations in PBS pH 7.2-7.4. a) Absorbance of [A3G2-60]-[I-60] 
at 350 nm during a temperature ramp experiment (0.2 °C/min) at different protein 
concentrations. B) Absorbance of [I-60] at 350 nm during a temperature ramp 
experiment (0.2 °C/min) at different protein concentrations. C) The normalized count 
rate measured by dynamic light scattering of [A3G2-60]-[I-60] during a temperature ramp 
experiment (0.5 °C/step). D) Hydrodynamic radius (mean + SD) of [A3G2-60]-[I-60] 
measured by dynamic light scattering during a temperature ramp experiment (0.5 
°C/step). 
Figures 2.6C, D show the derived count rate, indicative of particle 
concentration or, in the case ELPs, monomer to particle transition, and 
the respective hydrodynamic radius rh,n of the diblock [A3G2-60]-[I-60] at 
varying concentrations. The monomer to micelle transition temperatures, 
based on the maximum of the first derivative of the derived count rate are 
depicted in Table 2.2 and Figure 2.7. DLS also confirmed the presence 
of monodisperse particles for all diblocks in PBS at pH 7.4 at 37 °C 
(Figure 2.8, Table 2.3). The transition temperatures from monomer to 
micelle of the diblock ELPs were very similar (data not shown), as 
expected, since both the hydrophobic and hydrophilic block are identical. 
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Table 2.2. Calculated and measured masses of various ELPs and their respective transition 
temperature at 10 µM [ELP] in PBS pH 7.4. 
Construct Calculated 
mass (Da) 
Measured 
mass (Da) 
Transition 
to micelle 
Transition to 
aggregate 
[A3G2-60] 22782 22787 NA NA 
[I-60] 25649 25648 NA 17 °C 
[A3G2-60]-[I-60] 48198 48198 21 °C 57 °C 
[I-60]-[A3G2-60] 48198 48198 21 °C 57 °C 
R8-[A3G2-60]-[I-60] 49505 49503 21 °C 49 °C 
[I-60]-[A3G2-60]-R8 49505 49504 21 °C 48 °C 
 
 
Figure 2.7. Lin-log plot of transition temperatures plotted versus protein concentration. 
In the case of the ELP diblock, bold letters indicate the respective blocks. The solid lines 
represent apparent linear fits. 
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Figure 2.8. Volume-average hydrodynamic radii of different ELP blocks. All constructs 
form well-defined nanoparticles at 37 °C in PBS pH 7.4. Protein concentration was 10 
µM. 
Table 2.3. DLS data of micelles formed from diblock ELPs at 10 µM in PBS pH 7.4 at 37 
°C. Radii reported are volume-averaged sizes. 
Construct Hydrodynamic radius (nm) Polydispersity Index1 
[A3G2-60]-[I-60] 29.3 0.031 
[I-60]-[A3G2-60] 30.2 0.021 
R8-[A3G2-60]-[I-60] 31.5 0.062 
[I-60]-[A3G2-60]-R8 29.0 0.054 
1Polydispersity index (PDI) is defined as the square of the standard deviation divided by the square 
of the mean. Values reported for hydrodynamic radii and PDI are averaged from 3 independent 
measurements. 
Particles displaying R8 aggregated 8 – 9 °C earlier at 10 µM in PBS 
pH 7.4, probably due to their amphipathic nature. The effect of the 
hydrophilic ELP block on the transition temperature of the hydrophobic 
block was evident: while [I-60] aggregated at 17 °C at 10 µM in PBS pH 
7.4, the hydrophobic block in [A3G2-60]-[I-60], under the same 
conditions, showed a transition temperature of 21 °C.  
Similarly, the hydrophilic monoblock [A3G2-60] did not aggregate 
at all below 80 °C, but showed a transition temperature of 57 °C as part 
of the diblock polypeptide; in this case the particle to aggregate transition 
was independent of the overall ELP concentration within the measured 
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range (Figure 2.7). This probably occurs due to the high local 
concentration of ELPs within the micelle, increasing the ‘perceived’ 
protein concentration and lowering their transition temperature. The lin-
log plot shows the linear relation of the logarithmic value of protein 
concentration to the transition temperature. This relation can be fitted 
with a logarithmic function 
 
!" =  $ + & '()*+, (1)[47]  
in which Tt is the transition temperature, x is the concentration in µM, α 
is the transition temperature for log(x) = 0 and β the slope (R2 = 0.99, α = 
24.97 + 0.21, β = -3.97 + 0.19 for [A3G2-60]-[I-60]; R2 = 0.99, α = 19.83 + 
0.01, β = -2.74 + 0.01 for [I-60]). The same equation could also be used 
to estimate the critical micelle concentration (CMC) at 37 °C, which in the 
case of [A3G2-60]-[I-60] leads to a CMC of 0.97 nM + 0.22 nM and for [I-
60] to a CMC of 0.54 pM + 0.03 pM. It is however unclear whether 
equation 1 is also valid in a low concentration regime. With DLS it was 
possible to confirm the formation of particles down to 3.2 nM before 
reaching the sensitivity limit of the instrument (Figure 2.9). Interestingly, 
the size as measured by DLS increased from a hydrodynamic radius of 
32.0 + 10.8 nm at 10 µM to 63.7 + 18.0 nm at 3.2 nM. This may be due 
to better hydration of the hydrophilic ELP block, which can adapt a 
‘mushroom’ conformation, or a state described as ‘weak’ micelles at 
higher concentrations[37]. As described in Chapter 3, functionalized 
particles stay active, and therefore assembled, down to 6 nM or 0.3 
µg/mL, the lowest concentration tested.  We therefore concluded that the 
CMC would be sufficiently low for in vitro applications. In vivo, the 
influence of blood constituents and their interactions with ELP particles 
are hard to predict and would have to be experimentally validated by 
probing the activity of assembled particles.  
To determine the molecular weight and the aggregation number 
of particles assembled from [A3G2-60]-[I-60] and [I-60]-[A3G2-60], size-
exclusion chromatography was used, followed by multi-angle light 
scattering (Figure A2.3, Table 2.4). The refractive index increment dn/dc 
was determined experimentally by direct injection of [A3G2-60]-[I-60] and 
was assumed to be equal for [I-60]-[A3G2-60]. A molecular weight of 10.8 
MDa for [A3G2-60]-[I-60] and [I-60]-[A3G2-60] resulted in an average 
aggregation number of 224 monomers per particle.  
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Figure 2.9. Hydrodynamic radius of [A3G2-60]-[I-60] depending on concentration as 
measured by dynamic light scattering. Values plotted represent the mean + standard 
deviations from 3 independent measurements. 
 
 
Table 2.4. Data obtained for ELP nanoparticles from multi-angle light scattering. 
ELP dn/dc Rh (nm) Rg (nm) Rg/Rh Molecular 
mass Mw 
(MDa) 
N Mw/
Mn 
[A3G2-60]-[I-60] 1.586 + 
0.001 
24.2 + 
0.1 
17.1 + 
0.6 
0.706 + 
0.028 
10.8 + 0.1 224 1.019 
[I-60]-[A3G2-60] 1.586 + 
0.001 
23.4 + 
0.1 
16.7 + 
0.4 
0.714 + 
0.021 
10.8 + 0.1 224 1.001 
dn/dc: refractive index increment; Rh: hydrodynamic radius; Rg: radius of gyration; N: aggregation 
number; Mw: weight-average molecular weight; Mn: number-average molecular weight. 
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2.2.5 Uptake of ELP-R8 nanoparticles directly correlates with CPP density 
Toxicity of ELP particles was tested in fibroblasts. Little toxicity was 
observed for particles without R8 (Figure A2.4). In contrast, toxicity 
increased with the display of R8 on the particle surface, though up to a 
density of 25% R8, toxicity was low. This observation of low toxicity 
stands in contrast to the multivalent presentation of nona-arginine on a 
linear backbone,[25] demonstrating that geometry of presentation has a 
major impact on the toxicity of oligo-arginines. Next, we determined the 
effect of R8 on the cellular uptake of ELP nanoparticles. ELP 
nanoparticles were formed without and with increasing percentage of R8-
[A3G2-60]-[I-60] (nR8-ELP). A fixed ratio (5 %) of Alexa647-labeled ELP 
(Figure A2.2) was incorporated for detection. Particles (concentration 10 
µM ELP) were added to the cell culture medium.  After two hours of 
incubation, cellular uptake and subcellular distribution were determined 
by flow cytometry and confocal laser scanning microscopy. Cell-
associated fluorescence showed a strong linear increase with the ratio of 
nR8-ELP in the particles (Figure 2.10). The uptake was independent of 
the orientation of the CPP on the ELP, as [I-60]-[A3G2-60]-R8 (cR8-ELP) 
showed a similar dependence as nR8-ELP. However, at lower percentages 
of R8 (0 % - 25 %), cellular uptake tended to be lower than observed for 
nR8-ELP. This may be attributed to the negatively charged C-terminus 
counteracting the positive charge of octa-arginine. We continued the 
following experiments with nR8-ELP. Whether cell-associated 
fluorescence reflected particles taken up into cells was investigated with 
confocal laser scanning microscopy. As for flow cytometry, only little cell-
associated fluorescence was observed for ELP nanoparticles not 
containing any CPP. At 5% nR8-ELP, the total fluorescence was localized 
inside cells. At 50 % nR8-ELP, fluorescence accumulated at the plasma 
membrane, which was even more prominent at 90 % (Figure 2.10). This 
cellular uptake of ELP nanoparticles was time-dependent. After one hour 
of incubation with 10 % nR8-ELP nanoparticles, fluorescence was 
primarily observed at the plasma membrane (Figure 2.11A). After two 
hours, particles were taken up and showed partial overlap with acidic 
vesicular structures (late endosomes and lysosomes) as evident from 
colocalization with lysotracker (Figure 2.11B). This colocalization further 
increased towards four hours (Figure 2.11C, D).  
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Figure 2.10. Uptake of ELP nanoparticles into human skin fibroblasts. Top: Mean 
fluorescence intensity of Alexa647-labeled cR8-ELP and nR8-ELP nanoparticles with 
increasing percentages of R8. Uptake of ELP nanoparticles after 2 h incubation was 
quantified with flow cytometry (mean fluorescence of live cells presented ± SEM, n = 3) 
Bottom:  Subcellular distribution of ELP nanoparticles (red) containing different fractions 
of nR8-ELP as imaged by confocal microscopy after 2 h incubation. Plasma membranes 
were visualized by Cell Mask Green (green) (scale bars 20 µm). 
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Figure 2.11. Endosomal uptake of 10 % nR8-ELP nanoparticles after A) 1 h, B) 2 h, C) 4 h 
incubation. Acidic compartments were labeled with LysoTracker Green. ELP 
nanoparticles; red, lysosomes; green, scale bars 20 µm. D) Mander’s Overlap Coefficient 
was calculated as a measure for colocalization. 
 
To move from a two- to a three-dimensional environment, the 
uptake and penetration capacity of R8-ELP nanoparticles were evaluated 
in spheroids consisting of U-87 human glioblastoma cells. Exposure to 
the nanoparticles had no impact on spheroid morphology in terms of area 
and aspect ratio (data not shown). A clear dependence of fluorescence 
and penetration depth on R8-ELP content could be observed after 24 
hours (Figure 2.12). ELP nanoparticles containing 25 % nR8-ELP 
displayed the highest number of fluorescent spots, representing ELP 
particles, and the deepest penetration into the spheroid. The dot-like 
distribution of ELP nanoparticles indicated intracellular localization.  
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Figure 2.12. Intracellular uptake of ELP nanoparticles (red) in U-87 spheroids. Spheroids 
of similar size (400 µm) were incubated with ELP nanoparticles containing 0 %, 10 % or 
25 % of nR8-ELP for 24 h and imaged by confocal laser scanning microscopy after fixation 
and sectioning. The actin-skeleton of the cells was stained with phalloidin (green) and 
the nucleus with DAPI (cyan) to evaluate the intra-cellular distribution. The box in the 
overview indicates the approximate size of the enlargements. Scale bar is 100 µm in the 
top figure and 20 µm in the enlargements. 
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This showed that on the one hand ELP nanoparticles functionalized with 
R8 were accumulated by cells as a result of the uptake-inducing effect of 
octa-arginine. On the other hand, the CPP also promoted penetration into 
the spheroids. This is reflected in the fluorescence intensity represented 
as function of the distance from the core to the outer edge in a line profile 
(Figure 2.13A). Penetration depth of nR8-ELP nanoparticles after 5 h and 
24 h incubation was independent of the size of the spheroids (data not 
shown). Interestingly, no penetration into spheroids could be observed 
for ELP nanoparticles not carrying the R8 functionality. Clearly, R8-
mediated association of the nanoparticles with cells is a prerequisite. 
Arginine-rich CPPs have been shown to interact with the negatively 
charged glycosaminoglycans of the extracellular matrix of cells.[48] At the 
same time, this interaction has also been associated with triggering of 
uptake.[49] Therefore, capture and uptake should compete with 
penetration.  
 
2.2.6 Penetration depth is time-dependent and scales with particle 
concentration 
If penetration of 25 % nR8-ELP nanoparticles after 24 h 
incubation was dependent on ELP concentration, it would indicate the 
presence of a binding site barrier, either due to cellular uptake or due to 
binding to the extracellular matrix. For both cases, ELP nanoparticles 
should penetrate deeper into the spheroids at higher concentrations. We 
tested three different concentrations of 25 % nR8-ELP nanoparticles (2.5 
µM, 10 µM and 25 µM). The highest concentration of 25 µM displayed 
consistently the highest intensities inside the spheroids (Figure 2.13B). 
However, after normalization of the 2.5 µM and 10 µM experiments to the 
same maximum intensities of the 25 µM experiment, 10 µM and 25 µM 
showed very similar intensity profiles, demonstrating that for these 
concentrations the penetration is independent of nanoparticle 
concentration (Figure A2.5). In contrast, for the 2.5 µM ELP 
nanoparticles fluorescence was only present in the periphery, indicative 
of a binding site barrier. After evaluating the effect of concentration of 
ELP nanoparticles on penetration depth, we measured the impact of 
incubation time on penetration depth of 25 µM 25 % nR8-ELP 
nanoparticles in U-87 spheroids. The highest penetration depth was 
observed after an incubation time of 24 h (Figure 2.13C).  
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Figure 2.13. Uptake quantification in spheroids. Lines indicate the 5-point moving 
average, while shaded areas denote the standard error of the mean (SEM), with two 
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independent experiments and at least two spheroids measured per condition per 
experiment. A) Moving average of the intensity of ELP nanoparticles with different ratios 
of R8-ELP after 24 h in the spheroid. B) The moving average intensity of the 25% R8-ELP 
(2.5 µM, 10 µM, 25 µM) nanoparticles in the spheroid, after background correction after 
24 h. C) The moving average intensity of 25 µM 25% nR8-ELP nanoparticles in the 
spheroid, after background correction for indicated incubation times. 
Fluorescent intensity values of ELP nanoparticles increased over time 
with a maximum at 4 h. When the incubation time was increased to 48 
h, intensity values decreased. This observation may be attributed to the 
degradation of ELP nanoparticles. The promotion of penetration by 
conjugation of R8 is in line with previous observations. For significantly 
smaller dendrimer structures than ELP-nanoparticles, positively charged 
terminal groups provided increased tumor penetration compared to 
neutral or negatively charged terminal groups.[50] Regardless of this 
addition, smaller dendrimers seemed to penetrate more quickly. Addition 
of R8 to somewhat larger dendrimers significantly boosted the 
penetration of dendrimers with positively charged terminal groups.[51] 
Similar observations were made for lipid nanoparticles.[52,53] However, in 
these and other studies penetration was inferred at best from confocal 
images of uncleared spheroids so that in fact, no information on 
penetration behavior could be derived.[54,55] With the use of cleared and 
halved spheroids, we quantified the cellular uptake and tumor 
penetration of R8-labeled ELP-nanoparticles to disclose the CPP’s role as 
dual functionality charge carrier. 
2.3 Conclusion 
We have created nanoparticles displaying octa-arginine groups on 
their surface by using elastin-like polypeptides. ELPs were successfully 
designed, recombinantly expressed and purified. We have characterized 
their assembly behavior by spectrophotometry and dynamic light 
scattering to show their transition from monomer to micelle to aggregate 
depending on concentration and block composition. We have shown with 
multi-angle light scattering that they form well-defined micellar 
structures with hydrodynamic radii of around 24 nm and aggregation 
numbers of around 220 monomers per micelle. They were stable until low 
nanomolar concentrations and able to display varying concentrations of 
octa-arginine moieties by co-assembly of different elastin-like 
polypeptides. The resulting nanoparticles were taken up by fibroblasts 
via endosomal pathways and uptake scaled with the concentration of 
octa-arginine presented on the surface.  
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By swapping the orientation of the hydrophilic and hydrophobic 
protein block, we evaluated both C-terminal and N-terminal conjugation 
of the CPP. Uptake of nanoparticles with R8 at the N-terminus of ELP 
constructs was slightly higher, which may be attributed to the negatively 
charged C-terminus counteracting the positive charge of octa-arginine. 
Octa-arginine by itself has little cytotoxicity, which may be attributed to 
the low membrane-activity of this CPP.[56] For ELP nanoparticles 
containing R8 up to 25 % functionalized end groups on the particle 
corona, toxicity was low. This observation is in contrast to the multivalent 
presentation of nona-arginine on a linear backbone,[25] demonstrating 
that geometry of presentation has a major impact on the toxicity of 
oligoarginines. In spheroids, uptake and penetration of nanoparticles 
could be followed well by halving and clearing spheroids prior to imaging. 
To describe the penetration of high-affinity binders into three-
dimensional tissues, the concept of the binding site barrier has been 
formulated. Even though the affinity of individual CPPs with the 
glycosaminoglycans is only in the upper nanomolar range,[57–59] the 
multivalent display on the surface of particles can strongly increase 
affinity through avidity effects.[25] We addressed the potential presence of 
a binding site barrier by varying the density of the CPP as well as the 
concentration of the ELP nanoparticles. The first intervention affected the 
avidity, while the second one should promote the saturation of binding 
sites. The penetration depth was dependent both on CPP density as well 
as particles concentration. Non-functionalized ELP nanoparticles did not 
penetrate glioblastoma spheroids. At a concentration of 2.5 µM, ELP-
nanoparticles with 25 % CPP were restricted to the periphery of the 
spheroids even after 24 h. In contrast, for concentrations of 10 µM and 
25 µM, penetration into spheroids was observed, while penetration depth 
of nanoparticles was indistinguishable for these concentrations. 
The observation that ELP nanoparticles not carrying any R8 did 
not show any penetration suggests that the binding site barrier is a 
consequence of uptake rather than saturation of binding sites on the 
glycosaminoglycans. At higher concentrations, the endocytic capacity 
may become increasingly exhausted. Rapid exchange between a bound 
and unbound state should promote percolation of the particles through 
the interstitial space. Apparently, even with an avidity effect in place, the 
interaction with the glycocalyx still has a high enough off-rate. In 
addition,  the formation of protein corona surrounding nanoparticles 
could influence penetration and accumulation.[60] ELP-based 
nanoparticles are being pursued as a strategy for targeted drug delivery 
and represent excellent candidates for this purpose because of their 
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biodegradability, biocompatibility, and the presence of both hydrophobic 
and hydrophilic components in the same system that provide flexibility 
in drug formulation.[9] Moreover, proteins can be easily extended with 
targeting moieties such as nanobodies[19] and delivery vehicles such as 
other cell-penetrating peptides.[61] Mixing of ELPs carrying different 
functionalities allows for a highly flexible adjustment of the density of the 
delivery moiety. An open question is to which degree the combination of 
CPP-conjugated ELPs with ELPs carrying receptor-specific targeting 
ligands will enable the fine-tuning of cellular uptake, penetration and 
targeting. 
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2.5 Experimental section 
All chemicals were purchased from Sigma-Aldrich and used as received 
unless specified otherwise.  
2.5.1 Cloning and expression of ELPs 
Primers (Biolegio) for the preparation of the modified pET24a(+) 
(Invitrogen) vector and ELP vectors are presented in the table below. The 
cloning protocol for recursive-directional ligation was adapted from 
literature.[40] In short, the plasmid containing the N-terminal part of the 
desired fusion was cut with BglI and AcuI, the one containing the C-
terminal part was cut with BglI and BseRI. Both parts were purified after 
separation on an agarose gel and ligated. The coding sequence for R8 was 
introduced into the modified pET24a(+) vector by designing oligos with 
compatible overhangs for BseRI and XbaI. Recursive-directional ligation 
was then used to add R8 to the ELP coding sequence. 
Table 2.5. Primers used for the generation of ELP sequences. 
Primer Sequence (5’-3’) 
Modified pET24a(+) 
sense 
gatcctgaagatcattatcagtagcccatatgtactcctccttctta
aagttaaacaaaattattt 
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Modified pET24a(+) 
antisense 
ctagaaataattttgtttaactttaagaaggaggagtacatatggg
ctactgataatgatcttcag 
[I-5] sense tggtacaccgatgcctggaaccccgatacccggcacaccgatgcc
cggcacaccgatacccggtacaccgatgcc 
[I-5] antisense catcggtgtaccgggtatcggtgtgccgggcatcggtgtgccgggt
atcggggttccaggcatcggtgtaccagg 
[A3G2-5] sense aggcacaccaccgcccggcacaccaccacccggtacgcccgca
cccggaacaccagcgcccggcacgcccgcgcc 
[A3G2-5] antisense cgcgggcgtgccgggcgctggtgttccgggtgcgggcgtaccgggt
ggtggtgtgccgggcggtggtgtgcctgg 
R8 sense acggcgacggcgacgacgacgacggcccatatgtactcctccttc
ttaaagttaaacaaaattattt 
R8 antisense ctagaaataattttgtttaactttaagaaggaggagtacatatggg
ccgtcgtcgtcgtcgccgtcgccgtgg 
 
Plasmids were transformed into E.coli BLR(DE3), BL21(DE3) or 
BL21Star(DE3) (Invitrogen) cells and grown on agar plates containing 30 
µg/mL kanamycin overnight at 37 °C. A single colony was grown 
overnight at 23 °C, 250 rpm in LB medium containing 50 µg/mL 
kanamycin and 0.5% w/v D-glucose. The overnight culture was diluted 
to an OD600 of 0.1 in filter-sterilized AIM TB medium (Formedium) 
containing 6 g/L glycerol, 0.005 % Antifoam 204 and 150 µg/mL 
kanamycin. Cells were grown at 300 rpm at 30 °C for 20 hours. Cells 
were collected by centrifugation at 4000 g, 4 °C for 30 minutes. For 
cytoplasmic extraction, 1 g of wet cell pellet was resuspended in 10 mL 
phosphate buffered saline pH 7.4. Cells were lysed by homogenization 
with an EmulsiFlex-C3 (Avestin). Alternatively, for cytoplasmic 
extraction, 1 g of wet cell pellet was resuspended in 2 mL lysis buffer (50 
mM Tris-HCl pH 8.0, 25 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, 
cOmplete™ Protease Inhibitor Cocktail, 0.5 mg/mL lysozyme) and 
incubated for 4 h at 4 °C. Lysis was followed by sonication on a Branson 
Sonifier 250 (power level 2-4, 12 cycles of 10 s sonication, 10 s breaks). 
Cell debris was collected by centrifugation at 15,000 g at 4 °C for 15 min. 
Residual DNA was precipitated by adding 0.5 % w/v poly(ethylene imine) 
and removed by centrifugation at 15,000 g at 4 °C for 15 min. ELPs were 
precipitated by adding a saturated solution of (NH4)2SO4 up to 10-25 
v/v% either at room temperature or 4 °C depending on the construct. 
Proteins were collected by centrifugation at 15,000 g at 4 °C or RT for 15 
min. The pellet was resuspended in phosphate buffered saline and 
centrifuged to remove insoluble contaminants at 15,000 g at 4 °C for 20 
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min. This cycle was repeated until sufficient purity was achieved, usually 
after 2-4 cycles. ELPs were resuspended in MilliQ, purified on a HiLoad 
16/600 Superdex 200 and desalted on a HiPrep 26/10 (GE Healthcare 
Life Sciences) with an AKTA Explorer 10 (GE Healthcare Life Sciences) at 
1 mL/min PBS and 4 mL/min MilliQ, respectively. Residual salt 
concentration was below 0.01 mg/mL as determined by conductivity. The 
ELP solution was filter-sterilized with 0.22 µm PES syringe filters 
(Nalgene) and freeze-dried. Yield was determined by weighing. 
2.5.2 Agarose gel electrophoresis 
1.5 % agarose gels were made with and run in tris-acetate EDTA 
(TAE) buffer at 100 V. SYBR Safe (Life Technologies) was used as a nucleic 
acid stain and added during the preparation of the gel. Around 200 ng of 
plasmid DNA was added to each well. 
2.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were run under reducing conditions on 12% SDS-PAGE 
gels. Gels were either silver-stained or stained with coomassie brilliant 
blue (CBB). 
2.5.4 Electrospray ionization – time of flight mass spectrometry (ESI-TOF) 
Mass was determined by ESI-TOF on a JEOL AccuTOF. Freeze-
dried samples were resuspended in MilliQ to a concentration of 10 µM, 
samples containing buffer were first desalted with MilliQ using Amicon 
Ultra-0.5 spin filter units (Millipore, 10 kDa MWCO). All samples were 
acidified with 0.1% formic acid upon injection. Deconvoluted spectra 
were obtained using MagTran 1.03 b2.  
2.5.5 Size-exclusion chromatography (SEC) 
Samples were separated on a Bio-Sec 5 1000 Å + 300 Å  + 150 Å  
(guard) column (Agilent) at 0.5 mL/min; the mobile phase was 0.01 M 
phosphate buffer pH 7.0 at 4 °C to ensure the resolution of monomers. 
Typically, 10 µg of ELPs was injected. Absorbance was measured at 215 
nm. 
2.5.6 Size-exclusion chromatography followed by multi-angle light 
scattering (SEC-MALS) 
For SEC-MALS, the samples were separated on a Bio-Sec 5 1000 
Å column (Agilent) at 0.5 mL/min; the mobile phase was phosphate 
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buffered saline at pH 7.4 37 °C. Samples were equilibrated at 37 °C before 
injection of 20 µL ELP particle solution with a concentration of 1 mg/mL. 
Light scattering data were collected on a DAWN HELEOS II MALS detector 
(Wyatt) and differential refractive index was measured on an Optilab T-
rex refractometer (Wyatt). dn/dc values were determined experimentally 
by direct injection.  
2.5.7 Spectroscopy 
Spectroscopy experiments were performed with a V-750 UV-
Visible spectrophotometer (Jasco). Quartz cuvettes (Hellma) with a path 
length of 10 mm were used. For ramping experiments, the heating rate 
was set to 0.2 °C/min with data collection each 0.2 °C. 
2.5.8 Alexa647-labeled ELPs 
Freeze-dried ELPs were resuspended in 50 mM NaHCO3 pH 7.6-
7.9. Alexa647-NHS ester was resuspended in DMSO and added drop-wise 
to the protein solution. The molar ratio ELP to NHS ester was 1:2. The 
reaction was allowed to proceed for 4 hours at 21 °C, 300 rpm. Unreacted 
dye was removed by dialysis against MilliQ using Amicon Ultra-0.5 spin 
filter units (Millipore, 10 kDa MWCO). The volume of the dialyzed protein 
samples was determined; efficiency of conjugation was determined by 
measuring dye concentration and weighing protein samples after freeze-
drying. Concentration of the dye was determined at 650 nm (ε = 270,000 
cm-1M-1). Mass was confirmed by ESI-TOF. 
2.5.9 Dynamic light scattering  
Samples were diluted in PBS pH 7.4. Measurements were 
performed on a Malvern Zetasizer Nano. Samples were incubated for 5 
minutes at 37 °C before data collection. Reported values are averages of 
3 independent measurements. For temperature ramping, values were 
collected every 0.5 °C. 
2.5.10 Cell culture  
Primary human skin fibroblasts were cultured in medium 199 (M-
199) with Earle’s Salts, L-glutamine, 25 mM HEPES, L-amino acids and 
phenolred (GIBCO, Life Technologies Invitrogen, Breda, The Netherlands) 
supplemented with 10% (v/v) fetal calf serum (FCS) (GIBCO, Life 
Technologies) in a humidified atmosphere of 95% air – 5% CO2 at 37 °C. 
Chapter 2 
62 
2.5.11 Confocal microscopy of uptake of ELP nanoparticles in a cell 
monolayer  
One day prior to imaging, primary human skin fibroblasts were 
seeded at 40,000 cells/well on an 8-well coverglass slide (Nunc Lab-Tek 
Chamber slide #1.0 Borosilicate coverglass, Nunc, Wiesbaden, Germany). 
On the day of imaging, the medium was replaced by serum-containing 
medium containing 10 µM ELP nanoparticles labeled with 5 % 
AlexaFluor647-peptides including various fractions (0-25%) of R8-ELP for 
an incubation time of 1, 2, 4 or 24 hours. After incubation, the medium 
including particles was removed and the cells were washed three times 
with PBS and imaged in M-199 with Earl’s Salts, L-glutamine, 2.2 g/L 
sodium bicarbonate and without phenolred (GIBCO, Life Technologies), 
supplemented with 10% (v/v) FCS. CellMask Green (Life Technologies 
Invitrogen) was used to stain the plasma membranes. Cells were 
incubated with the 1x working solution (provided solution is 1000 x) for 
three minutes, washed three times with PBS and imaged within 10 
minutes in M-199 without phenolred, to prevent redistribution of the dye 
into the cytoplasm. To stain the lysosomes, the cells were incubated with 
50 nM LysoTracker Green DND-26 (Thermo Fisher Scientific) for one 
hour. After staining, the cells were washed three times with PBS and 
imaged in M-199 without phenolred. Imaging was performed with a TCS 
SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) 
equipped with an HCX PL APO 63x N.A. 1.2 water immersion objective. 
Cells were maintained at 37 ºC on a temperature-controlled microscope 
stage. The ELP nanoparticles labeled with Alexa647 were excited with a 
633 nm HeNe laser and emission was collected between 655 and 750 nm. 
The green co-localization markers (CellMask Green, LysoTracker Green) 
were excited by an argon laser at 488 nm and emission was collected 
between 500 and 550 nm. The obtained images were further processed 
using FIJI (http://fiji.sc/). 
2.5.11 Flow cytometry  
Human primary skin fibroblasts were seeded in 24-well plates 
(Sarstedt, Numbrecht, Germany) for one day (80,000 cells/well) or for two 
days (40,000 cells/well) prior to measurement. Cells were incubated with 
the indicated concentration of ELP nanoparticles for two hours. After 
incubation, the cells were washed with PBS and cells were detached by 
trypsinisation for 5 minutes, spun down and resuspended in 100 µL M-
199 without phenolred. The fluorescent signal of the nanoparticles was 
measured using a FACSCalibur flow cytometer (BD BioSciences, 
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Erembodegem, Belgium) and subsequently data was analyzed with 
Flowing Software (http://www.uskonaskel.fi/flowingsoftware/). The cells 
were gated on the live population by forward and side scatter and 10,000 
cells were counted to determine cellular nanoparticle uptake by measure 
of mean cellular fluorescence. 
2.5.12 Cell death assay  
Toxicity of ELP nanoparticles with different fractions of R8-ELP 
(0-90%) was evaluated after 24 h using the propidium iodide assay. Two 
days prior to measuring cell death, 40,000 cells were seeded in 24-well 
plates (Sarstedt). The following day, cells were incubated with a range of 
concentrations (0-100 µM) of ELP nanoparticles. After 24 h of incubation, 
the cell medium was collected, the cells were washed three times with 
PBS, then trypsinized and spun down. Subsequently, the cells were 
resuspended and incubated for 30 min at 4 °C with 100 µL Nicoletti buffer 
(0.1% Na3C6H5O7, 50 µg/mL propidium iodide, 0.01% Triton X-100) and 
no less than 10,000 cells were measured with flow cytometry to determine 
cell death. 
 
2.5.13 Formation of spheroids  
Human glioblastoma cells (U-87) (gift from Dr. Joost Schalkwijk, 
Department of Dermatology, RIMLS, Radboudumc, Nijmegen) were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 
g/L D-glucose, GlutaMAX and pyruvate (no. 31966-021, GIBCO, Life 
Technologies) and supplemented with 10% (v/v) FCS (no. 10270, GIBCO, 
Life Technologies) in a humidified atmosphere of 95% air – 5% CO2 at 37 
°C. Spheroids were formed by plating 100 µL of a 10,000 cells/mL single 
cell suspension of U-87 onto agarose (Sigma) (0.75% (w/v) in PBS) coated 
96-well plates (Corning). Cells were allowed to aggregate for 5 days 
without motion, resulting in the formation of a single spheroid per well. 
On day 5, the spheroids were incubated with the appropriate 
concentration of ELP nanoparticles for the indicated incubation times. 
After incubation, the spheroids were washed three times with PBS. 
Subsequently, the spheroids were fixed in paraformaldehyde (Sigma) (4% 
(v/v) in PBS). After fixation, the spheroids were carefully cut in half with 
a sharp razor blade and placed with the flat side (inner half) on a coverslip 
in a drop of gelatin (4% (w/v in PBS). Nuclei were stained with DAPI 
(ThermoFisher Scientific), and the actin filaments with AlexaFluor488 
phalloidin (ThermoFisher Scientific). Clearing was performed based on a 
protocol adapted from Ke et al.[62] A 115% w/v fructose stock solution was 
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prepared by dissolving fructose (Sigma) in MQ for 30 minutes at 80 °C 
under stirring. Three solutions were prepared (28.75% w/v, 57.5% w/v, 
and 115% w/v) and 0.5% v/v 1-thioglycerol was added to all solutions. 
Cells were incubated with 200 µL preheated (60°C) fructose solutions in 
ascending order, each for 1 hour at RT. Spheroids were imaged in 115% 
w/v fructose in an 8-well coverglass slide.  
The HeLa T-Rex Flp-in cell line (a kind gift of Dr. Stephen Taylor, 
Faculty of Life Science, Manchester, United Kingdom) stably expressing 
COX8-AcGFP1 was created as described previously.[63] These cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 
g/L D-glucose, GlutaMAX and pyruvate (no. 31966-021, GIBCO, Life 
Technologies), supplemented with 10% (v/v) fetal bovine serum (no. 
10270, GIBCO, Life Technologies), 1% (v/v) penicillin/streptomycin 
(Gibco), 4 µg/mL blasticidin (Gibco), 200 µg/mL hygromicin (Invitrogen) 
in a humidified atmosphere of 95% air, 5% CO2 at 37 °C. To induce 
expression of COX8-AcGFP1, 1 µg/mL doxycyclin was added to the 
medium. Spheroids were formed by plating 200 µL of a 12,500 cell/mL 
single cell suspension of HeLa-AcGFP1 onto agarose (0.75% (w/v) in PBS) 
coated 96-well plates (Corning). Cells were allowed to aggregate for 4 days 
without motion, resulting in the formation of a single spheroid per well. 
On day 4, the spheroids were fixed and cut, or cleared as described above 
prior to confocal imaging. 
 
2.5.14 Confocal microscopy of spheroids 
 Imaging of spheroids was performed using a TCS SP5 confocal 
microscope equipped with an HC PL FLUOTAR 20x N.A. 0.5 dry objective. 
The ELP nanoparticles labeled with AlexaFluor647 were excited with a 
633 nm HeNe laser and emission was collected between 655 and 750 nm. 
The COX8-AcGFP1 construct expressed in the HeLa cells was excited by 
an argon laser at 488 nm, and emission was recorded between 500 and 
550 nm.  The samples co-stained with DAPI (Life Technologies) (excited 
with a 405 nm diode laser) and AlexaFluor488 phalloidin (Life 
Technologies) were imaged with a Zeiss LSM510 META confocal 
microscope (Carl Zeiss, Sliedrecht, The Netherlands) using a 63x oil 
immersion objective (N.A. 1.4). Images were analyzed with Image Pro Plus 
6.1 (Media Cybernetics, Rockville, MD, USA) and FIJI. 
2.5.15 Statistical analysis on spheroid data 
The number of independent experiments is marked by n, each 
experiment was performed in duplicate. Average values are represented 
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as mean ± SD. Values were tested for significance using the two-way 
analysis of variance (ANOVA) at 95% confidence level (p < 0.05), followed 
by Tukey’s multiple comparisons test (Graph Pad Prism software, version 
6), unless stated otherwise. Significant differences are indicated by *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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2.6 Appendix 
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Figure A2.1. Electrospray ionisation time-of-flight mass spectra and deconvoluted 
masses of ELP constructs. A) [A3G2-60] (expected mass 22782 Da, observed mass 22787 
Da); B) [I-60] (expected mass 25649 Da, observed mass 25648 Da); C) [I-60]-[A3G2-60] 
(expected mass 48198 Da, observed mass 48198 Da); D) [A3G2-60]-[I-60] (expected 
mass 48198 Da, observed mass 48198 Da); E) R8-[A3G2-60]-[I-60] (expected mass 49505 
Da, observed mass 49503 Da); F) [I-60]-[A3G2-60]-R8 (expected mass 49505 Da, 
observed mass 49504 Da).  
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Figure A2.2. Electrospray ionisation time-of-flight mass spectra and deconvoluted 
masses of ELP constructs modified with Alexa647. A) Alexa647-[A3G2-60]-[I-60], B) 
Alexa647-[I-60]-[A3G2-60]. Expected molecular mass for both constructs was 49037 Da. 
Measured mass was 49036 for both constructs. 
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Figure A2.3. Size-exclusion chromatography coupled to multi-angle light scattering and refractive 
index measurements. Top: Particles formed by [A3G2-60]-[I-60]. Bottom: Particles formed by [I-
60]-[A3G2-60]. 
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Figure A2.4. Determination of toxicity. Cell damage was determined via the fraction of propidium 
iodide positive fibroblasts (sub-G1 phase) after 24 h treatment with ELP nanoparticles. Error bars 
denote the standard error of the mean (SEM), n = 3. Significance was assessed using two-way 
ANOVA, followed by Tukey’s multiple comparisons test. Significant differences are indicated by *P 
< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.  
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Figure A2.5. Intensity of ELP nanoparticles in the spheroid, after background correction and 
normalization to similar peak intensities for 25% R8-ELP (2.5 µM, 10 µM, 25 µM) after 24 hours.  
 
Elastin-like peptide sequences 
[I-60]: 
MGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGY 
[A3G2-60]: 
MGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGG
GVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVP
GGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
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PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGY 
[A3G2-60]-[I-60]: 
MGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGG
GVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVP
GGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGY 
[I-60]-[A3G2-60]: 
MGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVP
GAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAG
VPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGY 
R8-[A3G2-60]-[I-60]: 
MGRRRRRRRRGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAG
VPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPG
AGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGV
PGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGA
GVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVP
GAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAG
VPGAGVPGAGVPGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
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VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGY 
[I-60]-[A3G2-60]-R8: 
MGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVP
GAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAG
VPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGRRRRR
RRRGY 
The first methionine of all sequences was cleaved off as expected.[64] 
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3.1 Introduction 
The variable region of heavy-chain antibodies found in cameloids, 
called VHH, is of great interest to the field of nanomedicine.[1–3] VHHs are 
thermo- and pH-stable proteins that are well tolerated by the human 
immune system. Their affinity can equal or even supersede that of 
conventional antibodies. In combination with cytotoxic agents, tumor-
targeting VHHs can specifically recognize and kill cancer cells.[4,5] 
Although their small size of 15-20 kDa allows deeper tissue penetration 
than conventional antibodies, it also results in a low circulation half-life. 
Nanoparticles decorated with VHHs have been developed to overcome the 
short blood-circulation time by increasing the hydrodynamic radius; the 
nanoparticle structure furthermore enables increased and more versatile 
drug loading.[6–8]  
 
Figure 3.1. Schematic representation of photodynamic therapy with self-assembling 
recombinant Llama heavy-chain antibody fragments (VHHs). Amphiphilic diblock elastin-
like polypeptides (ELPDB) are mixed at low temperatures with ELPDB functionalized with 
a photosensitizer and ELPDB functionalized with a VHH directed against the epidermal 
growth factor receptor (EGFR) at a known ratio. Upon heating to 37 °C, components 
spontaneously assemble into supramolecular structures simultaneously displaying VHHs 
and photosensitizer. Only EGFR expressing cells die after incubation with particles and 
subsequent illumination. Adapted with permission from reference[9]. 
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Decoration with VHHs usually follows particle formation, and 
encapsulation or attachment of a desired payload is typically achieved 
during particle formation or via an additional coupling step. This 
procedure makes it difficult to precisely assess and reproducibly control 
the resulting VHH concentration on the particles’ surface and the VHH-
to-payload ratio. Controlling these parameters is essential to achieve 
maximum efficacy with minimal side effects. Thus, there is a clear need 
for optimally defined and controlled VHH-displaying nanoparticles. 
Elastin-like polypeptides (ELPs) are biocompatible polypeptides that form 
amorphous aggregates in a temperature-dependent fashion as described 
in earlier chapters of this thesis.[10–12] They are composed of repeating 
pentameric units with the sequence glycine-X-glycine-valine-proline 
(GXGVP), where X can be any amino acid.[12,13] ELPs reversibly change 
from a soluble, disordered state below the transition temperature to an 
aggregated state consisting of type-II β-turns, type-I β-turns and β-
strands above the transition temperature.[14–17]. This transition 
temperature depends on the nature of the guest residue X, with 
hydrophilic residues raising the transition temperature and hydrophobic 
residues lowering it. ELP length, concentration and presence of salts also 
affect the transition temperature.[18]  
VHH-ELP fusion proteins have previously been synthesized with 
the aim to allow easy purification via inverse transition cycling (ITC), 
followed by VHH cleavage via introduced protease-sensitive tags.[19] ELP-
based nanoparticles have been prepared out of amphiphilic block 
copolymers, either by employing ELP diblock polypeptides with different 
guest residues and hence different transition temperatures[10,11,20], or by 
coupling ELPs with low transition temperature to hydrophilic polymers 
such as poly(ethylene glycol)[21]. Given the excellent bio-compatible 
properties of ELPs[22,23], we envisioned the possibility of integrating VHH-
ELP expression systems with the nanoparticle-forming potential of ELPs, 
yielding well-defined nanoparticles decorated with VHHs for biomedical 
applications. The ELP diblock (ELPDB) is composed of a ‘hydrophilic’ and 
a ‘hydrophobic’ block, terms that relate to the aggregation state of the 
ELP block at physiological conditions. The hydrophilic block consists of 
60 pentamers with alanine or glycine guest residues in a ratio of 3 to 2. 
The hydrophobic block contains 60 pentamers with isoleucine as guest 
residues. We used the VHH 7D12 that targets the epidermal growth factor 
receptor (EGFR).[24,25] Fc5, an unrelated VHH directed against the 
endothelial receptor Cdc50A[26], was used as control. Well-defined 
composite nanoparticles were reproducibly made by combining 7D12-
ELPDB or Fc5-ELPDB fusion proteins with ELPDB as molecularly dissolved 
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species at predetermined ratios, followed by heating the solution above 
the transition temperature of the hydrophobic block (Figure 3.1). The 
7D12-decorated ELP micelles were able to selectively target tumor cells 
that (over)express EGFR. Upon incorporation of a third ELPDB to which 
the photosensitizer IRDye700DX was conjugated, the composite 
nanoparticles could be used for highly effective and specific 
photoimmunotherapy (PIT). 
 
3.2 Results and discussion 
3.2.1 Design, cloning, expression and purification of (VHH)-ELPSBs 
The VHH-ELPDBs were prepared by cloning cDNA sequences 
coding for 7D12 and Fc5 in frame with ELPDB into a modified pET24a(+) 
vector as described in Chapter 2. An intervening cysteine residue was 
introduced as a handle for maleimide-based modification. Fusion 
proteins were successfully expressed in BLR(DE3) Escherichia coli cells 
by auto-induction (Figure 3.2). The sequences were preceded by a pelB 
leader sequence to direct the protein to the periplasm of E. coli.[27] The 
slightly oxidative milieu in the bacterial periplasm allowed the proper 
formation of internal disulfide bonds present in 7D12 and Fc5. Proteins 
were purified by inverse-transition cycling. ELPDB and VHH-ELPDB fusion 
proteins were obtained in > 95% purity with 20-50 mg/L yield (Table 3.1, 
Figure 3.2A).  
Table 3.1. Overview of proteins used in this study.  
Construct1 Yield 
(mg/L)2 
Theoretical 
mass (Da)3 
Observed 
mass (Da)4 
Labelling 
efficiency (%)5 
ELPDB 43 48198 48198 NA 
7D12- ELPDB 33 63049 63031/63049 NA 
Fc5-ELPDB 47 61903 61904 NA 
Alexa647-ELPDB NA 49037 49036 61 + 2 
PS-ELPDB NA 49951 49951 Quantitative 
7D12FL-ELPDB NA 63475 63457/63475 89 + 12 
Fc5FL-ELPDB NA 62330 62332 88 + 3 
1PS: Photosensitizer IRDye 700DX; FL: fluorescein.  2Yield specifies obtained product per 
liter of bacterial culture. 3The theoretical mass was determined with ExPASy 
(http://www.expasy.org/) excluding the N-terminal methionine for ELPDB or the pelB 
sequence for 7D12-ELPDB and Fc5-ELPDB. 4Mass found after deconvolution of mass 
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spectra. 5Percentage of labeled protein calculated by measuring fluorescence and 
protein mass/concentration after purification.  
Molecular masses of the protein samples were measured via 
electrospray ionization time-of-flight spectrometry (ESI-ToF) and agreed 
well with the predicted masses (Figure 3.2B). The N-terminal formyl 
methionine of ELPDB was cleaved off as expected.[28] For 7D12-ELPDB and 
Fc5-ELPDB, complete removal of the pelB sequence was observed. For 
7D12-ELPDB, an additional peak was found (Table 3.1). 7D12 contains 
an N-terminal glutamine, which is known to be converted in an 
autocatalytic or enzymatic step to pyroglutamate, resulting in the loss of 
ammonia, explaining the 18 Da difference.[29] Fc5-ELPDB, which does not 
contain N-terminal glutamine, did not show this side product (Table 3.1). 
 
3.2.2 Well-defined ELP nanoparticles displaying VHHs 
ELPDB nanoparticles were generated by gradually heating purified ELPDB 
to 37 °C after which hydrodynamic radius, radius of gyration and 
molecular weight were determined by size-exclusion chromatography 
followed by multi-angle light scattering (Figure 3.2C, A3.1). The 
hydrodynamic radius was approximately 24 nm (Table 3.2). The ratio of 
radius of gyration to hydrodynamic radius, an indication of the 
morphology of particles, was close to the theoretical value of a 
homogeneous sphere (0.778).[30,31] The mass distribution (with an average 
of 10.3 MDa) revealed that particles consisted of on average 214 
monomers per micelle, in agreement with comparable ELP particles.[12] 
By introducing a cysteine between the VHH and ELP sequence, we labeled 
the VHH-ELP fusion proteins with maleimide-fluorescein, creating 
VHHFL-ELPDB. In order to determine the maximum possible 
functionalization degree of the nanoparticles with VHH, we proceeded by 
systematically mixing ELPDB with different percentages of 7D12-ELPDB or 
Fc5-ELPDB. We observed a transition point at 50% 7D12FL-ELPDB and 
60% Fc5FL-ELPDB, respectively. Above this ratio, uncontrolled aggregation 
resulted in micrometer-sized aggregates (Figure 3.2D). The loss of 
particle stability can be explained by a geometrical model. Assuming a 
homogenous sphere with a radius of 24 nm, consisting of 214 monomers, 
each exposed monomer terminus occupies a surface of 33.8 nm2, or a 
sphere with a radius of approximately 2 nm. Since the radius of VHHs is 
around 2-3 nm[32], it is highly plausible that steric hindrance at high 
VHH-ELPDB ratios occurs, leading to rearrangement and/or aggregation. 
Incorporation of 10% VHH-ELPDB resulted in well-defined micelles with 
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physicochemical characteristics similar to ELPDB micelles (Table 3.2, 
Figure 3.2C, A3.1). 
 
Figure 3.2. Characterization of expressed proteins and formed nanoparticles. A) SDS-
PAGE of ELPDB (silver-stained, absence of aromatic amino acids in the ELP prevents 
Coomassie Brilliant Blue (CBB) staining), 7D12-ELPDB and Fc5-ELPDB (stained with CBB). 
B) Mass spectra and deconvoluted masses of i) ELPDB, ii) 7D12-ELPDB and iii) Fc5-ELPDB. 
C) Size-exclusion chromatography coupled to multi-angle light scattering of 
nanoparticles containing 10% 7D12-ELPDB. D) Evaluation of nanoparticle stability as a 
function of the fraction of 7D12-ELPDB or Fc5-ELPDB. X-axis represents the ratio of VHH-
ELPDB to ELPDB in the micelles. 
3.2.3 Binding and uptake of VHH-displaying nanoparticles 
A percentage of 10% ELP fusion protein should result in a display 
of approximately 20 VHH molecules per micelle. In order to mimic in vivo 
conditions we investigated the effect of the presence of human serum (HS) 
on the particle properties. ELP micelles in HS were shown to be stable for 
at least 2 h at 37 °C, and furthermore could be reversibly assembled in a  
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temperature-dependent manner (Figure A3.2). To separately follow the 
fate of VHH-ELPDB and ELPDB after cellular uptake of composite micelles, 
we labeled VHH-ELPDB with fluorescein-5-maleimide (FL), yielding 
7D12FL-ELPDB and Fc5FL-ELPDB. ELPDB was labeled with Alexa647-N-
hydroxysuccinimide (NHS) ester or IRDye700DX (PS) via NHS chemistry 
at the N-terminal amino group of ELPDB, yielding Alexa647-ELPDB and 
PS-ELPDB, respectively (Table 3.1, Figure A3.3).  
 
Table 3.2. Results from SEC-MALS measurements of the different nanoparticle 
formulations. 
Sample Rh 
(nm)1 
Rrms 
(nm)2 
ρ3 Mass 
(kDa)4 
Monomers 
/micelle5 
 
ELPDB 24.0 + 
0.5 
17.2 + 
0.1 
0.72 + 
0.02 
10300 + 
15 
214 
10% 7D12-ELPDB 24.6 + 
0.6 
17.4 + 
0.1 
0.71 + 
0.02 
9958 + 
17 
200 
10 % Fc5-ELPDB 24.3 + 
0.6 
19.8 + 
0.3 
0.81 + 
0.02 
10470 + 
16 
211 
1Hydrodynamic radius. 2Radius of gyration. 3Radius of gyration divided by the 
hydrodynamic radius. 4Average molecular mass. 5Monomers per micelle calculated with 
the weighted average molecular mass of ELPDB particles and monomers. 
FL-fluorescence-based flow cytometry, performed at 4 °C to 
prevent self-assembly into micelles and internalization, showed that 
monomeric 7D12FL-ELPDB, but not Fc5FL-ELPDB, effectively bound to 
EGFR-expressing A431 cells (Figure 3.3A), demonstrating that the 7D12 
moiety had retained its EGFR affinity. 7D12FL-ELPDB binding was slightly 
less than the 7D12FL control, indicating that the fusion to ELPDB may 
induce some steric hindrance at low temperatures. No binding to the 
EGFR-negative E98 cell line was observed for either 7D12FL-ELPDB or 
Fc5FL-ELPDB. These experiments clearly illustrate that the specificity of 
7D12 remains unchanged in the context of a fusion protein with ELPDB, 
and that ELPDB itself did not show aspecific binding to the cell lines 
tested. 
We next prepared micelles by heating a mixture of ELPDB, 
Alexa647-ELPDB and VHHFL- ELPDB (ratio 17:1:2) to 37 °C, and analyzed 
in vitro binding and uptake by measuring cell-associated FL fluorescence 
and Alexa647 fluorescence in flow cytometry experiments. 7D12FL-
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Alexa647-micelles associated with A431 cells but not with EGFR-negative 
E98 cells (Figure 3.3B).  
 
 
Figure 3.3. Cellular binding and uptake of VHHFL-ELPDB monomers and micelles, 
respectively. A) Cell-associated FL fluorescence as determined with flow cytometry after 
cold (4°C) incubation with 1 µM 7D12FL, 7D12FL-ELPDB or Fc5FL-ELPDB monomers. B) Cell 
associated FL and Alexa647 fluorescence as determined with flow cytometry after 37 °C 
incubation with 10 µM of 7D12FL-Alexa647-micelles or Fc5FL-Alexa647-micelles. C) Cell-
associated FL and Alexa647 fluorescence as determined with flow cytometry after 37 °C 
incubation with a concentration range of 7D12FL-Alexa647-micelles or Fc5FL-Alexa647-
micelles. * indicates significance with p<0.05, ** indicates significance with p<0.01.  
Incubation with composite 7D12FL-Alexa647-micelles resulted in 
44% higher cell-associated FL fluorescence relative to the situation in 
which equal concentrations of (monomeric) 7D12FL were used. Of note, 
incubation of A431 with 7D12FL-Alexa647-micelles also resulted in cell-
associated Alexa647 fluorescence (Figure 3.3B), and fluorescence 
microscopy revealed membranous and intracellular colocalization of both 
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Alexa647 and FL (data now shown), indicating that 7D12FL associated 
with the cells as part of intact micelles. Fc5FL-Alexa647-micelles showed 
little background association with A431 cells. These data show that 
composite 7D12FL-Alexa647-micelles that target tumor cells in an EGFR-
specific manner can be created. Binding of 7D12FL to EGFR is dependent 
on additional factors that are manifested at the cell surface[33], and since 
the VHH is internalized upon EGFR binding at 37 oC, it is difficult to 
quantitatively compare avidity effects of 7D12FL in micellar or monomeric 
form with suitable techniques such as isothermal titration calorimetry. 
In an effort to determine the CMC of the functionalized particles in vitro, 
we varied the concentration of all components, maintaining the same 
ratios. As shown in Figure 3C, 7D12-induced binding and uptake of 
Alexa647-ELPDB occurred at concentrations as low as 160 nM (VHH 
concentration of 16 nM), showing the presence of co-functionalized 
micelles and agreeing with results obtained by DLS. Using lower ELPDB 
concentrations for more accurate determination of the CMC was not 
feasible due to insufficient fluorophore signal-to-noise ratio. For a more 
accurate determination in vitro, we used the photodynamic therapy assay 
as described below. 
3.2.4 Photodynamic therapy with VHH-displaying nanoparticles 
To test whether EGFR-targeting ELPDB-based micelles can be 
used in a therapeutic manner, we prepared 7D12FL-micelles containing 
the photosensitizer IRDye700DX, conjugated to ELPDB (PS-ELPDB). To 
achieve maximum drug loading while maintaining sufficient targeting 
capacity, we prepared micelles containing 2% VHHFL-ELPDB and 98% PS-
ELPDB. Cell-killing efficiency of these micelles was compared to cell killing 
by monomeric 7D12, directly conjugated with IRDye700DX (7D12PS). 
7D12FL-PS-micelles actively killed cells in a light-dependent and 7D12-
specific manner at VHH concentrations as low as 120 pM, corresponding 
to an ELPDB concentration of 6 nM (Figure 3.4A). This indicates that 
micelles were still stable at this concentration. No toxicity was observed 
towards E98 cells, proving that 7D12-mediated binding and/or uptake is 
necessary for toxicity. Control micelles composed of 2% Fc5FL-ELPDB and 
98% PS-ELPDB showed no light-dependent toxicity upon illumination of 
either A431 or E98 cells. Importantly, no dark toxicity of either particle 
was found (Figure 3.4B). 
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Figure 3.4. Phototoxicity induced by VHHFL-PS-micelles in A431 and E98 cells. A) Relative 
cell viability after incubation and illumination with either 7D12FL-PS-micelles, Fc5FL-PS-
micelles or 7D12PS control. B) Relative cell viability after incubation without illumination 
with either 7D12FL-PS-micelles or Fc5FL-PS-micelles or 7D12PS control. Note the absence 
of dark toxicity. C) Fluorescence microscopy of DiD labeled A431 (green) and DiO labeled 
E98 (blue) (co-)cultures that are incubated with propidium iodide (red) after incubation 
with 30 nM 7D12-ELPDB or Fc5-ELPDB based PS-particles or  equimolar VHH 7D12PS and 
illumination. The scale bar denotes 100 µM, all images have the same magnification. 
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The cell-killing efficiency of 7D12-ELPDB particles pre-incubated 
in human serum at 37 °C for up to 4 hours, was surprisingly increased 
compared to particles diluted in DMEM/10%FCS (Figure A3.4), 
indicating that particles are stable and therapeutically active in 100% 
serum. The cell-specificity of the particles was further confirmed by co-
culturing DiO-labeled A431 (green) and DiD-labeled E98 (blue) cells and 
performing photo-immunotherapy as described above. By staining dead 
cells with propidium iodide, it was observed that only EGFR expressing 
A431 cells died (Figure 3.4C). 
Thus, targeted photoimmunotherapy with 7D12FL-PS-micelles is 
highly specific for target-expressing cells without harming neighboring 
target-negative cells. Assuming Poisson distribution, 2% VHH-ELPDB are 
sufficient to ensure that ~ 98% of all particles contain at least one 
targeting moiety. This leaves ample opportunities to combine several 
targeting groups in one particle and to further optimize their composition. 
 
3.3 Conclusion 
In conclusion, we have shown successful self-assembly of VHH-
ELPDB conjugates into micelles that can be used for targeted 
photodynamic therapy in vitro and potentially in vivo. The 24 nm radii of 
these micelles are considered excellent for nanomedicine; large enough 
to avoid rapid clearance from the circulation, yet small enough to 
extravasate and penetrate the intercellular space of tumors. The system 
allows implementation of multiple VHHs to generate multi-targeted drug 
delivery nanoparticles. Spontaneous micelle formation required 
concentrations as low as 6 nM. Further efforts will focus on validating 
the in vivo stability and activity of ELPDB nanoparticles. Combining the 
system with therapeutic and diagnostic molecules may result in an 
interesting theranostic platform.  
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3.5 Experimental section 
All chemicals and consumables were purchased from Sigma-Aldrich and 
used as received unless specified otherwise. 
3.5.1 Cloning and protein expression 
The VHHs 7D12 and Fc5 were used in this study; 7D12 is directed 
against EGFR, and Fc5 targets the luminal brain endothelial cell protein 
Cdc50A.[26] 7D12 and Fc5 were expressed as fusion products with ELPDB 
and 7D12-C-LPETG-HIS-VSV, hereafter 7D12, was produced as a control 
for the in vitro studies. The gene sequences encoding for ELPDB, pelB-Fc5-
ELPDB and pelB-7D12-ELPDB were cloned into pET-24a(+) (Novagen) 
expression vectors, by recursive directional ligation[34], transformed into 
E.coli BLR(DE3) cells and grown on agar plates containing 30 µg/mL 
kanamycin overnight at 37 °C. A single colony was grown overnight at 30 
°C, 250 rpm in LB medium containing 50 µg/mL kanamycin and 0.5% 
w/v D-glucose. The overnight culture was diluted to an OD600 of 0.1 in 
filter-sterilized AIM TB medium (Formedium) containing 6g/L glycerol, 
0.005% Antifoam 204 and 50 µg/mL kanamycin. Cells were grown at 300 
rpm at 37 °C for 20 hours. For 7D12-ELPDB and Fc5-ELPDB, the culture 
was shifted to 30 °C after 4 hours of growth. The pHENIX-7D12-C-
LPETG-HIS-VSV plasmid was transformed in E.coli strain ER2566. Cells 
were grown at 37 °C in 2xTY medium containing 3.5% (w/v) glycerol and 
50 µg/ml ampicillin till an OD600 of 0.6-0.8. Protein expression was 
induced with 1.0 mM isopropyl β-D-thiogalactoside (IPTG, Serva, 
Heidelberg, Germany) at 30 °C for 2.5 hrs.  
3.5.2 Protein extraction and purification 
Cells were collected by centrifugation at 2000 g, 4 °C for 30 
minutes. For cytoplasmic extraction, 1 g of wet cell pellet was 
resuspended in 2 mL lysis buffer (50 mM Tris-HCl pH 8.0, 25 mM NaCl, 
1 mM EDTA, 0.1 mM PMSF, cOmplete™ Protease Inhibitor Cocktail, 0.5 
mg/mL lysozyme) and incubated for 4 h at 4 °C. Lysis was followed by 
sonication on a Branson Sonifier 250 (power level 2-4, 12 cycles of 10 s 
sonication, 10 s breaks). Cell debris was collected by centrifugation at 
15,000 g at 4 °C for 15 min. Residual DNA was precipitated by adding 
0.5% w/v poly(ethylene imine) and removed by centrifugation at 15,000 
g at 4 °C for 15 min. ELPDB was precipitated by adding a saturated 
solution of (NH4)2SO4 up to 10-25 v/v%. Proteins were collected by 
centrifugation at 15,000 g at 4 °C for 15 min. The pellet was resuspended 
in phosphate buffered saline and centrifuged to remove insoluble 
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contaminants at 15,000 g at 4 °C for 20 min. This cycle was repeated 
until sufficient purity was achieved, usually after 2-4 cycles. ELPs were 
resuspended in MilliQ, desalted on a HiPrep 26/10 (GE Healthcare Life 
Sciences) with an AKTA Explorer 10 (GE Healthcare Life Sciences) at 1 
mL/min MilliQ. Residual salt concentration was below 0.001 mg/mL as 
determined by conductivity. The ELP solution was filter-sterilized with 
0.22 µm PES syringe filters (Nalgene) and freeze-dried. Yield was 
determined by weighing and varied around 43 mg/L culture (Table 1). 
For periplasmic extraction of 7D12, 7D12-ELPDB and Fc5-ELPDB, 
1 g of wet cell pellet was resuspended in 10 ml extraction buffer A (0.2 M 
TRIS pH 8.0, 0.5 mM EDTA, 20 w/v% sucrose, 0.1 mM PMSF, cOmplete™ 
protease inhibitor cocktail) and incubated for 30 min at 4 °C. Cells were 
pelleted by centrifugation at 2000 g for 30 minutes at 4 °C and the 
supernatant collected. The extraction was repeated with extraction buffer 
B (0.2 M TRIS pH 8.0, 15mM MgSO4, cOmplete™ protease inhibitor 
cocktail). Both supernatants were pooled before further processing. ELPs 
were precipitated as described above. Yield was determined by integration 
of the absorbance at 280 nm after separation with a Bio-Sec 5 300 Å 
column on an Agilent Bio-Inert HPLC with a flow rate of 1 mL/min PBS 
(Table 1). Aliquots were flash-frozen in liquid nitrogen and stored at -80 
°C. 7D12 was purified using Ni-NTA sepharose (IBA, Goettingen, 
Germany) by incubating the extraction supernatant with pre-equilibrated 
Ni-NTA sepharose for 1 h at 4 °C, and after washing, the proteins were 
eluted with 500 mM imidazole. The eluate was dialyzed against 50 mM 
Tris-HCl pH 7.5 and 150 mM NaCl. 
 
3.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were run under reducing conditions on 12% SDS-PAGE 
gels. Gels were either silver-stained in the case of ELPDB or stained with 
Coomassie brilliant blue (CBB) in the case of 7D12, 7D12-ELPDB and Fc5-
ELPDB. Purity was calculated from integrated pixel intensity after 
scanning the gels with ImageJ (https://imagej.nih.gov/ij/). 
3.5.4 Electrospray ionization – time of flight mass spectrometry (ESI-TOF) 
Mass was determined by ESI-TOF on a JEOL AccuTOF. Freeze-
dried samples were resuspended in MilliQ to a concentration of 10 µM, 
samples containing buffer were first desalted with MilliQ using Amicon 
Ultra-0.5 spin filter units (Millipore, 10 kDa MWCO). All samples were 
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acidified with 0.1% formic acid upon injection. Deconvoluted spectra 
were obtained using MagTran 1.03 b2.  
3.5.5 Size-exclusion chromatography followed by multi-angle light 
scattering (SEC-MALS) 
For SEC-MALS, the samples were separated on a Bio-Sec 5 1000 
Å column (Agilent) at 0.4 mL/min; the mobile phase was 0.15 M 
phosphate buffer 0.15 M NaCl pH 7.0 at 25 °C. Samples were equilibrated 
at 25 °C before injection of 20 µL. Light scattering data were collected on 
a DAWN HELEOS II MALS detector (Wyatt) and differential refractive 
index was measured on an Optilab T-rex refractometer (Wyatt). Dn/dc 
values were determined theoretically.[35]  
3.5.6 Alexa647-ELPDB and PS-ELPDB 
Freeze-dried ELPs were resuspended in 50 mM NaHCO3 pH 7.84. 
Alexa647-NHS ester or IRDye 700DX-NHS ester was resuspended in 
DMSO and added drop-wise to the protein solution. The molar ratio 
ELPDB to NHS ester was 1:1 in the case of Alexa 647 and 1:1.3 in the case 
of IRDye 700DX. The reaction was allowed to proceed for 4 hours at 21 
°C, 300 rpm. Unreacted dye was removed by dialysis against MilliQ using 
Amicon Ultra-0.5 spin filter units (Millipore, 10 kDa MWCO). The volume 
of the dialyzed protein samples was determined; efficiency of conjugation 
was determined by measuring dye concentration and weighing protein 
samples after freeze-drying. Concentrations of the dyes were determined 
at 650 nm (ε = 270,000 cm-1M-1) and at 689 nm (ε = 165,000 cm-1M-1) for 
Alexa647 and IRDye700 DX, respectively. Mass was determined by ESI 
TOF (Table 1). 
3.5.7 7D12FL and 7D12PS 
Fluorescein-5-maleimide and maleimide-PEG4-DBCO (Jena 
Bioscience, Jena, Germany) were conjugated to 7D12. The free thiol of 
the C-terminal cysteine in 7D12 was reduced by incubation with 20 mM 
TCEP for 15 min at RT. TCEP was removed by dialysis to 20 mM 
phosphate buffer pH 7.0, 150 mM NaCl and 5 mM EDTA in a 10 kDa 
MWCO centrifugal unit (Amicon, Millipore, Billerica, MS, USA). The VHH 
was incubated with either maleimide-5-fluorescein or maleimide-PEG4-
DBCO in a 1:3 molar ratio for 2 hrs at RT. Excess of maleimide probes 
was removed by dialysis to 50 mM Tris-HCl pH 7.5 and 150 mM NaCl in 
a 10 kDa MWCO centrifugal filter unit. IRDye700DX-NHS ester (LI-COR, 
Lincoln, NE, USA) was incubated with H2N-PEG3-N3 (Jena Bioscience, 
Self-assembling VHH-elastin-like polypeptides for photodynamic nanomedicine 
 
93 
Jena, Germany) in a 3:1 molar ratio for 7 h in 100 mM phosphate pH 8.6 
and 150 mM NaCl. Subsequently 7D12DBCO was incubated with PS-N3 in 
a 1:2 molar ratio o/n at RT. 7D12PS was purified by filter centrifugation 
in a 10 kDa MWCO filter unit using 50 mM Tris-HCl pH 7.5 and 150 mM 
NaCl. Protein purity was analyzed with SDS-PAGE gel electrophoresis, 
and concentration was determined by measuring ultraviolet absorbance 
at 495 or 689 nm for FL and PS conjugates, respectively. Aliquots were 
stored at -80 °C. 
3.5.8 7D12FL-ELPDB and Fc5FL-ELPDB 
7D12-ELPDB and Fc5-ELPDB were dialyzed to 0.1 M phosphate 
buffer pH 7.0. TCEP was added in a ratio of 20:1 to reduce the introduced 
cysteine. Fluorescein-5-maleimide was dissolved in DMSO and added to 
7D12-ELPDB at a ratio of 10:1. Unbound fluorescein-5-maleimide was 
removed by dialysis using Amicon Ultra-0.5 spin filter units (Millipore, 10 
kDa MWCO). Labeling efficiency and protein concentration were 
determined by integration of the absorbance at 280 and 495 nm after 
separation with a Bio-Sec 5 300 Å column on an Agilent Bio-Inert HPLC 
with a flow rate of 1 mL/min 0.1 M NH4HCO3 pH 8.62 (Table 1). Mass 
was determined by ESI TOF. 7D12FL-ELPDB and Fc5FL-ELPDB were flash-
frozen in liquid nitrogen and stored at -80 °C. 
3.5.9 Dynamic light scattering and stability of ELP particles in human 
serum 
Samples were diluted to a final concentration of 2 µM in PBS. 
Measurements were performed on a Malvern Zetasizer Nano. Samples 
were incubated for 5 minutes at 37 °C before data collection. Reported 
values are averages of 3 independent measurements. For particle 
stability, 10 µM of 2% 7D12FL-ELPDB, 98% PS-ELPDB was added to human 
serum. Human serum alone, to which an equal volume of PBS alone was 
added, was taken as control. Light scattering data was collected at 4 °C 
and 37 °C. Aggregation was inspected visually. Reported values are 
averages of 3 independent measurements. 
3.5.10 Cell culture 
Human epidermoid carcinoma A431 cells with amplification of 
EGFR and high grade astrocytoma E98 cells without EGFR expression 
were cultured in DMEM (Lonza, Basel, Switzerland), supplemented with 
10% FCS (Gibco) and 40 µg/ml gentamycin (Centrafarm, Etten-Leur, The 
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Netherlands). Cells were cultured at 37 °C in 5% CO2 in a humidified 
atmosphere. 
3.5.11 Flow cytometry 
To determine functionality of 7D12FL-ELPDB monomers, binding to 
A431 and E98 cells was determined under non-internalizing conditions 
at 4 °C. A431 and E98 cells were dissociated from culture flasks using 
10 mM EDTA in PBS and transferred to V-bottom shaped 96-wells 
microplates (BD Biosciences, Franklin Lakes, NJ, USA) at 5 x 105 cells 
per well. Cells were blocked with PBA (PBS, 0.5% BSA and 2% FCS) for 
10 minutes at 4 °C, after which they were incubated with 1 µM 7D12FL-
ELPDB or controls Fc5FL-ELPDB and 7D12FL in PBA for 30 min at 4 °C. 
After washing twice with cold PBA, cell-associated fluorescence was 
quantified on the Cyan flow cytometer (Beckman Coulter, Fullerton, CA, 
USA) with parameter FL-1. To determine uptake of VHH functionalized 
ELP nanoparticles and compare this to monomeric VHHs, A431 and E98 
cells were grown to 80% confluency in 8 well chambered Lab-Tek 
chambers (NUNC) after which cells were incubated with a concentration 
range of pre-warmed 7D12FL; 10% 7D12FL-ELPDB, 5% Alexa647-ELPDB, 
85% ELPDB particles or 10% Fc5FL-ELPDB, 5% Alexa647-ELPDB, 85% 
ELPDB particles in DMEM with 10% FCS for 30 min at 37 °C. Cells were 
washed twice with warm DMEM with 10% FCS, dissociated with trypsin 
and taken up in PBA, and cell associated fluorescence was quantified on 
the Cyan flow cytometer with parameters FL-1 and FL-8. Furthermore, 
cells were imaged after incubation with 10 µM of the particles (or 
equimolar VHH of 7D12FL) on the EVOS microscope using LED cubes GFP 
(fluorescein) and Cy5 (Alexa647). 
3.5.12 In vitro PDT assays 
A431 and E98 cells were cultured in clear 96 wells plates till 80% 
confluency. Then cells were incubated with a concentration range of pre-
warmed 7D12PS or 2% 7D12FL-ELPDB, 98% PS- ELPDB particles or 2% 
Fc5FL-ELPDB, 98% PS- ELPDB particles in DMEM with 10% FCS for 30 min 
at 37 °C. Cells were washed twice with warm DMEM with 10% FCS, and 
subsequently cells were illuminated with 100 mW/cm2 for 600 sec, 
reaching a total light dose of 60 J/m2, using a standardized light emitting 
diode device (690 ± 10 nm). Cells were incubated with 729 nM of 10% 
7D12-ELPDB 10% PS-ELPDB, 10% Fc5-ELPDB 10% PS-ELPDB particles or 
73 nM 7D12PS without subsequent illumination to determine dark 
toxicity. Cell viability was quantified using sulforhodamine B (SRB) 
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colorimetric assays, and results were expressed as cell viability relative 
to untreated illuminated cells. To examine selectivity of PDT-induced 
cytotoxicity, 5x105 cells were labeled with DiO (A431) or DID (E98) dye 
(Life technologies, Thermo Fisher Scientific, Waltham, MA, USA) 
according to manufacturers’ protocol. A431, E98 or 1:1 mixtures of the 
cells were plated and subjected to PDT with 30 nM of the particles or 
equimolar VHH concentrations of the 7D12PS control as described above. 
Four hours after illumination, cells were incubated with 1 µg/ml 
propidium iodide (Thermo Fisher Scientific, Waltham, MA, USA) in PBS 
for 15 min. Cells were visualized with the EVOS microscope using the 
RFP channel (propidium iodide), the GFP channel (DiO labeled cells) and 
the Cy5 channel (DiD labeled cells). 
3.5.13 Stability of ELPDB particles in human serum 
Stability of ELPDB particles in serum was evaluated further by 
incubating 2 % 7D12FL-ELPDB, 98 % PS-ELPDB or 2 % Fc5FL-ELPDB, 98 % 
PS-ELPDB (96 nM total concentration) in freshly obtained human serum 
(HS) for either 30 minutes, 2 hours and 4 hours at 37 °C.  Subsequently, 
the 96 nM stocks were diluted in DMEM with 10% FCS and PDT assays 
were performed with A431 cells as described earlier. Cell viability was 
compared to controls incubated with diluted serum without PS-micelles 
and with PS-micelles directly diluted in DMEM with 10 % FCS.  
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3.6 Appendix 
 
Figure A3.1. SEC-MALS of nanoparticles composed of ELPDB (left) and ELPDB with 10 % 
Fc5-ELPDB (right). 
 
 
Figure A3.2. Stability of ELPDB particles in human serum (HS). The temperature-
dependent change in derived count rate shows the formation of larger species, which 
increases the total amount of light scattered, conformant to the transition of ELPDB 
monomers to micelles (data not shown) in the sample containing ELPDB (HS + ELP). As 
aggregation into precipitates was not observed with visual inspection, these data 
strongly indicate stable particles in the timeframe shown. 
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Figure A3.3. Obtained masses from a) Fc5FL-ELPDB (expected mass 62330 Da, observed 
mass 62332 Da); b) 7D12FL-ELPDB (expected mass 63475 Da, observed mass 63457); c) 
Alexa647-ELPDB (expected mass 49037 Da, observed mass 49036 Da); d) PS-ELPDB 
(expected mass 49551 Da, observed mass 49951 Da). 
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Figure A3.4. Efficiency of PDT in A431 cells after incubation of the VHHFL-PS-micelles in 
human serum (HS). The graphs depict the relative cell viability after incubation with 
either 7D12FL-PS-micelles or Fc5FL-PS-micelles that are pre-incubated for 30, 120 or 240 
min in HS and subsequent illumination with a total light dose of 60 J/m2. HS only (HS 
control) and 7D12FL-PS-micelles or Fc5FL-PS-micelles directly diluted in DMEM (DMEM 
control) were taken as controls.   
Sequences of ELPs used (N-terminal fMet and pelB sequence in red): 
ELPDB: 
MGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGG
GVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVP
GGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGY 
7D12-ELPDB: 
MKYLLPTAAAGLLLLAAQPAMAQVKLEESGGGSVQTGGSLRLTCAASGRT
SRSYGMGWFRQAPGKEREFVSGISWRGDSTGYADSVKGRFTISRDNAKN
TVDLQMNSLKPEDTAIYYCAAAAGSAWYGTLYEYDYWGQGTQVTVSAEPK
TPKPQPAAAGSCGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVP
GAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAG
VPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPG
AGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGV
PGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGA
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GVPGAGVPGAGVPGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGY 
Fc5-ELPDB: 
MKYLLPTAAAGLLLLAAQPAMAEVQLQASGGGLVQAGGSLRLSCAASGFKI
THYTMGWFRQAPGKEREFVSRITWGGDNTFYSNSVKGRFTISRDNAKNTV
YLQMNSLKPEDTADYYCAAGSTSTATPLRVDYWGKGTQVTVSSAAAGSCG
AGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGV
PGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGG
GVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVP
GGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGY 
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4.1 Introduction 
Exposure of humans to reactive oxygen species (ROS) is caused 
by external sources, such as UV light, chemicals and via endogenously 
created by-products of cellular metabolism. An example of the latter 
process is the mitochondrial oxidative phosphorylation (OXPHOS) 
system[1], which is embedded in the inner mitochondrial membrane. 
OXPHOS produces superoxide anions (O2-) during the synthesis of ATP 
due to imperfect electron transfer.[2] Superoxide anions are precursors to 
other non-radical oxidants such as hypochlorous acid and hydrogen 
peroxide, and radical oxidants such as hydroxyl and superoxide radicals. 
In healthy cells, the level of ROS is regulated by small molecules such as 
α-tocopherol, ascorbic acid and glutathione, or enzymes such as 
superoxide dismutases and catalase.[3,4] Aging and diseases affect these 
mechanisms and can lead to detrimental oxidative stress[3,5]. 
Abnormalities in redox-controlled and thiol-based cell signaling, lipid 
peroxidation and protein carbonylation may occur.[6–9] In humans, this 
can lead to cellular malfunction, cell death, organ and organismal 
failure.[10]  
Mutation in genes coding for or related to the OXPHOS system 
often lead to oxidative stress due to increased ROS production and are 
generally classified as ‘mitochondrial disorders’.[11] Some sub-types of 
OXPHOS-related disorders also manifest themselves in the central 
nervous system. Patients affected by genetically acquired subacute 
necrotizing encephalomyelopathy, or Leigh Syndrome, suffer from the 
inability of the central nervous system to control normal organ function, 
typically resulting in death after around two years due to respiratory 
failure.[12–14] Small molecules that either act as antioxidants and/or as 
redox modulators may restore cellular balance and function, and alleviate 
symptoms.[15,16] One of the compounds currently in clinical trials for 
Leigh Syndrome is KH176, which has a dual functionality of an 
antioxidant and redox modulator, developed by Khondrion.[17]  
For treating diseases of the central nervous system, it is critical 
that the active compounds actually reach the brain in a sufficient dose, 
which may be hampered by the blood-brain barrier. The blood-brain 
barrier (BBB) is a tight endothelial cell layer, separating blood veins from 
brain tissue and the cerebrospinal fluid.[18] The formation of tight 
junctions prohibits the diffusion of hydrophilic molecules larger than 
300-500 Da. On the apical (blood) side, transporters and receptors 
mediate the transport of necessary metabolites and macromolecules 
across the BBB by trans-membrane transport or transcytosis, 
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respectively. One example is the transferrin receptor, which recognizes 
the iron transporter glycoprotein transferrin on the apical side and 
mediates its endosomal uptake and recycling.[19,20] Due to the lower pH 
after endosomal uptake, Fe3+ ions are released to ensure iron 
homeostasis. Despite the recycling mechanism for transferrin, various 
studies have shown that targeting the transferrin receptor mediates the 
transcytosis of macromolecules and nanoparticles.[21–25] However, since 
questions remain about the interference of this targeting approach with 
normal transferrin homeostasis and about the efficiency of transcytosis 
versus apical cycling, other ligands are investigated to induce 
transcytosis across the BBB.  
Recently, glucose-modified micelles were transported into the 
brain by glycaemic control of glucose-receptor presentation and recycling 
on the blood-brain barrier.[26] During periods of low blood sugar, glucose-
receptors are increasingly displayed on the apical side of the blood-brain 
barrier to ensure nutrient homeostasis in the brain. Kataoka et al. 
observed that nanoparticles displaying glucose may bind to these 
receptors and are actively shuttled across the BBB when blood sugar 
levels rise again. They showed that this is due to receptor balancing on 
the BBB itself: at high blood sugar levels, apical receptors are 
internalized, transcytosed and displayed on the basolateral (brain) side, 
releasing bound nanoparticles. Nanoparticles may also target other 
molecules on the BBB that are subject to continuous cycling, such as 
sugar-modified lipids (gangliosides). In previous work, our group used the 
peptide G23, which binds gangliosides GM1 and GT1b. When attached 
to polymersomes, it triggered uptake and transcytosis of nanoparticles in 
vitro and in vivo.[27,28]  
Instead of using particles made from non-degradable polymers, 
macromolecular carriers based on protein-based materials and polymers 
combine complete sequential control with bio-compatibility; using 
natural and unnatural amino acids, a wide range of nanoparticles can be 
created that have a programmable size, shape, surface structure and 
targeting moieties.[29,30] Elastin-like polypeptides (ELPs) are derived from 
natural elastin[29,31] and can form temperature-dependent nanoparticles 
as described in earlier chapters. The repeating unit is a pentamer of 
glycine-X-glycine-valine-proline (GXGVP), in which X can be any amino 
acid.[32,33] Below their respective transition temperature, ELPs are soluble 
and show a disordered structure. Above their transition temperature, 
they coacervate due to thermodynamically driven structural changes.[34–
36] By combining ELP blocks with different transition temperatures 
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recombinantly, ELP micelles can be created[37–42] that are stable in a 
physiologically relevant temperature range, i.e. 37 °C. 
Here we developed a carrier based on elastin-like peptides for the 
cellular delivery of KH176. They are further functionalized with G23 to 
induce transcytosis across the blood-brain barrier. 
 
4.2 Results & Discussion 
4.2.1 Covalent modification of ELPs with KH176 via copper-catalyzed click 
reaction 
ELPs [A3G2-60]-[I-60], [I-60]-[A3G2-60] and R8-[A3G2-60]-[I-60] 
were made as described in Chapter 2. (S)-6-hydroxy-2,5,7,8-tetramethyl-
N-((R)-piperidin-3-yl)chromane-2-carboxamide (KH176) was covalently 
attached to ELPs by a copper-catalyzed click reaction (CuAAC) (Figure 
4.1, A4.1, A4.2). Due to the lack of reactive side chains within the ELP 
amino acid sequence, the N-terminal amino acid was selectively 
converted into an azide by utilizing imidazole-1-sulfonylazide (Figure 
4.1).[43–46] KH176 was modified on the piperidine group via standard 
peptide chemistry with an alkyne group on a short poly(ethylene glycol) 
(PEG) spacer.  
 
Figure 4.1. Scheme of KH-ELP synthesis. The ELP diblock copolymer 1 was first modified 
with imidazole-1-sulfonylazide 2 to yield ELP-N3 3. (S)-6-hydroxy-2,5,7,8-tetramethyl-N-
((R)-piperidin-3-yl)chromane-2-carboxamide 4 was modified with alkyne PEG(4)-COOH 
5 to yield (S)-N-((R)-1-(3,6,9,12-tetraoxapentadec-1-yn-15-oyl)piperidin-3-yl)-6-
hydroxy-2,5,7,8-tetramethylchromane-2-carboxamide 6. The final product 7 was 
obtained by copper(I)-catalyzed azide-alkyne cycloaddition. 
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CuAAC was performed in buffered aqueous medium between KH176-
alkyne and ELP-N3. The reaction went to completion and yielded 70-80 % 
of the functionalized ELP after inverse-transition cycling purification to 
remove excess KH176 and sodium ascorbate, which may interfere with 
functional assays due to its antioxidative properties. 
4.2.2 Encapsulation of KH176 in R8-functionalized nanoparticles is 
orientation dependent 
Particle formation was tested with 10 % R8-[A3G2-60]-[I-60] (for 
efficient cell uptake as described in Chapter 2) and different ratios of 
KH176-[A3G2-60]-[I-60] and KH176-[I-60]-[A3G2-60]. Aggregation was 
observed when particles displayed both KH176 and R8 on the surface 
(Figure 4.2 and Table 4.1).  
  
Figure 4.2. Nanoparticle formation probed by dynamic light scattering. KH = KH176. 
Different ratios of KH-modified ELPs were mixed with R8-[A3G2-60]-[I-60]. All 
formulations result in stable nanoparticles, with the exception of particles displaying 
both R8 and > 20 % KH176   on the surface. Measurements were done at 37 °C in PBS 
pH 7.2-7.4 at 10 µM [ELP]. 
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Table 4.1. Hydrodynamic radii of different particle compositions. KH = KH176. 
Compositions are displayed as molar percentages. Hydrodynamic radii and standard 
deviations are derived from 3 independent measurements. 
Particle composition Hydrodynamic radius (nm) 
KH-[I-60]-[A3G2-60] 21.3 + 9.6 
10% R8-[A3G2-60]-[I60], 90 % KH-[I-60]-[A3G2-60] 24.6 + 11.5 
10% R8-[A3G2-60]-[I60], 40 % KH-[I-60]-[A3G2-60] 28.9 + 9.7 
10% R8-[A3G2-60]-[I60], 20 % KH-[I-60]-[A3G2-60] 22.1 + 7.8 
KH-[A3G2-60]-[I60] 23.3 + 9.3 
10% R8-[A3G2-60]-[I60], 90 % KH-[A3G2-60]-[I60] 277.8 + 160.3 
10% R8-[A3G2-60]-[I60], 40 % KH-[A3G2-60]-[I60] 22.4 + 13.7 
10% R8-[A3G2-60]-[I60], 20 % KH-[A3G2-60]-[I60] 22.1 + 7.8 
 
The interaction between KH176 and R8 induced aggregation of micelles, 
since particles formed by only KH176-[A3G2-60]-[I-60] were stable with 
low polydispersity. In order to achieve maximum loading of particles with 
KH176, 5 % R8-[A3G2-60]-[I-60] and 95 % KH176-[I-60]-[A3G2-60] 
(hereafter KH-ELP) was used as the final formulation. The capability of 
KH-ELP nanoparticles to rescue patient cells[17] from oxidative stress was 
tested in a glutathione-depletion survival assay. 
4.2.3 KH-ELP nanoparticles restore cell viability after oxidative stress 
induced by buthionine sulfoximine 
Buthionine sulfoximine (BSO) reduces cellular glutathione levels 
by inhibiting gamma-glutamylcysteine synthetase. This leads to 
increased oxidative stress in cells with mutations in the OXPHOS system, 
reducing cell viability. This can be measured by a calcein fluorescein 
assay; in healthy cells, calcein-acetoxy methylester is transported across 
the cellular membrane and converted by esterases to fluorescent calcein. 
If cellular function is impaired, less calcein/fluorescent signal is 
observed. Figure 4.3A shows calcein accumulation in cells after being 
challenged by BSO and treated with ELP nanoparticles containing 
KH176. Optimal effects were achieved at intermediate KH-ELP 
concentrations; the ability to rescue cells from BSO-induced oxidative 
stress was highest at 3 µM but decreased again at higher concentrations. 
This proved that no free KH176 was present after the purification of 
modified ELPs, since pure KH176 rescued cells independent of BSO 
concentration. This discrepancy between KH176 and KH-ELP particles 
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may stem from the impaired or delayed function of KH176 when 
encapsulated in nanoparticles. While its antioxidative property was likely 
unaffected by cellular localisation after endosomal uptake, its redox 
function is dependent on the interaction with peroxiredoxins present in 
the cytosol and mitochondria.[17] Therefore, KH176 would have to diffuse 
from the lysosome into the cytosol after the degradation of the 
proteinaceous carrier material. It is also possible that the modification of 
the piperidine ring may impact its effect as a redox regulator. ELP 
nanoparticles without KH176 were unable to rescue cells from BSA-
induced stress (Figure 4.3B).  
 
Figure 4.3. Quantification of the effect of co-treatment with KH-ELP nanoparticles on 
the BSO-induced decrease in the number of calcein-positive pixels per well. KH = KH176. 
Cells were co-treated with the indicated concentrations of KH-ELP nanoparticles and 
BSO for 24 h, washed, and stained with Calcein-AM. Next, the cells were imaged to 
extract the number of calcein-positive pixels per well A) after treatment with KH-ELP 
particles and B) after treatment with unmodified ELP particles. Error bars denote the 
standard error of the mean of 3 independent experiments for the KH-ELP nanoparticles 
and 2 independent experiments for the unmodified ELP nanoparticles. Significance was 
assessed using two-way ANOVA, followed by Tukey’s multiple comparisons test. 
Significant differences are indicated by *P < 0.05, **P < 0.01, ****P < 0.0001.  
4.2.4 G23-ELPs form stable nanoparticles when mixed with unmodified 
ELPs 
After establishing the potency of KH176-loaded nanoparticles, 
further modifications were necessary to ensure delivery across the blood-
brain barrier. We chose the peptide G23, which binds the gangliosides 
GM1 and GT1b on the BBB. The orientation of the peptide respective to 
the ELP construct may or may not be critical; in Chapter 2 we observed 
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no difference whether R8 is displayed via the N- or C-terminus, while in 
Chapter 3 single-domain antibody fragments were displayed on the N-
terminus to retain native their activity. While in this case the peptide is 
comparably small, overall stability might be affected. Indeed, we observed 
that the construct displaying the hydrophilic ELP+G23 on the N-terminus 
was less prone to degradation during expression/purification (Figure 
A4.3); we therefore chose to proceed with G23-[A3G2-60]-[I-60]. The 
peptide itself is quite hydrophobic; micelles formed by pure G23-[A3G2-
60]-[I-60] quickly aggregated (Figure 4.4).  
 
Figure 4.4. Dynamic light scattering results of nanoparticles (partly) displaying G23. A 
low percentage of G23 is tolerated on the particles’ surface. Higher percentages result 
in particle aggregation. Measurements were performed at 37 °C in PBS pH 7.2-7.4 at 10 
µM total protein concentrations; particles were incubated for 15 min before measuring. 
Surface hydrophobicity was reduced by mixing G23-modified ELPs with 
unmodified ones; as can be seen in Figure 4.4, nanoparticles with 25 % 
G23 form nanoparticles indistinguishable from particles solely consisting 
of unmodified ELPs, with hydrodynamic radii of 29.9 nm + 9.2 nm and 
29.9 nm + 5.2 nm. 
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4.2.5 Nanoparticles displaying G23 cross the blood-brain barrier in vitro 
In order to test the capability of G23-modified nanoparticles to 
cross the blood-brain barrier, an in vitro assay was performed using an 
immersed porous membrane on which HBMEC/ciβ cells were grown to 
confluency. Under appropriate conditions, these cells form tight 
junctions, preventing macromolecules to cross this artificial BBB, while 
expressing the receptors necessary for active transcytosis. Fluorescently 
labeled samples were subsequently added to the apical side, and signal 
was recorded in the basolateral culture medium and expressed as % 
transcytosis. Free diffusion would result in 75 % ‘transcytosis’, as the 
apical to basal culture medium volume ratio was 1 to 3.  
 
Figure 4.5. Transcytosis across an in vitro BBB assay. Results are plotted as mean average 
+ standard deviation. For 0 % G23 and 25 % G23, n = 6. For dextran and free fluorescein, 
n = 4. Statistical significance was tested with an unpaired two-side Student’s T-test, * p 
= 0.05. 
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As seen in Figure 4.5, the formed cell layer was impervious to 
fluorescently labeled dextran (violet bars, ~10 kDa) for the first two hours 
of the experiment with only 1.7 % + 1.0 of the fluorescent signal reaching 
the basolateral side. Without the cell layer, free diffusion could be 
observed (Figure A4.4). After 24 hours, about 35 % of the fluorescent 
signal permeated from the apical to the basolateral side of the cell layer, 
indicating that the assay layer performs well for up to 2 hours, but breaks 
down within 24 hours. Fluorescein was used as an unimpaired diffusion 
control. G23-modified and fluorescently labeled nanoparticles showed 
significantly faster transcytosis after 30 minutes and 1 hour than 
dextran, non-modified particles or fluorescein alone. This indicates that 
the transport of particles is G23-dependent and, since it is faster than 
the diffusion of free fluorescein, mediated by active transcytosis. As the 
fluorescent label was not attached to a G23-modified ELP diblock, but to 
other ELPs monomers, we concluded that the whole particle was 
transported across the cell layer and released. Of note, unmodified ELP 
particles also passed the in vitro BBB significantly in comparison to 
dextran, most likely indicating non-specific transcytosis. This 
phenomenon is expected to be negligible in vivo. 
4.2.6 Modification of nanoparticles reduces liver uptake and prolongs 
circulation time 
Before testing the capability of G23 to direct ELP nanoparticles 
across the BBB in vivo, we tested the biodistribution of non-modified 
particles. Since the surface charge of particles has a large influence on 
the clearance and other in vivo properties of nanoparticles[47–49], we 
chemically modified [A3G2-60]-[I-60] with either succinic anhydride or 
acetic anhydride (Figure 4.6). At physiological pH, these modifications 
should change the surface charge from positive to negative or neutral, 
respectively. Additionally, modification of the N-terminus should slow 
down proteolytic degradation during circulation. As expected, the 
modifications did not change the hydrodynamic radius of the particles 
significantly when probed by DLS (data not shown). In order to follow the 
biodistribution of ELP nanoparticles, they were modified with the chelator 
diethylene triamine pentaacetic acid (DTPA) for labelling with 111In prior 
to tail-vain injection into mice after particle formation. In addition to 
[A3G2-60]-[I-60], COOH-[A3G2-60]-[I-60] and CH3CO-[A3G2-60]-[I-60], the 
reverse sequence with the native C-terminus was used as well, since it 
was expected that a slight negative charge would be most advantageous. 
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Figure 4.6. Modification of [A3G2-60]-[I-60] with either a) succinic anhydride or b) acetic 
anhydride. The modification with succinic anhydride was completed to 90 %; a small 
peak of 8 NH2-[A3G2-60]-[I-60] (expected molecular mass 48198 Da, observed mass 
48198 Da) remains, while the majority has reacted to 9 COOH-[A3G2-60]-[I-60] (expected 
mass 48299 Da, observed mass 48298 Da). The reaction with acetic anhydride was 
quantitative; only 10 CH3CO-[A3G2-60]-[I-60] (expected mass 48241 Da, observed mass 
48241) was observed. 8)-10) Top: mass spectrum; bottom: deconvoluted mass. 
Blood samples were drawn after 1 h and 4 h, and the organ distribution 
of nanoparticles was investigated (Figure 4.7). Particles formed from 
Chapter 4 
114 
CH3CO-[A3G2-60]-[I-60] were still present in blood after 1 hour with 14 % 
+ 4 % injected dose per gram tissue (% ID/g). All other constructs were 
very quickly removed from circulation, with only about 1 % ID/g retained 
after 1 h. Uptake was most prominent in the liver and the spleen, with 
neutral particles being retained least in the liver. These results stand in 
contrast to in vivo application of ELP nanoparticles described so far; even 
though this is, to our knowledge, the first time a biodistribution of pre-
formed ELP nanoparticles is described, previous studies on ELP 
monomer blood circulation times and the application of ELP 
nanoparticles in other studies, as described in Chapter 1, would indicate 
the suitability of ELP as nano-sized delivery agents. 
 
Figure 4.7. Biodistribution of ELP nanoparticles in mice. Particles were injected (15 
mg/kg) into the tail-vain. Blood samples were taken after 1 h and 4 h and the organ 
distribution of 111In-labeled ELPs was determined after 4 h. 3 animals were used for each 
condition. Results are plotted as mean + standard deviation. 
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4.2.7 Nanoparticles displaying G23 are rapidly removed from the 
circulatory system and do not reach the brain 
Next, we evaluated G23-functionalized nanoparticles. A 
percentage of CH3CO-[A3G2-60]-[I-60] was replaced with G23-[A3G2-60]-
[I-60] and the biodistribution was repeated as described above. Again, 
neutral, non-functionalized particles were still detectable in the 
circulation after 1 h, though with increasing ratio of G23 particles were 
cleared faster from circulation; accumulation tended to increase in the 
liver and decreased in the spleen (Figure 4.8). 
 
Figure 4.8. in vivo biodistribution of G23-modified nanoparticles. Blood samples were 
taken after 1 h and 4 h and the organ distribution of 111In-labeled ELPs was determined 
after 4 h. 5 animals were used for each condition. Results are plotted as mean + standard 
deviation. 
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No significant increase in brain targeting was observed. The 
hydrophobicity of G23 may have increased the clearance of ELP 
nanoparticles to an extent that prevents recognition of the particles on 
the BBB. It is also possible that protein-corona formation on the particles 
masked the peptide, preventing it from binding to GM1 and GT1b for 
transcytosis. 
4.3 Conclusion 
In this chapter we have shown the creation of ELP nanoparticles 
that are able to rescue cells from oxidative stress. ELPs were modified via 
copper-catalyzed azide-alkyne cycloaddition to bear a small molecule 
currently in development as an orphan drug for Leigh syndrome. Particles 
encapsulating the compound and functionalized with a cell-penetrating 
peptide for cell uptake showed monodisperse micelles with hydrodynamic 
radii of about 25 nm. Displaying the compound on the surface together 
with the CPP resulted in aggregation, highlighting the importance of 
control over drug localization within the nanoparticle. Patient cells 
experiencing oxidative stress through BSO were successfully rescued by 
anti-oxidant loaded nanoparticles in a concentration-dependent manner; 
interestingly, an intermediate concentration was most advantageous. 
Due to the dual action of the compound used, which can act both as an 
antioxidant and redox modulator, intracellular localization is likely 
important.[17] Adding e.g. pH labile linker between ELP and KH176 could 
improve the efficacy of the formed nanoparticles. 
In order to target the brain, ELP nanoparticles were modified with 
a BBB targeting peptide, G23. In vitro BBB transcytosis was shown with 
a permeation assay using HBMEC/ciβ cells cultured to form a tight 
endothelial layer. Active transport of G23-displaying nanoparticles 
showed faster transcytosis than non-modified nanoparticles or the 
diffusion of small molecule across the barrier. In vivo, we observed 
relatively short circulation times that were enhanced by surface 
modifications. Transforming the amino group into a methyl ketone was 
most advantageous in terms of blood half-life. Unfortunately, when these 
particles were modified with G23, we did not observe increased brain 
uptake. Instead, clearance was enhanced, possibly due to the 
hydrophobic nature of the targeting peptide. This shows that further 
development is necessary; possibly crosslinking or adapting the corona 
would result in better circulation properties.  
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4.5 Experimental section 
All materials were obtained from Sigma-Aldrich and used as 
delivered unless stated otherwise. (S)-6-hydroxy-2,5,7,8-tetramethyl-N-
((R)-piperidin-3-yl)chromane-2-carboxamide hydrochloride was provided 
by Khondrion BV. Imidazole-1-sulfonylazide hydrochloride was 
synthesized as described previously by Goddard-Borger et al.[50]  
 
4.5.1 Electrospray ionization – time of flight mass spectrometry (ESI-TOF) 
Mass was determined by ESI-TOF on an AccuTOF (JEOL) or a 
Xevo G2QTOF (Waters). Freeze-dried samples were resuspended in MilliQ 
to a concentration of 10 µM, samples containing buffer were first desalted 
with MilliQ using Amicon Ultra-0.5 spin filter units (Millipore, 10 kDa 
MWCO). All samples were acidified with 0.1% formic acid upon either 
direct injection or on-line fractionation on a Polaris 3 C18 column 
(Agilent) with water/acetonitrile gradients. Deconvoluted spectra were 
obtained using MagTran 1.03 b2 or Mass Lynx v4.1. 
 
4.5.2 Expression and purification of ELPs 
The ELP constructs were cloned by recombinant DNA technology 
as previously described.[51] Oligonucleotides coding for the G23 (sense = 
5’-acggtatttccacagggtagacaggatgttcaggtggcccatatgtactcctccttcttaaagttaaa 
caaaattattt-3’ and antisense = 5’-ctagaaataattttgtttaactttaagaaggaggagtac 
atatgggccacctgaacatcctgtctaccctgtggaaataccgtgg-3’) were inserted into a 
pET24a(+) plasmid (Invitrogen) after digestion with BseRI and XbaI. 
Recursive directional ligation as described in Chapter 1 and 2 was used 
to combine G23 with ELP coding sequences. Plasmids were transformed 
into E.coli BLR(DE3) (Invitrogen) cells and grown on agar plates 
containing 30 µg/mL kanamycin overnight at 37 °C. A single colony was 
grown overnight at 23 °C, 250 rpm in LB medium containing 50 µg/mL 
kanamycin and 0.5% w/v D-glucose. The overnight culture was diluted 
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to an OD600 of 0.1 in filter-sterilized AIM TB medium (Formedium) 
containing 6g/L glycerol, 0.005% Antifoam 204 and 150 µg/mL 
kanamycin. Cells were grown at 300 rpm at 30 °C for 20 hours. For G23-
modified ELPs, the overnight culture was diluted to an OD600 of 0.1 in 
filter-sterilized TB medium and induced with 1 mM IPTG at an OD600 of 
around 1 for 2 hours at room temperature. Cells were collected by 
centrifugation at 4000 g, 4 °C for 30 minutes. For cytoplasmic extraction, 
1 g of wet cell pellet was resuspended in 10 mL phosphate buffered saline 
pH 7.4. Cells were lysed by homogenization with an EmulsiFlex-C3 
(Avestin). Cell debris was collected by centrifugation at 15,000 g at 4 °C 
for 15 min. Residual DNA was precipitated by adding 0.5% w/v 
poly(ethylene imine) and removed by centrifugation at 15,000 g at 4 °C 
for 15 min. ELPs were precipitated by adding a saturated solution of 
(NH4)2SO4 up to 10-25 v/v% either at room temperature or 4 °C. Proteins 
were collected by centrifugation at 15,000 g at 4 °C or RT for 15 min. The 
pellet was resuspended in phosphate buffered saline and centrifuged to 
remove insoluble contaminants at 15,000 g at 4 °C for 20 min. This 
inverse-transition cycling (ITC) was repeated until sufficient purity was 
achieved, usually after 2-4 cycles. ELPs were resuspended in MilliQ, 
purified on a HiLoad 16/600 Superdex 200 and desalted on a HiPrep 
26/10 (GE Healthcare Life Sciences) with an AKTA Explorer 10 (GE 
Healthcare Life Sciences) at 1 mL/min PBS and 4 mL/min MilliQ, 
respectively. Residual salt concentration was below 0.01 mg/mL as 
determined by conductivity. The ELP solution was filter-sterilized with 
0.22 µm PES syringe filters (Nalgene) and freeze-dried. Yield was 
determined by weighing and varied between 25-100 mg/L bacterial 
culture. 
 
4.5.3 Synthesis of ELP-(S)-N-((R)-1-(1-(1H-1,2,3-triazol-4-yl)-2,5,8,11-
tetraoxatetradecan-14-oyl)piperidin-3-yl)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxamide 
The ELP diblock copolymers 1 (50 mg each, 1.04 µmol) were 
dissolved in MilliQ and imidazole-1-sulfonylazide hydrochloride 2 was 
added to a 50 fold excess (10.5 mg, 50 µM) to yield ELP-N3 3. The reaction 
proceeded for 4 hours at room temperature. The ELPs were purified by 
inverse transition cycling as described above, dialysed to MilliQ and 
lyophilised. (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-
yl)chromane-2-carboxamide hydrochloride (300 mg) was partitioned 
between saturated aqueous sodium carbonate solution (20 mL) and 
CH2Cl2 (20 mL). The organic layer was dried with Na2SO4 and evaporated 
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to dryness to afford (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-
yl)chromane-2-carboxamide free base 4 as off-white solid. Under inert-
gas atmosphere, (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-
yl)chromane-2-carboxamide free base (122 mg, 0.37 mmol), 
alkyne-PEG(4)-COOH 5 (149 mg, 0.57 mmol), OxymaPure® (11 mg, 0.08 
mmol) and EDCI (109 mg, 0.57 mmol) were dissolved in dry DMF (5 mL). 
The reaction mixture was cooled on an ice-water bath and N-ethyl-N′-(3-
dimethylaminopropyl) carbodiimide hydrochloride (short: EDCI, 86 mg, 
0.449 mmol) was added in one portion. The cooling bath was removed 
and stirring was continued at room temperature overnight. Then, the 
reaction mixture was quenched by adding saturated aqueous ammonium 
chloride solution and the aqueous phase was extracted with EtOAc (3x 
10 mL). The combined organic extracts were consecutively washed with 
saturated aqueous sodium bicarbonate solution and brine (20 mL each), 
dried (Na2SO4) and evaporated to dryness. After purification via flash 
column chromatography (EtOAc/MeOH 98/2→95/5), ((S)-N-((R)-1-
(3,6,9,12-tetraoxapentadec-1-yn-15-oyl)piperidin-3-yl)-6-hydroxy-
2,5,7,8-tetramethylchromane-2-carboxamide 6 was obtained as light 
yellow oil (mixture of rotamers, 176 mg, 82%). Rf = 0.40 (EtOAc/MeOH 
9/1); 1H NMR (CHLOROFORM-d, 400MHz): δ = 6.52 - 6.73 (m, 1 H), 5.38 
(br. s., 1 H), 4.17 - 4.21 (m, 2 H), 4.03 - 4.10 (m, 1 H), 3.84 - 3.99 (m, 1 
H), 3.27 - 3.77 (m, 16 H), 3.16 - 3.25 (m, 1 H), 2.94 - 3.10 (m, 2 H), 2.44 
- 2.69 (m, 3 H), 2.42 (t, J=2.3 Hz, 1 H), 2.06 - 2.39 (m, 11 H), 1.43 - 1.92 
ppm (m, 11 H); ESI-MS m/z: 575.3 [M+H]+, 597.3 [M+Na]+.  
ELP-N3 3 (45 mg, 0.93 µmol) was dissolved in 10 mM potassium 
phosphate buffer pH 7.0. 3 molar equivalents of 6 (1.6 mg, 2.8 µmol) were 
dissolved in 10 mM potassium phosphate buffer pH 7.0 and added to 3. 
Additionally, CuSO4 (final concentration 3 mM), sodium ascorbate (final 
concentration 50 mM) and tris(3-hydroxypropyltriazolylmethyl)amine 
(final concentration 12 mM) were added to the reaction. The reaction was 
performed at RT for 2 hours, after which the ELP-KH conjugate was 
purified with ITC and desalted as described above. Mass was confirmed 
by ESI-ToF. 
 
4.5.4 Dynamic light scattering  
Samples were diluted in PBS pH 7.4 to 10 µM. Measurements 
were performed on a Malvern Zetasizer Nano. Samples were incubated 
for 5 minutes at 37 °C before data collection. Reported values are 
averages of 3 independent measurements.  
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4.5.5 Alexa647-labeled ELPs 
Freeze-dried ELPs were resuspended in 50 mM NaHCO3 pH 7.6-
7.9. Alexa647-NHS ester was resuspended in DMSO and added drop-wise 
to the protein solution. The molar ratio ELP to NHS ester was 1:2. The 
reaction was allowed to proceed for 4 hours at 21 °C, 300 rpm. Unreacted 
dye was removed by dialysis against MilliQ using Amicon Ultra-0.5 spin 
filter units (Millipore, 10 kDa MWCO). The volume of the dialyzed protein 
samples was determined; efficiency of conjugation was determined by 
measuring dye concentration and weighing protein samples after freeze-
drying. Concentrations of the dyes were determined at 650 nm (ε = 
270,000 cm-1M-1). Mass was confirmed by ESI TOF. 
 
4.5.6 In vitro BBB assay 
HBMEC/ciβ cells were cultured at 33 ˚ C, 5% CO2 and 95% relative 
humidity atmosphere in CSC complete medium (CSC Certified™) 
activated for use with 2% (v/v) CSC CultureBoost (CSC Certified™) 
containing CSC Non-Recombinant Growth Factors. The cells were 
passaged every 3-4 days at ~90% confluency up to passage number 15. 
After aspirating the medium cells were washed once with 3 mL trypsin-
EDTA and subsequently trypsinized with 1 mL trypsin-EDTA for 1-2 
minute(s) to detach the cells from the 75 cm2 cell culture flask). 9 mL 
medium was added to the flask to stop trypsinization. 3 mL cell 
suspension was added to fresh medium in a new flask up to a maximal 
volume of 15 mL. The flask was pre-coated with 10 mL collagen Type l 
solution (1.15% collagen type l from rat tail (v/v) and 0.12% (v/v) acetic 
acid in distilled water) and incubated for 30 min at 37 ˚C. The number of 
cells per mL was determined using an automated cell counter. 50.000 or 
100.000 cells were seeded in 500 µL medium on pre-coated transwells 
(ThinCerts™ 12 well, Pore size 3.0 µm Greiner Bio-One) in a 12 well 
polystyrene culture plate (CELLSTAR, Greiner Bio-One GmbH). The 
transwells were coated with 1 mL collagen Type l solution and incubated 
30 minutes 37 ˚C. The plate was incubated overnight at 33 ˚C and 
subsequently at 37 ˚C for 11 days. The medium was exchanged, 
supplemented with 200 µm Hydrocortisone (Sigma-Aldrich), three days 
after seeding and after that every other day. 
On day 12 after seeding HBMEC/ciβ cells on the transwells, the 
medium was aspirated both apically and basolaterally. Fresh medium 
was pipetted apical of the transwell containing either the tracers 
Rhodamine-Dextran (Molecular probes® Thermo Fisher scientific) and 
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Fluorescein (Molecular probes® Thermo Fisher scientific) or an ELP sample 
creating a total volume of 500 µL. Subsequently 1500 µL medium was 
pipetted basolateral of the transwells. ELP samples always contained 
10% ELP-Alexa®Fluor 647. The samples were prepared on ice and 
subsequently heated at 37 °C for 5 minutes. Incubation with ELPs and 
tracers proceeded for 24 hours at 37 ˚C. Between the start of the 
experiment and 24 hours 100 µL samples were taken from the basolateral 
side after which 100 µL fresh medium was added. After 24 hours a 100 
µL sample was also taken apically which was the ending of the 
experiment. All samples were collected in a 96 well plate (Falcon®-
corning, 96 well, black/clear, Tissue Culture Treated Plate Flat Bottom 
with Lid). The fluorescent signal per well was measured on a (Synergy™ 
2 microplate reader, BioTek). Rhodamine-Dextran was excited at 540 nm 
and fluorescent emission was detected at 620 nm. Fluorescein was 
excited at 485 nm and fluorescent emission was detected at 528 nm. 
Alexa®Fluor 647 was excited at 640 nm and fluorescent emission was 
detected at 675 nm.  
 
4.5.7 Glutathione Depletion Assay  
Cells were seeded at a density of 3500 cells/well into 96 wells 
black plates (665090, Greiner Bio-one) in a humidified atmosphere of 
95% air – 5% CO2 at 37 °C. After 24 h, the cells were treated with culture 
medium containing semi-logaritmic concentrations of buthionine 
sulphoximine (BSO, #B2515, Sigma Aldrich), ELP nanoparticles (with 
and without KH176 covalently attached) and 1 µM KH176 for 24 h in a 
humidified atmosphere of 95% air – 5% CO2 at 37 °C. Subsequently, cells 
were gently washed twice with 100 µL of assay medium. Cells were loaded 
with 100 µL 2.5 µM final concentration of Calcein-AM (#65-0853-39, 
Affimetrix eBioscience) for 20 min in a humidified atmosphere of 95% air 
– 5% CO2 at 37 °C. Again, the cells were washed two times with 100 µL 
of assay medium. Images of the Calcein-AM staining were acquired using 
an environmentally controlled (37 °C and 5 % CO2) BD Pathway 885 
microscopy system. Images were analyzed following the protocol 
described in Iannetti et al., 2016.[52] In contrast to the protocol described, 
excitation light was directed to the cells via an air (dry) 10× objective 
instead of an air 40× objective.  
 
4.5.8 Modification of ELPs with acetic anhydride and succinic anhydride 
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ELP was dissolved in DMF and 5 molar equivalents of pyridine 
and either acetic anhydride or succinic anhydride was added. The 
reaction proceeded for 2 hours at RT, after which 1 volume equivalent of 
water was added to the solution. Modified ELPs were purified by ITC and 
desalted as described above. Mass was confirmed with ESI-ToF. 
 
4.5.9 Modification of ELPs with DTPA and 111In labeling 
Acid washed plastic-ware was used for all DTPA labeling steps 
and described buffers were treated with Chelex (Bio-Rad). [A3G2-60]-[I-
60] was modified with S-2-(4-isothiocyanatobenzyl)-diethylene-triamine 
pentaacetic acid (Macrocyclics) under basic conditions (100 mM NaHCO3 
pH 9.5) for 60 minutes at RT and 60 minutes at 4 °C. The conjugate was 
dialyzed against 250 mM NH4Ac pH 5.5 in a Slide-A-Lyzer 
(TermoScientific) with a MWCO of 3 kDa for 24 hours. The buffer was 
refreshed after 2 h, 4 h and 20 h. Typically, 1 µg of ELP was labeled with 
an 111In dose of 37 kBq in 250 mM 2-(N-morpholino)ethanesulfonic acid 
pH 5.5 for 20 minutes at room temperature. Material was used without 
further purification if labeling efficiency was above 95 % as determined 
by thin layer chromatography using 0.15 M citrate buffer, pH 6.0, as the 
mobile phase and mixed at 4 °C with unlabeled ELPs before injection. 
Typically, 2 mol% of ELPs nanoparticle compositions for in vivo studies 
were labeled with 111In. 
 
4.5.10 In vivo biodistribution 
Female balb/c mice (Charles River) (age between 6-8 weeks, 12-
20 g) were injected with 200 µL ELP nanoparticles solution (0.1-1 mBq) 
via tail-vain injection. 1 h after injection, blood was collected by a tail 
puncture. 4 h after injections, mice were euthanized by CO2/O2 
asphyxiation. Tissues of interested were dissected and the amount of 
signal from injected radiotracer was compared to a standard and 
determined as percentage injected dose per gram tissue (%ID/g). 
 
 
 
 
 
 
Elastin-like polypeptide nanoparticles for drug delivery across the blood-brain barrier 
 
123 
4.6 Appendix 
 
Figure A4.1. Mass spectrum and deconvoluted mass of a) [I-60]-[A3G2-60] (expected 
molecular mass 48197 Da, observed mass 48197 Da), b) N3-[I-60]-[A3G2-60] (expected 
mass 48223 Da, observed mass 48223 Da) and c) KH176-[I-60]-[A3G2-60] (expected 
mass 48798 Da, observed mass 48797 Da). 
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Figure A4.2. Mass spectrum and deconvoluted mass of a) [A3G2-60]-[I-60] (expected 
molecular mass 48197 Da, observed mass 48197 Da), b) N3-[A3G2-60]-[I-60] (expected 
mass 48223 Da, observed mass 48223 Da) and c) KH176-[A3G2-60]-[I-60] (expected mass 
48798 Da, observed mass 48798 Da). 
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Figure A4.3. Mass spectrum and deconvoluted mass of a) [I-60]-[A3G2-60]-G23 
(expected mass 49781 Da, observed masses 49781 Da and 49113 Da) and b) G23-[A3G2-
60]-[I-60] (expected mass 49781 Da, observed mass 49780 Da). 
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Figure A4.4. Diffusion across an in vitro BBB assay without cell layer. Results are plotted 
as mean average + standard deviation. For 0 % G23 and 25 % G23, n = 3. For dextran and 
free fluorescein, n = 3. Equilibrium is reached at 75 % signal on the basolateral side due 
to the respective apical to basolateral volume ratios.  
Sequences: 
G23-[A3G2-60]-[I-60]: 
MGHLNILSTLWKYRGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVP
GAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAG
VPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPG
AGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGV
PGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGA
GVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVP
GAGVPGAGVPGAGVPGGGVPGGGVPGIGVPGIGVPGIGVPGIGVPGIGVPG
IGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
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VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGY 
[I-60]-[A3G2-60]-G23: 
MGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVP
GIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGV
PGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIG
VPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGI
GVPGIGVPGIGVPGIGVPGIGVPGIGVPGIGVPGAGVPGAGVPGAGVPGGG
VPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPG
GGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGAGV
PGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVPGA
GVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAGVP
GAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGAGVPGAG
VPGAGVPGGGVPGGGVPGAGVPGAGVPGAGVPGGGVPGGGVPGHLNILS
TLWKYRGY 
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5.1 Introduction 
Elastin-like polypeptides (ELPs) have unique self-assembly 
properties.[1,2] As described in earlier chapters, ELPs show a reversible, 
temperature-dependent coacervation behavior. Upon raising the 
temperature above the transition temperature, they undergo a 
conformational transition from a disordered, soluble to a spiral-like state 
consisting of type-II β-turns, type-I β-turns and β-strands, exposing the 
(hydrophobic) side chains.[3] This behavior is thermodynamically driven; 
by changing the guest residue or length of the polymer, its concentration 
or the electrolyte concentration, it is possible to tune the transition 
temperature Tt of ELPs.[1,4] Nanoparticles may be formed by using diblock 
ELPs that have been designed with a ‘hydrophilic’ ELP sequence (high 
transition temperature) and a ‘hydrophobic’ ELP domain (low transition 
temperature).[5–8] These diblock ELPs exist as micellar structures between 
the two respective transition temperatures. In contrast to comparable 
synthetic temperature-responsive polymers such as poly(N-
isopropylacrylamide)[9], each ELP block shows separate transitions even 
when blended.[10] The exclusive interaction of one ELP species with itself 
is even retained in complex surroundings such as the cytoplasm.[11] This 
normally prevents the co-assembly or co-precipitation[12] of different ELPs 
into mixed macromolecular assemblies. While the hydrophilic part of an 
ELP diblock may be modified in order to create functionalized ELP 
micelles displaying various moieties, modification of the hydrophobic 
block could lead to a significant change in its transition temperature, 
leading to separate species when particles are formed.  
We hypothesized that this issue could be circumvented by 
kinetically trapping different ELP species into co-assembled structures 
(Scheme 5.1). Traditionally, if two separate ELP species are heated slowly 
from a dissolved state (low temperature, Scheme 5.1A), each block will 
go through its unique transition temperature and assemble independent 
of the other blocks. If there is e.g. an ELP monoblock that has a lower 
transition temperature than either block of an ELP diblock copolymer, it 
will aggregate first (Scheme 5.1B). If then the temperature is raised 
further, the diblock will assemble independently of the monoblock, 
leading to segregated assembly states (Scheme 5.1D). The pathway A  
B  D in Scheme 5.1 is the usual behavior of an ELP mixture. Cooling 
would dissolve ELPs in the opposite order (Scheme 5.1 D  B  A).  
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Scheme 5.1. Pathway dependent self-assembly of a monoblock polypeptide with a low 
transition temperature and a diblock polypeptide with a high and low transition 
temperature domain. A) In their dissolved state at low temperatures or low salt 
concentration, both biopolymers are fully hydrated and show a disordered structure. 
The first possible pathway goes from A via B to D: slow heating or incremental addition 
of salt triggers the transition of the hydrophobic monoblock selectively and leads to 
coacervation of the monoblock in presence of dissolved diblock polypeptide as 
presented in B. Upon further heating or addition of salt, the diblock polypeptide forms 
a micellar morphology next to the monoblock aggregates as shown in D. This process is 
fully reversible upon cooling or removal of salt. The other possible pathway goes from A 
to C: if the system is heated from the dissolved state rapidly above the transition 
temperatures of both the hydrophobic monoblock and the hydrophobic block in the 
diblock copolymer, a co-operative stable state C is reached, in which the hydrophilic part 
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of the diblock stabilizes the coacervates formed. This is also possible by abruptly adding 
salt. This state is reversible and upon cooling, the dissolved state A is reached via state 
B.  
If however the solution of dissolved ELPs is heated rapidly, triggering the 
transition temperatures of the two hydrophobic blocks simultaneously, 
they may interact and form co-assembled structures (Scheme 5.1C). In 
the case of a monoblock and a diblock ELP, the monoblock would be 
accommodated in the hydrophobic core of the diblock micelle, which 
would lead to an increase in size of this assembly (Scheme 5.1 A  C). 
This behavior could also be triggered by adding or removing electrolytes. 
Cooling these co-assembled micelles would lead to disassembly upon 
reaching the transition temperature of the hydrophobic block of the 
diblock ELP. This would lead to larger aggregates of the monoblocks since 
they are not stabilized anymore within the particles (Scheme 5.1 C  B). 
Further cooling would then dissolve all ELPs (Scheme 5.1 B  A). In this 
chapter, we investigate this pathway-dependent co-assembly and show 
that it has potential for the encapsulation of macromolecular cargo in 
ELP micelles with a high efficiency. 
 
5.2 Results & Discussion 
5.2.1 Transition temperatures of [A3G2-60]-[I-60] and [I-60] 
In order to investigate the co-assembly behavior of mono and 
diblock ELPs, we made two ELP variants as described in Chapter 2. The 
monoblock consisted 60 repeats of GXGVP, in which the guest residue X 
was isoleucine, [I-60]. [I-60] was fused to an ELP block in which the guest 
residues were replaced for the more hydrophilic amino acids alanine or 
glycine in a 3 to 2 ratio, creating the [A3G2-60]-[I-60] diblock copolymer.[13] 
For clarity, when referring specifically to either block within the diblock 
copolymer, only that part is annotated in bold letters.  
First, the transition temperatures of these ELP blocks were 
determined by regular heating, using UV-Vis spectroscopy and dynamic 
light scattering (DLS) as described in Chapter 2. These experiments were 
performed at different protein concentrations in phosphate buffered 
saline pH 7.2 – 7.4 (PBS) (see Figure 2.6 and Table A5.1). [A3G2-60]-[I-
60] showed two transitions when probed with a temperature ramp-up 
spectroscopy experiment (Figure 2.6A); the intensity of absorbance at 
350 nm scaled with concentration between 20 °C and 30 °C, as expected 
during micelle assembly.  
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The second transition resulted in a visibly cloudy solution with a high 
increase of absorbance independent of the initial ELP concentration due 
to the aggregation of micelles. The [I-60] monoblock showed a single 
transition between 15 °C and 19 °C as expected; the monomer directly 
aggregated into large coacervates upon heating. This transition 
temperature also depended on the protein concentration. To better probe 
the monomer to micelle transition of [A3G2-60]-[I-60], the experiment was 
repeated with dynamic light scattering (DLS). Both the normalized count 
rate (Figure 2.6C), as well as the measured hydrodynamic radius (Figure 
2.6D), confirmed the transition from the monomer to a supramolecular 
assembly state. Similarly, the transitions of [A3G2-60]-[I-60] and [I-60] 
were probed as a function of the salt concentration at a fixed protein 
concentration (10 µM). A 1:1 molar mixture of potassium phosphate and 
sodium chloride at pH 7.0 was used (Figure 5.1, Table A5.2).  
 
Figure 5.1. Determination of the transition temperatures of [A3G2-60]-[I-60] and [I-60] 
at 10 µM in a buffer at pH 7.0 (1 to 1 molar ratio of potassium phosphate to sodium 
chloride).  A) Absorbance of [A3G2-60]-[I-60] at 350 nm during a temperature ramp 
experiment (0.2 °C/min) at different salt concentrations. B) Absorbance of [I-60] at 350 
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nm during a temperature ramp experiment (0.2 °C/min) at different salt concentrations. 
C) The normalized count rate measured by dynamic light scattering of [A3G2-60]-[I-60] 
during a temperature ramp experiment (0.5 °C/step). D) Hydrodynamic radius of [A3G2-
60]-[I-60] measured by dynamic light scattering during a temperature ramp experiment 
(0.5 °C/step).  
With increasing salt concentration, transition temperatures were lowered 
for the monomer to micelle and micelle to aggregate transition in case of 
[A3G2-60]-[I-60] (Figure 5.1A, C, D). Notably, the absorbance of the 
monomer to micelle transition decreased with increasing salt 
concentration, even though no size differences could be measured with 
DLS after assembly (Figure 5.1D). The transition temperature of [I-60] 
decreased with increasing salt concentration (Figure 5.1B). 
As the transition of [I-60] and [A3G2-60]-[I-60] coincides with a 
sharp increase in absorbance during temperature ramping, the transition 
temperature was defined as the maximum of the first derivative of the 
normalized absorbance signal at 350 nm. For [A3G2-60]-[I-60], the 
maximum of the first derivative of the normalized derived count rate 
defined the transition temperature, which coincides with particle 
assembly (Figure 5.2, Tables A5.1, A5.2). The normalized count rate 
seemed a more reliable measure of the transition temperature, since the 
hydrodynamic radius of ELP monomers could not always be reliably 
detected by DLS when using electrolytes to modify the transition 
temperature (Figure 5.1D).  
 
 
Figure 5.2. Transition temperatures of [I-60], [A3G2-60]-[I-60] and [A3G2-60]-[I-60] in A) 
PBS pH 7.2-7.4 at different protein concentrations and B) at 10 µM protein 
concentration in buffer (1 to 1 molar ratio of potassium phosphate to sodium chloride) 
at pH 7.0. 
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The presence of the hydrophilic block raised the transition 
temperature of the hydrophobic block in the copolymer; the difference 
increased with decreasing polymer and electrolyte concentration (Figure 
5.2A); the effects of varying electrolyte concentrations were less 
prominent (Figure 5.2B). The transition temperature of [A3G2-60]-[I-60] 
was hardly dependent on the initial protein concentration, it was however 
clearly affected by the amount of electrolyte present in solution. Micellar 
assembly thus negated the effect of protein concentration on the Tt of the 
hydrophilic block, but remained still susceptible to salt concentration 
changes. 
5.2.2 Pathway-dependent co-assembly of ELPs 
The significant difference in Tt between the monoblock and the 
hydrophobic domain of the diblock ELP allowed us to investigate the 
effect of heating rate and salt addition on the assembly properties. When 
a 1:1 molar mixture of [I-60] and [A3G2-60]-[I-60] (10 µM each) was heated 
slowly or treated via step-wise, gradual addition of salt, large, ill-defined 
aggregates were obtained with high absorbance (Figure 5.3A, B, black 
lines).  
 
 
Figure 5.3. Pathway-dependent assembly of ELPs measured by spectroscopy and 
dynamic light scattering. A) Absorbance measurements of a 10 µM 1 to 1 molar mixture 
of [I-60] and [A3G2-60]-[I-60] in PBS pH 7.2-7.4 gradually heated with 0.2 °C/min (black  
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line) or rapidly from 10 °C to 37 °C by placing a cold solution into a pre-heated cuvette 
(red line). B) Absorbance measurements of a 10 µM 1 to 1 molar mixture of [I-60] and 
[A3G2-60]-[I-60] at 16 °C, to which electrolytes (1 to 1 molar ratio of potassium 
phosphate to sodium chloride at pH 7.0) were added in incremental steps of 60 mM 
(black line) or rapidly from 60 mM to 240 mM (red line). Arrows indicate the 
continuation of measurements after rapid heating/stepwise addition of salt. C) 
Hydrodynamic radii of transitioned ELPs by the different pathways. Values reported are 
number-averaged hydrodynamic radii in nm (in brackets averaged polydispersity 
indexes) of 3 independent measurements. 
This is consistent with the working model of ELPs, in which a 
mixture of different polymers will aggregate separately solely based on 
their specific transition temperature (Scheme 1, pathway A  B  D). 
As the monoblock ELP didn’t yield stable assemblies, a strong increase 
in absorbance was observed, and ill-defined particles were found by DLS 
(Table C in Figure 5.3). If however the temperature was raised rapidly 
above the transition temperature of both [I-60] and [A3G2-60]-[I-60] 
(Figure 5.3A, red line), the increase in absorbance was less pronounced, 
indicative of the formation of nanoparticles. This was confirmed by DLS 
(Table C in Figure 5.3). Similarly, rapid addition of salt to a 
concentration that triggers both [I-60] and [A3G2-60]-[I-60] assembly, led 
also to the formation of well-defined nanoparticles (Figure 5.3B, red line). 
This showed the co-assembly of different ELP blocks into supramolecular 
structures via a kinetic mechanism (Scheme 1, pathway A  C).  
5.2.3 (Dis)assembly and particle characterization 
Next we investigated if a memory or hysteresis effect could be 
observed. Repeated heating and cooling showed the absence of such an 
effect (Figure 5.4A); only the path taken from the state in which all 
polymers were molecularly dissolved, affected the final morphology 
independent of previous phase transitions. The size of formed particles 
scaled with the molar percentage of [I-60] (Figure 5.4B, Table A5.3). 
Particles composed of [A3G2-60]-[I-60] alone had number-average 
hydrodynamic radii between 21.4 nm and 22.2 nm, and increased in size 
up to 117.4 and 120.3 nm for 94 mol% [I-60] (formed by heat shock) and 
92 mol% [I-60] (formed by salt shock), respectively. This is in agreement 
with our hypothesis that [I-60] co-assembled with [A3G2-60]-[I-60] and 
was stabilized by the presence of the outer hydrophilic block. Assuming 
similar surface densities of diblock copolymer, the coacervate core 
became larger as the ratio of [I-60] to [A3G2-60]-[I-60] increased. Larger 
ratios of [I-60] led to irreproducible results with occasional visible 
aggregation (data not shown).  
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This showed that the radius of co-assembled particles can be controlled 
over a 6-fold dynamic range, with the whole range falling into the 
optimum size of nanoparticles for biomedical applications such as drug 
delivery.[14,15]  
Particles remained stable over extended periods of time and did 
not show significant alterations of size (Figure 5.4C), showing that, while 
the assembly process must be dependent on the kinetics of aggregation 
to occur simultaneously, formed particles are energetically trapped 
during the timeframe measured. Interestingly, there was also no 
hysteresis observed while cooling down co-assembled particles, as one 
might expect due to the interaction of the different hydrophobic domains 
(Figure 5.4D).  
 
Figure 5.4. Characterization of assembly behavior. A) Formation of particles was 
independent of previous assembly pathways. A 1 to 1 molar mixture of [I-60] and [A3G2-
60]-[I-60] at 10 µM in PBS pH 7.2-7.4 was repeatedly heated either gradually or rapidly 
(slow or fast). Absorbance (black line) and hydrodynamic radii (red circle) were 
measured after each transition step. Slow heating resulted in large, polydisperse 
aggregates with high absorbance while rapid heating led to monodisperse nanoparticles 
with lower absorbance. Disassembly by cooling reset the system to a molecularly 
dissolved state. Hydrodynamic radii are displayed as mean + standard deviation of 3 
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independent measurements. B) The hydrodynamic radius of nanoparticles formed by 
heat or salt shock increased with the presence of [I-60] in the co-assembled system. C) 
Particles remained stable over extended periods of time without a significant change in 
hydrodynamic radius. D) Slowly cooling (0.2 °C/min) of co-assembled particles (10 µM 
in PBS) resulted in disassembly of [A3G2-60]-[I-60] and aggregation of [I-60] before 
disassembly to the ground state. Solid horizontal lines indicate the difference in 
transition temperature of [I-60] and [A3G2-60]-[I-60]. PBS served as a control sample. 
Amount of [I-60] is given in molar percentage in B-D). 
Aggregation of [I-60] was observed before complete disassembly, 
agreeing both with the transition temperature of the diblock copolymers 
as well as with the transition temperature of the monoblock. This is an 
intriguing property of the co-assemblies; while (surface) interactions 
between the different ELPs were necessary to form co-assembled micelles, 
each separate ELP sequence retained its specific transition temperature 
when cooled. This could allow gel formation from co-assembled micelles 
due to environmental changes when appropriate ELPs would be 
combined. Analysis of co-assembled particles by size-exclusion 
chromatography showed elution times corresponding with increasing 
particle size (Figure 5.5A).  
 
 
 
Figure 5.5. Characterization of particles formed by [I-60] and [A3G2-60]-[I-60] by means 
of size exclusion chromatography and multi-angle light scattering. A) Nanoparticles 
formed by [I-60] and [A3G2-60]-[I-60] elute according to their hydrodynamic radius and 
show no detectable amounts of free proteins; intensity was area normalized to the 
elution peak of 0% [I-60]. Elution volumes for dissolved, monomeric [I-60] and [A3G2-
60]-[I-60] are shown in black and red, respectively. Amount of [I-60] is given in molar 
percentage. B) The hydrodynamic radii, radii of gyration and the molecular mass of 
nanoparticles with varying amounts of [I-60] were characterized by size-exclusion 
chromatography coupled to multi-angle light scattering.  
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Table 5.1. Properties of nanoparticles as a function of mol% [I-60] measured by size-
exclusion chromatography coupled to multi-angle light scattering. 
Molar percentage 
[I-60] (mol%) 
Rh1 (nm) Rg2 (nm) MW3 
(MDa) 
ρ4 Capp5 
(mg/mL) 
0 25.6 + 0.9 14.6 + 0.5 12.1 + 0.1 0.570 + 0.029 286 
17.5 28.5 + 1.2 16.6 + 0.5 17.3 + 0.1 0.583 + 0.029 297 
35 33.0 + 1.2 20.8 + 0.4 27.5 + 0.1 0.629 + 0.026 302 
52.5 35.8 + 1.2 22.9 + 0.5 44.4 + 0.1 0.639 + 0.027 383 
70 41.6 + 1.4 27.1 + 0.3 89.0 + 0.1 0.651 + 0.022 490 
1Hydrodynamic radius; 2radius of gyration; 3molecular weight; 4ρ is defined as Rh / Rg; 
5apparent protein concentration within the particle, assuming a perfect sphere of 
homogenous density with a radius of Rh and molecular weight MW.  
 
Figure 5.6. Stochastic optical reconstruction microscopy measurements. A-D) 
Representative 2D reconstruction of ELP nanoparticles. Scale bars = 100 nm. E) 3D 
reconstruction of an ELP nanoparticle with 92 mol% [I-60]. F) Size distributions obtained 
by stochastic optical reconstruction microscopy measurements. Obtained radii were 42 
nm ± 6 nm for 70 mol% [I-60]; 64 nm ± 10 nm for 80 mol% [I-60]; 127 nm ± 24 nm for 90 
mol% [I-60]; 200 nm ± 39 nm for 92 mol% [I-60]. Values are presented as mean + 
standard deviation. 
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The absence of detectable monomers after particle formation 
indicated quantitative assembly, or a large equilibrium towards 
assembly. This also showed that the formed particles were stable enough 
to be manipulated, i.e. separated. The formed morphology was 
determined to be micellar by analyzing eluted particles with multi-angle 
light scattering (Figure 5.5B, Table 5.1). Hydrodynamic radii ranged 
from 25.6 nm + 0.9 nm for particles assembled from the diblock 
copolymer only to 41.6 nm + 1.4 nm for 70 mol% [I-60]. The molecular 
mass scaled accordingly from 12.1 MDa + 0.1 MDa to 89.0 MDa + 0.1 
MDa. The ratio of radius of gyration to hydrodynamic radius increased 
from 0.570 for 0 mol% to 0.651 for 70 mol% [I-60] respectively, indicating 
micelles with an increasing core size of homogenous density.[16,17] The 
apparent protein concentration within the nanoparticles was 
approximated by dividing the molecular mass by the volume based on 
the hydrodynamic radii. For 70 mol% [I-60] the apparent protein 
concentration amounted to 490 mg/mL. Stochastic optical 
reconstruction microscopy was used as a supplementary technique to 
visualize larger co-assembled nanoparticles and measure their 
hydrodynamic radii. 2D (Figure 5.6A-D) and 3D (Figure 5.6E) 
reconstruction was successful for particles comprising from 70 mol% to 
92 mol% [I-60]. Measured values agreed with values obtained from multi-
angle light scattering and dynamic light scattering (Figure 5.6F). With 
hydrodynamic radii of 42 nm ± 6 nm for 70 mol% [I-60]; 64 nm ± 10 nm 
for 80 mol% [I-60]; 127 nm ± 24 nm for 90 mol% [I-60]; 200 nm ± 39 nm 
for 92 mol% [I-60], sizes were on average slightly larger than measured 
with DLS.   
 
5.2.4 Encapsulation of macromolecular cargo 
Due to the near quantitative assembly, stability and nanoparticle 
size the particles would be suited as delivery vehicles for nanomedicine 
applications for the encapsulation of hydrophilic, macromolecular cargo. 
We therefore created recombinant fusions of [I-60] with two fluorescent 
proteins, mTurquoise2[18] and mNeonGreen[19] (Figures 5.7A, A5.1-
A5.4). Particle analysis confirmed the presence of well-defined 
nanoparticles after encapsulation of the proteins by the kinetic co-
assembly pathway (data not shown). Proteolytic protection of 
incorporated cargo was quantified with a tryptic digest-activity assay with 
trypsin and chymotrypsin (Figure 5.7B). When mTurquoise2 was present 
as a fusion protein with a hydrophilic ELP block, the fusion protein was 
completely cleaved after 1 hour of incubation. 
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Figure 5.7. Stochastic encapsulation of active macromolecular cargo within 
nanoparticles. mTq2 = mTurquoise2; mNG = mNeonGreen. A) SDS-PAGE of purified 
proteins. B) Tryptic digestion assay. Particles were formed with 10 mol% [A3G2-60]-[I-
60], 80 mol% [I-60] and 10 mol% mTq2-[I-60] or mTq2-[A3G2-60]. mTq2 is protected from 
proteolytic degradation by trypsin and chymotrypsin if encapsulated within the particle 
as mTq2-[I-60], while mTq2-[A3G2-60] is rapidly degraded. C) FRET measurement by 
using mTq2 and mNeonGreen as a donor / acceptor pair. Particles were formed with 10 
mol% mTq2/mNG. mTq2/mNG-[I-60] was used to encapsulate the fluorescent proteins 
within the particles, mTq2/mNG-[A3G2-60] served as a non-encapsulated control. A 
hyphen indicates no donor / acceptor in the nanoparticle formulation, respectively. Co-
encapsulated mTq2-[I-60] and mNG-[I-60] showed Förster resonance energy transfer, 
visible by the sensitized emission of the acceptor, mNeonGreen. Emission spectra are 
scaled to the emission peak of mTq2. D) Partial encapsulation of mNG inside 
nanoparticles in the presence of mTq2-[I-60] reveals the scaling of sensitized emission 
from mNG. 
On the other hand, when incorporated into ELP particles as a [I-
60]-fusion protein, only around 50 % was cleaved after 2 hours, proving 
prolonged protection from degradation. Since degradation of mTq2-[I-60] 
was still possible, this also indicates that the co-assembled particles were 
still permeable to some extent to macromolecular compounds. As the 
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precise localization of the fluorescent guest in the particle remains to be 
determined, it is still unclear if the accessibility is restricted to the outer 
corona or also extends to the particle core. mTurquoise2 and 
mNeonGreen form a Förster resonance energy transfer (FRET) pair with 
a R0 of 6.2 nm[20], with mTurquoise2 being the donor and mNeonGreen 
being the acceptor. Particles were created with a molar ratio of 1:8:1 
[A3G2-60]-[I-60] to [I-60] to mTurquoise2 / mNeonGreen – [I-60] (Figure 
5.7C). Fusions with the more hydrophilic [A3G2-60] monoblock served as 
non-encapsulated controls. 
When both fluorescent proteins were incorporated, energy 
transfer was observed, which scaled with the presence of mNeonGreen 
within the particles up to a FRET efficiency of 82 % (Figure 5.7C, D). 
While the determination of the average intermolecular distance was not 
feasible based solely on this data due to the complexity of the co-
assembled system, this showed that both proteins were encapsulated 
within the same macromolecular structure. Based on these data, it was 
also not possible to conclude whether the proteins are homogenously 
distributed within the coacervate core, orient themselves towards the 
more hydrophilic corona, or form hydrophilic ‘spots’ within the 
coacervate. 
 
5.2.5 Co-delivery of active macromolecular cargo to cells 
In order to test the capability of co-assembled ELP nanoparticles 
to deliver their macromolecular cargo to cells, particles were made 
consisting of 7D12-[A3G2-60]-[I-60], [A3G2-60]-[I-60], [I-60], mTq2-[I-60] 
and mNG–[I-60]. 7D12 is the variable domain of a single-domain antibody 
raised against the epithelial growth factor receptor (EGFR). As described 
in Chapter 3, ELP nanoparticles decorated with 7D12 were able to 
specifically recognize cells displaying EGFR and induce particle uptake. 
After incubation of EGFR-displaying cells with ELP nanoparticles, they 
were washed and imaged with confocal microscopy. When mTurquoise2 
and mNeonGreen were co-encapsulated, the sensitized emission by 
mNeonGreen could be observed intracellularly (Figure 5.8). The FRET 
signal was calculated with PixFRET[21], taking into account the spectral 
bleed-through for mTurquoise2 and mNeonGreen (Figure 5.8D). 
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Figure 5.8. Intracellular FRET after co-delivery of mTurquoise2 and mNeonGreen in co-
assembled ELP particles. Membrane stain is visualized in red, the emission of 
mTurquoise2 is represented in cyan, while the emission of mNeonGreen, the sensitized 
emission and the FRET signal is shown as green. mTq2 = mTurquoise2, mNG = 
mNeonGreen. A431 cells expressing the EGF receptor were incubated with particles 
consisting of 3 mol% 7D12-[A3G2-60]-[I-60], 7 mol% [A3G2-60]-[I-60], 80 mol% [I-60], 5 
mol% mTq2-[I-60]/[A3G2-60] and 5 mol% mNeonGreen-[I-60]/[A3G2-60]. Notation above 
the columns indicate which proteins were encapsulated inside ELP nanoparticles. A) 
Direct excitation and emission of the FRET donor, mTurquoise2. B) Direct excitation of 
the acceptor, mNeonGreen. C) Sensitized emission (plus spectral bleed-through) after 
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donor excitation visible by acceptor emission. D) Calculated FRET signal. Scale bars = 50 
µm. 
When either fluorescent protein was present as [A3G2-60] 
conjugate, little to no FRET was observed for mTurquoise2 and no 
sensitized emission (plus spectral bleed-through) at all for mNeonGreen 
as expected. This proved that only encapsulated cargo is taken up by 
cells. The observation of FRET proved the functional interaction of 
encapsulated cargo even after (endosomal) uptake. This raised the 
question whether the particles stay assembled after uptake or fall apart; 
as we have shown in Chapter 4, assembled particles are actively 
transported across an in vitro blood-brain barrier, which indicates that 
endosomal uptake does not lead to particle disassembly within a short 
time-frame. It can however not be excluded; if a nanoparticle falls apart 
in an intracellular compartment, the released fluorescent proteins may 
still be at a sufficient high concentration to show FRET. An interesting 
assay would be the transcytosis of mTq2/mNG encapsulating particles 
across an in vitro BBB barrier. The FRET signal could then be quantified 
before and after transcytosis to show particle stability. This might 
however be confounded by the act of transcytosis; as we have shown, 
encapsulated cargo is not completely protected from proteolytic cleavage. 
Imaging the size of intracellular compartments in which the particles are 
taken up may also give an answer to the question whether disassembly 
would still allow significant FRET signal to be visible. 
 
5.3 Conclusion 
We have shown that elastin-like peptides may undergo pathway-
dependent co-assembly. We used a hydrophobic ELP monoblock and an 
ELP diblock. The monoblock showed a consistently lower transition 
temperature than the hydrophobic part of the diblock (Figure 5.2). When 
the transition temperature was reached gradually by either heating or the 
addition of salt, each ELP showed a separate transition into either large 
ill-defined coacervates in the case of the ELP monoblock, or a micellar 
assembly in the case of the ELP diblock (Figure 5.3, Scheme 1 A  B  
D). If the transition of two separate ELPs was triggered simultaneously, 
they co-assembled into larger micelles in which the hydrophobic core was 
stabilized by the ELP diblock (Figure 5.3, Scheme 1 A  C). This 
behavior was reversible and showed no hysteresis (Figure 5.4A). Upon 
cooling, once below the transition temperature of the diblock, the micelles 
disassembled and large aggregates were formed again by the monoblock 
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(Figure 5.4D). Upon further cooling, the monoblock returned to a 
dissolved state as well.  
The co-assembled particles were stable for at least 24 hours 
(Figure 5.4C). Their radii scaled with the ratio of hydrophobic 
monoblock, ranging from around 20 nm to 120 nm (Figure 5.4B). A 
micellar conformation was proven by multi-angle light scattering 
experiments, where the ratio of radius of gyration to hydrodynamic radius 
increased from 0.570 to 0.651 from 0 mol% [I-60] to 70 mol% [I-60] 
(Figure 5.5 B). The theoretical value for a sphere of homogenous density 
would be 0.775.[16,17] Therefore, with an increasing amount of ELP 
monoblock a more homogenous sphere was formed. This is in line with 
the model of an ELP micelle with denser coacervate core and a less dense 
hydrophilic corona, in which the core scales with the amount of ELP 
monoblock co-encapsulated, and the thickness of the hydrophilic corona 
stays constant. Encapsulation during co-assembly was quantitative as 
far as determined by size-exclusion chromatography (Figure 5.5A). 
Stochastic optical reconstruction microscopy allowed 2D and 3D 
reconstruction of particles, and radii determined agreed well with data 
obtained by dynamic light scattering (Figure 5.6).  
Macromolecular cargo was encapsulated in co-assembled 
particles by fusing two fluorescent proteins, mTurquoise2 and 
mNeonGreen, to [I-60]. Encapsulation into ELP particles showed 
prolonged protection from degradation by proteases (Figure 5.7B). Co-
encapsulation was proven by the Förster resonance energy transfer 
between mTurquoise2 and mNeonGreen (Figure 5.7C-D). Whether the 
fluorescent cargo is distributed homogenously within the particles’ core 
or is localized to the hydrophilic corona was not tested in this chapter. 
The behavior of pathway-dependent co-assembly of ELPs is 
unique: proteins that normally would not interact can be trapped in 
stable conformations by a kinetic pathway of either rapid heating or 
addition of electrolytes. Whether the co-assembled (Scheme 5.1C) or 
segregated (Scheme 5.1D) is the most thermodynamically stable state is 
an open question. Intuitively, one would assume the state that is reached 
the slowest (Scheme 5.1 A  B  D), the segregated state, should be the 
thermodynamically most stable state, as shown in various materials. 
However, when considering that in the segregated state there is always a 
highly hydrated surface around ELP monoblock coacervates, one could 
argue that the co-assembled state (Scheme 5.1 A  C) actually 
minimizes hydration of hydrophobic, coacervating moieties.  
The possibility of encapsulating macromolecular cargo to a very 
high efficiency inside an ELP particle opens many opportunities for 
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(macromolecular) drug delivery. As we have shown, two proteins can be 
co-delivered while their functionality and interaction is undisturbed 
(Figure 5.8). The system presented here may possess several advantages 
when compared to existing systems. The first one is the high 
encapsulation efficiency. Since the property of assembly would be 
inherent to the cargo to be encapsulated due to the ELP tag, a very high 
encapsulation efficiency can be expected independent of the cargo’s 
molecular size. While it would be necessary to either chemically or 
genetically attach an ELP block to the protein of interest, many 
therapeutic proteins of interest (POIs) have been successfully purified 
with an ELP tag and are therefore suited for this assembly approach.[22–
34] The second advantage would be the lack of a membrane. If the protein 
of interest has to interact with its environment, e.g. to use or detect 
(small) hydrophilic molecules present in blood, an impermeable lipid 
barrier as in liposomes would be detrimental. While a POI may be used 
without encapsulation, many proteins are rapidly removed passively or 
actively from circulation or show immunogenic responses. The coacervate 
core of co-assembled ELPs should shield POIs from clearance and 
degradation longer and minimize immunogenic responses. We showed 
that functional macromolecular cargo can be co-assembled and delivered 
into cells without negating their function and retaining their interaction. 
In the future, the delivery of therapeutic macromolecular cargo into cells 
would be highly interesting; since endosomal uptake is expected, enzyme 
delivery by ELP nanoparticles could alleviate lysosomal storage diseases. 
Endosomal escape could be incorporated into co-assembled particles as 
well by introducing pH sensitive guest residues coupled with endosomal 
escape peptides that stay ‘hidden’ until pH-induced disassembly.  
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5.5 Experimental section 
All chemicals were obtained from Sigma-Aldrich and used as delivered, 
unless stated otherwise. 
5.5.1 Recombinant proteins 
ELPs were cloned, expressed and purified according to earlier 
published protocols.[13] Coding sequences for mTurquoise2 and 
mNeonGreen were ordered as double stranded DNA fragments (IDT) 
compatible with recursive directional ligation and inserted in pET24a(+) 
vectors. Sequences were verified by sequencing. Plasmids were 
transformed into E.coli BL21(DE3) (Invitrogen) cells and grown on agar 
plates containing 30 µg/mL kanamycin overnight at 37 °C. A single 
colony was grown overnight at 23 °C, 250 rpm in LB medium containing 
50 µg/mL kanamycin and 0.5% w/v D-glucose. The overnight culture 
was diluted to an OD600 of 0.1 in filter-sterilized AIM TB medium 
(Formedium) containing 6g/L glycerol, 0.005% Antifoam 204 and 150 
µg/mL kanamycin. Cells were grown at 300 rpm at 30 °C for 20 hours. 
Cells were collected by centrifugation at 4000 g, 4 °C for 30 minutes. For 
cytoplasmic extraction, 1 g of wet cell pellet was resuspended in 10 mL 
phosphate buffered saline pH 7.4.  
Cells were lysed by homogenization with an EmulsiFlex-C3 
(Avestin). Cell debris was collected by centrifugation at 15,000 g at 4 °C 
for 15 min. Residual DNA was precipitated by adding 0.5% w/v 
poly(ethylene imine) and removed by centrifugation at 15,000 g at 4 °C 
for 15 min. ELPs were precipitated by adding a saturated solution of 
(NH4)2SO4 up to 10-25 v/v% either at room temperature or 4 °C 
depending on the construct. Proteins were collected by centrifugation at 
15,000 g at 4 °C or RT for 15 min. The pellet was resuspended in 
phosphate buffered saline and centrifuged to remove insoluble 
contaminants at 15,000 g at 4 °C for 20 min. This cycle was repeated 
until sufficient purity was achieved, usually after 2-4 cycles. ELPs were 
resuspended in MilliQ, purified on a HiLoad 16/600 Superdex 200 and 
desalted on a HiPrep 26/10 (GE Healthcare Life Sciences) with an AKTA 
Explorer 10 (GE Healthcare Life Sciences) at 1 mL/min PBS and 4 
mL/min MilliQ, respectively. Residual salt concentration was below 0.01 
mg/mL as determined by conductivity. The ELP solution was filter-
sterilized with 0.22 µm PES syringe filters (Nalgene) and freeze-dried. 
Yield was determined by weighing. For fluorescent protein fusions, 
solutions were desalted to 10 mM potassium phosphate buffer pH 7.0, 
concentrated, flash-frozen in liquid nitrogen and stored at -80 °C. 
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Concentration was determined by measuring absorbance at 280 nm 
(mTurquoise2-[A3G2-60]/[I-60] ε280nm = 27390 M-1 cm-1, mNeonGreen-
[A3G2-60]/[I-60] ε280nm = 45840 M-1 cm-1) 
 
5.5.2 Electrospray ionization – time of flight mass spectrometry (ESI-TOF) 
Mass was determined by ESI-TOF on an AccuTOF (Jeol) or a Xevo 
G2QTOF (Waters). Samples in buffered aqueous solutions were first 
desalted with MilliQ using Amicon Ultra-0.5 spin filter units (Millipore, 
10 kDa MWCO) and diluted in MilliQ to 10 µM. All samples were acidified 
with 0.1% formic acid upon direct injection or fractionation on a Polaris 
3 C18 column (Agilent) with water/acetonitrile gradients, respectively. 
Deconvoluted spectra were obtained using Mass Lynx v4.1. 
5.5.3 Pathway dependent co-assembly of ELPs 
Unless stated otherwise, these protocols were used to form co-
assembled particles for analysis. For temperature-induced assembly, 
PBS pH 7.2-7.4 at 42 °C, was added to a stock solution of dissolved ELP 
at 4 °C in PBS pH 7.2-7.4 to reach an average temperature of 35 °C to 37 
°C. Typically, the volume ratio of warm PBS to cold samples was 4 to 1. 
For salt induced assembly, to a stock solution of dissolved ELPs at 16 °C 
in MilliQ an equal volume of 300 mM potassium phosphate and 300 mM 
sodium chloride pH 7.0 at 34 °C was added. 
5.5.4 Spectrophotometry 
Spectroscopy experiments were done with a V-750 UV-Visible 
Spectrophotometer (Jasco). Quartz cuvettes (Hellma) with a path length 
of 10 mm were used. For ramping experiments, the heating or cooling 
rate was set to 0.2 °C/min with data collection each 0.2 °C. For rapid 
heating, the holding block of the spectrophotometer allowed to equilibrate 
for 5 minutes at 37 °C before inserting the pre-cooled sample. The sample 
was allowed to equilibrate for 5 minutes before continuation of 
measuremts. 
5.5.5 Dynamic light scattering 
Typically, samples were diluted in PBS pH 7.4 to 1 µM. 
Measurements were performed on a Malvern Zetasizer Nano. Samples 
were incubated for 5 minutes at 37 °C (heat shock) or 25 °C (salt shock) 
before data collection. Reported values are averages of 3 independent 
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measurements. For temperature ramping, values were collected every 0.5 
°C. 
5.5.6 Size-exclusion chromatography 
Monomers were separated on a Bio-Sec 5 1000 Å + 300 Å  + 150 
Å  (guard) column (Agilent) at 0.5 mL/min; the mobile phase was 0.01 M 
phosphate buffer pH 7.0 at 4 °C to avoid aggregation of monomers.. 
Typically, 10 µg of ELPs was injected. Absorbance was measured at 215 
nm. Particles were separated on a BioInert HPLC (Agilent) with Bio-Sec 5 
1000 Å + 300 Å + 150 Å  (guard) columns (Agilent) at 0.5 mL/min; the 
mobile phase was 0.15 M phosphate buffer pH 7.0 0.15 M NaCl at 25 °C. 
Absorbance was measured 215 nm. 
5.5.7 Multi-angle light scattering 
Light scattering data were collected in combination with SEC as 
described above on a HPLC (Shimadzu) coupled to a DAWN HELEOS II 
MALS detector (Wyatt); differential refractive index was measured on an 
Optilab T-rex refractometer (Wyatt). dn/dc values were determined 
experimentally by direct injection of [A3G2-60]-[I-60] at measurement 
conditions (Figure A5.5). 
5.5.8 Stability assay 
Particles were formed by salt shock in 150 mM potassium 
phosphate, 150 mM sodium chloride pH 7.0 with a final protein 
concentration of 0.5 mg/mL and incubated at 25 °C, 300 rpm. At each 
time point, an aliquot was removed and measured by dynamic light 
scattering.  
5.5.9 Labeling of [A3G2-60]-[I-60] with Sulfo-Cy5-succinimidyl ester 
[A3G2-60]-[I-60] was dissolved in 10 mM potassium phosphate 
buffer pH 7.0 to a final concentration of 100 µM. Sulfo-Cy5-succinimidyl 
ester was dissolved in DMSO and added drop-wise to the ELP solution to 
a final concentration of 200 µM. The reaction was allowed to proceed at 
room temperature for 2 hours at 300 rpm. The modified protein was 
dialyzed against MilliQ using Amicon Ultra-0.5 spin filter units (Millipore, 
10 kDa MWCO). The volume of the dialyzed protein samples was 
determined; efficiency of conjugation was determined by measuring dye 
concentration and weighing protein samples after freeze-drying. 
Concentration of the dye was determined at 646 nm (ε = 271,000 cm-1M-
1). Mass was confirmed by ESI TOF. 
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5.5.10 Stochastic optical reconstruction microscopy 
Elastin-like peptide particles (total concentration 10 µM) were 
labelled with Cy5 dye at a concentration of 0.5 µM. The labelled 
nanoparticles were injected in a homemade sample chamber assembled 
out of a coverslip (Menzel Gläser, No. 1.5, 24 × 24 mm, thickness 170 
µm) taped together with a coverglass (Menzel Gläser, 76 × 26 mm, 
thickness 1 mm). The coverslips were previously treated with piranha 
etching (3:1 v/v concentrated H2SO4:H2O2 (aq. 30%)) to remove 
impurities, washed sequentially with water, isopropanol and acetone to 
finally been blown dry with nitrogen. After sedimentation of the particles, 
the chamber was fluxed with a STORM buffer (160 µl TRIS buffer 50mM 
(pH 7.4), 20 µl mercaptoethylamine 10mM, 20 µl glucose 50% m/v, 2 µl 
oxygen scavenger (0.5 mg/ml glucose oxidase, 40 µg catalase)) to 
facilitate the Cy5 blinking. STORM images were acquired on an inverted 
N-Storm Nikon microscope provided with a ~1.3 W/cm2 red laser line (λex 
= 647 nm). After passing through a quad-band pass dichroic mirror 
(95335 Nikon), the incident beam was focused on the sample with a Nikon 
objective (oil immersion, 100×, NA = 1.49) in a quasi-Total Internal 
Reflection Fluorescence (TIRF) geometry. 
STORM images were taken on 128 × 128 pixels region of interest 
at an acquisition frame rate of 97 fps on an EMCCD Ixon3 Andor camera 
(pixel size: 17 µm). Images of elastin-like peptide nanoparticles were 
collected over 5 × 103 frames. The localization of single molecules was 
carried out by a NIS-element Nikon software.  
3D STORM measurements were performed inserting an 
cylindrical lens in the light path, as previously described.[35] Here, the 
ellipticity of the diffraction limited spot of a single molecule induced by 
the lens reveals the z-position of the molecule. A previous calibration 
curve to relate the astigmatism and z-position was carried out using 
fluorescent TetraSpeckTM microspheres (R = 50 nm, Lifetechnologies, 
Molecular Probes®). The image analysis to determine the size 
distributions of ELP nanoparticles was carried out in Matlab, and 
described elsewhere.[36] Briefly, iPAINT super-resolved images were 
corrected for background localizations using a density-based algorithm. 
Next, single particles were identified and saved in a separate file for 
further analysis of particle size and size distribution. Mean particle sizes 
were determined using freeware exchange Matlab files for two-
dimensional data, which minimizes the quantity ∑ +  − 	, with x 
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and y being the coordinates of the localizations and R the radius of the 
circle. This procedure was repeated for hundreds of nanoparticles for 
each composition.  
 
5.5.11 Tryptic digestion assay 
Nanoparticles were made from 10 mol% [A3G2-60]-[I-60], 80 mol% 
[I-60] and 10 mol% mTurquoise2-[I-60]/[A3G2-60] to a final concentration 
of 10 µM in PBS pH 7.2-7.4 at 37 °C. A 1 to 1 mass mixture of trypsin 
and trypsinogen was dissolved in PBS pH 7.2-7.4 and added to the 
solution to a final concentration of 0.05 mg/mL. The reaction proceeded 
at 37 °C, 300 rpm. Aliquots were removed and analyzed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. 
5.5.12 Förster resonance energy transfer experiments 
Particles were created by salt shock with a molar ratio of 1:8:1 
[A3G2-60]-[I-60] to [I-60] to mTurquoise2 / mNeonGreen – [I-60] / [A3G2-
60] with a final protein concentration of 5 µM. Emission spectra were 
recorded on a Cary Eclipse. Samples were excited at 430 nm (bandwidth 
5 nm) and emission was recorded between 450 nm and 600 nm 
(bandwidth 10 nm). 5 consecutive spectra were averaged and baseline 
subtracted. Sensitized emission spectra were obtained by subtracting the 
emission spectra of the donor and the direct excitation spectra of the 
acceptor. All spectra were scaled to the excitation maximum of the donor 
at 474 nm. FRET efficiency was calculated according 
 =  


 in which 
E is the FRET efficiency, IAD is the intensity of the normalized emission of 
the donor at 474 in the presence of the acceptor, and ID the normalized 
emission of only the donor at 474 nm. 
5.5.13 Confocal microscopy experiments  
A431cells were grown in Roswell Park Memorial Institute (RPMI) 
1640 Medium (Invitrogen), supplemented with 10% Fetal Bovine Serum 
(Gibco®) and 1% penicillin/streptomycin (Gibco®) and maintained at 37 
°C in a humidified atmosphere containing 5% CO2. Cells were seeded on 
96-wells plates (DB Falcon, transparent). The next day, cells were washed 
twice with preheated PBS and 500 µl of fresh medium was added. This 
was incubated for 5 minutes. The nanoparticles were formed externally 
using heat shock and kept at 37 °C; they consisted of 3 mol% 7D12-
[A3G2-60]-[I-60], 7 mol% [A3G2-60]-[I-60], 80 mol% [I-60], 5 mol% mTq2-
[I-60]/[A3G2-60] and 5 mol% mNeonGreen-[I-60]/[A3G2-60]. The 
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nanoparticle solution was added to the cells to a final protein 
concentration of 1 µM and incubated for 2 hours at 37 °C. After 2 hours, 
the solution was removed and cells were washed twice with PBS pH 7.2-
7.4. PBS containing Deep Red plasma membrane stain (CellMaskTM) was 
added to the cells and incubated for 3 minutes. The membrane stain was 
removed and cells were washed twice with preheated PBS pH 7.2-7.4 after 
which 300 µl of fresh preheated medium was added to the cells. 
Fluorescence microscopy pictures were taken with a Leica TCS SP5X 
confocal microscope with excitation wavelengths and emission filters set 
as stated in Table 5.2. FRET efficiency was calculated by PixFRET 
Table 5.2. Excitation wavelength and emission filter setting for confocal microscopy. 
Condition tested Excitation wavelength 
(bandwidth 5 nm) 
Emission filter  
Membrane stain 690 nm 700-800 nm 
mTurquoise2 405 nm 460-490 nm 
mNeonGreen  490 nm 505-515 nm 
Sensitized emission 405 nm 505-515 nm 
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5.6 Appendix 
 
Figure A5.1. Deconvoluted mass, mass spectrum and chromatogram of mTurquoise2-
[I-60]. Expected mass after chromophore formation[37,38] was 52451 Da, observed mass 
52449 Da. 
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Figure A5.2. Deconvoluted mass, mass spectrum and chromatogram of mNeonGreen-
[I-60]. Expected mass after chromophore formation[37,38] was 52187 Da, observed mass 
52186 Da. 
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Figure A5.3. Deconvoluted mass, mass spectrum and chromatogram of mTurquoise2-
[A3G2-60]. Expected mass after chromophore formation[37,38] was 49589 Da, observed 
mass was 49588 Da. 
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Figure A5.4. Deconvoluted mass, mass spectrum and chromatogram of mNeonGreen-
[A3G2-60]. Expected mass after chromophore formation[37,38] was 49324 Da, observed 
mass was 49325 Da. 
 
Table A5.1. Transition temperatures of used ELPs in phosphate buffered saline pH 7.2-7.4 
Construct Protein 
concentration (µM) 
First transition 
(°C) 
Second 
transition (°C) 
[I-60] 40 15.4 NA 
[I-60] 20 16.3 NA 
[I-60] 10 17.1 NA 
[I-60] 5 17.9 NA 
[I-60] 2.5 18.7 NA 
[A3G2-60]-[I-60] 40 18.5 57.0 
[A3G2-60]-[I-60] 20 20.0 56.6 
[A3G2-60]-[I-60] 10 21.0 57.1 
[A3G2-60]-[I-60] 5 22.0 57.1 
[A3G2-60]-[I-60] 2.5 23.5 56.7 
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Table A5.2. Transition temperatures of used ELPs at 10 µM in potassium phosphate buffered 
sodium chloride.  
Construct Salt concentration 
(mM) 
First transition 
(°C) 
Second 
transition (°C) 
[I-60] 300 8.0 NA 
[I-60] 240 10.5 NA 
[I-60] 180 12.5 NA 
[I-60] 120 15.3 NA 
[I-60] 60 17.5 NA 
[A3G2-60]-[I-60] 300 7.4 36.0 
[A3G2-60]-[I-60] 240 11.0 40.4 
[A3G2-60]-[I-60] 180 14.0 47.1 
[A3G2-60]-[I-60] 120 17.5 50.5 
[A3G2-60]-[I-60] 60 21.0 55.9 
 
Table A5.3. Hydrodynamic radii of co-assembled ELP particles. 
mol % of [I-60] RH by heat-shock (nm) RH by salt-shock (nm) 
0 21.4 + 7.7 22.2 + 3.7 
35 29.6 + 6.7 32.3 + 8.5 
70 47.0 + 9.3 41.0 + 14.2 
80 53.2 + 6.3 43.6 + 10.8 
82 57.3 + 8.7 45.3 + 21.7 
84 60.2 + 6.6 50.7 + 15.8 
86 71.2 + 11.3 58.3 + 15.5 
88 80.5 + 12.5 63.1 + 8.0 
90 96.5 + 18.8 77.0 + 9.1 
92 120.3 + 24.9 91.7 + 14.5 
94 - 117.4 + 14.2 
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Figure A5.5. dn/dc determination of [A3G2-60]-[I-60]. Purified material was injected into 
the RI detector at varying concentration. The fit resulted in a dn/dc of 0.1586 + 0.0003 
mL/g. 
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6.1 Nanoparticles made from elastin-like polypeptides for 
nanomedicine 
A more thorough understanding of nature and its buildings 
blocks feeds our capability of constructing functional components and 
vice versa. Understanding the workings of the human immune system 
has allowed us to generate monoclonal antibodies, which are currently 
one of our most powerful tools in the treatment of diseases with a ‘market 
value’ of above 100 billion dollars in 2017, and predicted to be growing. 
On the other hand, antibodies have vastly expanded our capabilities to 
stain, track and modulate cellular receptors and other bio-markers, 
allowing us to fundamentally understand the workings of intra- and 
intercellular signaling pathways, structural components and dynamics. 
The same is true for macromolecular assemblies derived from nature. 
Since the polymerization of the elastin-derived sequence VPGVG 
by Urry[1] to form a temperature-responsive polymer and the subsequent 
structural elucidation of its assembly properties, the knowledge of the 
physicochemical properties as well as the utility of elastin-like 
polypeptides (ELPs) has been expanded. We now have a better 
understanding of the structural changes and thermodynamics of these 
and other disordered peptides, also due to our enhanced capability of 
creating them.[2–5] They are utilized to purify biomolecules[6–10] used as a 
structural material for gels that retain and slowly release proteins or 
peptides of interest[11], or to guide cells during regeneration to a proper 
three-dimensional organization in vivo.[12]  
By combining ELPs with different properties, nanoparticles can 
be created that display ligands and encapsulate therapeutics for 
nanomedicine applications.[13–15] In this thesis we contributed to our 
understanding of the formation process of ELP nanoparticles as well as 
their application potential. We have shown that the penetration of ELP 
nanoparticles in glioblastoma spheroids can be described by a binding-
site barrier model and be modulated by the surface density of cell-
penetrating peptides in Chapter 2. We have shown that ELP 
nanoparticles can be created displaying single-domain antibody 
fragments and photosensitizers for selective photodynamic therapy in 
Chapter 3. Furthermore, we have functionalized ELP micelles to cross a 
blood-brain barrier model and to rescue cells from oxidative stress by 
acting as an antioxidant reservoir in Chapter 4. Elucidating a new 
pathway-dependent assembly mechanism, we have paved the way for 
creating complex ELP nanoparticles that are able to encapsulate 
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macromolecular cargo with unmet efficiency for cellular delivery in 
Chapter 5. 
 
6.2 Outlook 
6.2.1 Supramolecular assemblies for nanomedicine 
Nanoparticles will play an increasingly important role for 
developing new therapies and diagnostic assays. While the most common 
formulations currently used for clinical applications are based on 
liposomes[16,17], the adaptability of micelles, vesicles, rods etc. made from 
metals, synthetic and natural polymers have the potential to enhance 
targeting and reduce off-target toxicity. In the case of combination 
therapies, i.e. the simultaneous applications of different therapeutics, 
nanoparticles as drug reservoirs can significantly enhance the 
applicability of different drugs in one formulation.[18–20] In the field of 
immuno-engineering, supramolecular assemblies can display multiple 
adjuvants and antigens that can enhance or decrease the immunogenic 
reaction of the human body against the antigen of interest.[18,21,22] 
Systematic studies of surface, material and shape properties in vivo are 
increasing in number, with a drive towards standardization of reported 
experimental and material parameters to ensure reproducibility and 
comparability.[23–27] 
 
6.2.2 Development of elastin-like polypeptides nanoparticles 
ELP fusion proteins are already in clinical trials to act e.g. as an 
injectable gel for sustained stimulation of insulin release.[28] The 
suitability of ELP nanoparticles for clinical applications will depend on a 
series of factors such as efficacy, immunogenicity, the effect of 
degradation products and characterization data necessary for clinical 
approval. It is likely that ELP nanoparticles will enter clinical trials in the 
future, since a number of pre-clinical in vivo studies have shown good 
efficacy in cancer treatment or wound healing.[29–31] In my opinion, the 
first examples will include a combination of an ELP with a (hydrophobic) 
small therapeutic molecule. The solubilization of hydrophobic 
compounds can greatly reduce their toxicity upon administration as 
shown in vivo with a rapamycin-binding ELP conjugate.[32] Rapamycin is 
a potential therapeutic for the autoimmune disease Sjögren-Syndrome, 
but has significant side-effects such as liver toxicity. Using ELP as a 
delivery vehicle significantly reduced these effects. Encapsulating small 
molecules in ELP nanoparticles can improve pharmacokinetics and 
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enhance the efficacy of already approved therapeutics as shown with an 
ELP micelle encapsulating doxorubicin.[29] By coupling doxorubicin to 
ELPs, a micelle was created with doxorubicin forming the core. The 
resulting nanoparticles showed better plasma pharmacokinetics and 
tissue distribution than free doxorubicin and showed higher efficacy in a 
murine tumor model. In another example, it was shown that ELP 
nanoparticles modified with 131I by iodogen oxidation are excellent 
carriers for brachytherapy for the treatment of prostate and pancreatic 
tumors.[33]  
In these examples, the nanoparticles either retain their function 
even when disassembled after administration (rapamycin); or the core is 
formed due to a hydrophobic payload itself (doxorubicin); or due to a 
hydrophobic domain that forms β-sheets (brachytherapy). For the latter 
two cases, the assembly is less dynamic than the coacervate core formed 
by ELP diblocks and therefore less likely to be disturbed, exposed, 
opsonized and/or removed by macrophages and similar mechanisms. 
The former example does not suffer from particle disassembly or 
distortion, since the ELP is used as a solubilization agent only, without 
further targeting moieties. As we have seen in this thesis, non-
crosslinked ELP micelles have a significantly shorter blood half-life than 
what is known from their monomeric counterparts investigated in other 
studies. Cross-linking might improve the stability of nanoparticles and 
improve their pharmacokinetics. While achievable with ELP 
nanoparticles[34], cross-linking does add an additional parameter to an 
already complex structure, which is not readily desired in the formulation 
of therapeutics. 
I however believe that cross-linked, complex ELP nanoparticles 
will find their way into clinical trials due to their complementarity with 
macromolecules. As shown in this thesis, not only can ELP nanoparticles 
be readily modified to display targeting proteins such as single-domain 
antibody fragments, but they are also capable of encapsulating 
macromolecular cargo with a high efficiency. Since enzymes are already 
used clinically e.g. for treating lysosomal storage disorders[35,36] and show 
potential for treating mitochondrial diseases, inflammatory diseases, 
Alzheimer’s, different forms of cancer etc.[37–39], there is great potential in 
combining these with elastin-like peptides for more effective and new 
therapies. 
Therapeutic enzymes usually suffer from poor half-life, poor 
targeting and immunogenic reactions developed during consistent 
treatment, yet their catalytic prowess makes them valid therapeutic 
choices nonetheless. Combining them with a bio-compatible 
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macromolecular carrier made from ELPs can enhance their applicability. 
ELPs are less likely to elicit immunogenic responses or can be designed 
specifically to that end; Cho et al. presented a hypothesis for designing 
immunotolerant ELPs that are derived from human elastin sequences 
without alterations.[40] Using such an ELP block to form the hydrophilic 
corona of a nanoparticle could reduce the possible formation of ELP-
specific antibodies during sustained therapy. The ability to add additional 
targeting moieties would allow encapsulated cargo to reach parts of the 
body protected by additional cell layers, which cannot be easily reached 
by other means. The most prominent example is the brain and its 
surrounding blood-brain barrier. Direct access to the cerebrospinal fluid 
and brain tissue is only possible during surgery, injection into the spinal 
cord fluid or intracranial injection. Surgery and intracranial injection 
carry all the risks of surgical procedures and their effects of drug 
administration is typically very local. Injection into the cerebrospinal fluid 
directly through the spine is of limited effect regarding the distribution of 
delivered macromolecular compounds in the brain.  
In contrast, the blood-brain barrier, a tight endothelial cell layer 
separating blood from brain tissue, has several mechanisms of transport 
that can be exploited to administer macromolecules into the brain. By 
targeting e.g. the transferrin receptor[41], glucose-receptors[42] or 
gangliosides[43], nanoparticles can be delivered into the brain tissue after 
intravenous injection. This has the potential for treating 
neurodegenerative diseases such as Gaucher Disease Type II; this rare 
inherited form of lysosomal storage disease has currently no approved 
therapy and affected children have a life expectancy of about two years. 
Delivering enzymes such as glucocerebrosidase to the brain may have the 
potential to alleviate progression and symptoms of this disease and other 
diseases such as glioblastoma, Alzheimer’s disease and Leigh syndrome. 
In conclusion, I expect elastin-like peptide nanoparticles to enter 
clinical trials in the near future. These studies will give us further insight 
into the suitability of this material for further clinical applications. 
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Summary 
 
Elastin-like polypeptides (ELPs) are derived from natural elastin 
and possess intriguing properties. They are temperature-responsive 
polymers; upon reaching their respective transition temperature, they 
undergo conformational changes that induce coacervation of the 
previously dissolved monomers. Elastin-like peptides consist of repeats 
of 5 amino acids, glycine-guest residue-glycine-valine-proline. The guest 
residue may be any amino acid and has a strong influence on the 
transition temperature of the ELP. By combining ELP blocks that have 
different guest residues, and hence different transition temperatures, 
supramolecular structures can be created. By designing ELP sequences 
accordingly, micellar nanoparticles can be made that are stable at 
physiological conditions.  
These are highly interesting in the context of the development of 
nanomedicine – nano-sized therapeutics/carriers that can be combined 
with different targeting and therapeutic moieties. Within the framework 
of the Radboud Nanomedicine Alliance, we investigated the potential of 
ELP-based particles for biomedical applications, broadened their 
applicability and discovered a new co-assembly mechanism.  
Chapter 1 gives an introduction into the topic of elastin-like 
peptides. Their discovery, assembly properties and production is 
discussed as well as their applications as purification and fusion tags. 
The development of nanoparticles based on elastin-like peptides is 
highlighted with a focus on in vivo applications such as vaccination and 
tumor targeting. 
In Chapter 2, we describe how we generated nanoparticles based 
on ELPs that were functionalized with cell-penetrating peptides (CPPs). 
We genetically fused ELP blocks with either hydrophilic or hydrophobic 
guest residues to create micelles with hydrodynamic radii of about 25 
nanometer. We studied their assembly properties and their behavior in 
3D cell culture models, probing the mechanisms of cellular uptake and 
the degree of ‘tissue’ penetration. We observed a binding-site barrier that 
could be overcome by varying the concentrations of both ELP 
nanoparticles and CPPs on the particles’ surface. 
In Chapter 3, we showed that we could functionalize ELP 
nanoparticles with single-domain antibody fragments binding to the 
epidermal growth factor receptor (EGFR), which is overexpressed in 
certain tumors. Antibody affinity and specificity was retained upon fusion 
to ELPs. We combined these particles with photosensitizers - small 
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molecules that generate toxic singlet oxygen upon irradiation.  We 
showed that double functionalized micelles were able to selectively 
recognize and kill cancer cells expressing EGFR in co-culture with 
healthy cells.  
In Chapter 4, we described the combination of antioxidants and 
brain targeting peptides with ELP nanoparticles to make them suitable 
for treating mitochondrial diseases in the brain. One of the underlying 
causes of these diseases can be genetic mutations in the mitochondrial 
oxidative phosphorylation system, which can lead to the increased 
production of reactive oxygen species and thereby oxidative stress. We 
attached a known antioxidant and redox regulator to ELP nanoparticles. 
This mitigated oxidative stress in patient cells after delivery of functional 
nanoparticles. By using peptides that bind to the blood-brain barrier 
(BBB), we showed that ELP nanoparticles can transcytose across a 
cellular model of endothelial cells forming the BBB. In vivo, we showed 
that chemical modifications of the particles’ surface increased the blood 
half-life of ELP nanoparticles, but that it was not sufficient without 
further improvements to direct them efficiently into the brain. 
In Chapter 5, we showed a new co-assembly mechanism of 
elastin-like peptides. By kinetically overwriting the distinct assembly of 
different ELPs, we created co-assembled micelles. Their size could be 
adapted over a five-fold range and could be used to encapsulate proteins 
with a very high efficiency in the coacervate core. We used two fluorescent 
proteins to show that encapsulated cargo can interact, in this case by 
Förster resonance energy transfer. We also showed that co-assembled 
particles can be used to deliver functional proteins into intracellular 
compartments such as endosomes and lysosomes. The interaction of 
macromolecular cargo was intact even after intracellular delivery. 
In Chapter 6, the obtained results are put into perspective and 
an outlook is given towards possible developments and directions in the 
use of elastin-like polypeptides particles for nanomedicine. 
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Samenvatting 
 
Elastine-achtige polypeptides (ELPs) zijn afkomstig van natuurlijk 
elastine en hebben interessante eigenschappen. Ze zijn temperatuur-
gevoelige polymeren; als ze hun transitie temperatuur bereiken, 
ondergaan ze structurele veranderingen, wat leidt tot coacervatie van de 
voormalig opgeloste monomeren. Elastin-achtige polypeptides bestaan 
uit repeterende 5 aminozuren, glycine-gast-glycine-valine-proline. Op de 
‘gast’ positie kan elk (on)natuurlijke aminozuur staan; deze heeft een 
grote invloed op de transitie temperatuur van de ELP. Het combineren 
van ELP constructen met verschillende gast aminozuren – en dus 
verschillende transitie temperaturen – kan leiden tot de formatie van 
supramoleculaire structuren. Als men ELP sequenties gericht ontwerpt, 
kunnen micellaire nanodeeltjes worden gemaakt, die stabiel zijn in 
fysiologische omstandigheden.  
 Deze zijn heel interessant voor de ontwikkeling van 
nanomedicijnen – geneesmiddelen of dragermaterialen die enkele 
nanometer groot zijn en kunnen worden gecombineerd met verschillende 
functionele groepen en medicijnen. Binnen de Radboud Nanomedicine 
Alliance hebben wij de potentie van deeltjes gebaseerd op ELPs 
onderzocht voor biomedische applicaties. We hebben hun 
toepassingsmogelijkheden verbreedt en een nieuwe manier van co-
assemblage ontdekt. 
 Hoofdstuk 1 geeft een introductie over het thema  elastine-
achtige peptides. We bediscussiëren hun ontdekking, eigenschappen en 
productie, en eveneens hun toepassingen voor purificatie en 
biotechnologie. De ontwikkeling van nanodeeltjes gebaseerd op elastine-
achtige peptides wordt beschreven met de focus op in vivo toepassingen 
zoals vaccinaties en kanker bestrijding. 
 In Hoofdstuk 2 beschrijven we hoe we ELP nanodeeltjes hebben 
ontwikkeld en hoe we deze hebben gefunctionaliseerd met cel-
doordringende peptiden (CPPs). We hebben ELP constructen met 
hydrofiele of hydrofobe gast aminozuren aan elkaar gefuseerd om 
micellen met hydrodynamische radii van ongeveer 25 nanometer te 
creëren. We hebben hun assemblage eigenschappen en hun gedrag in 3D 
cel modellen onderzocht, in het bijzonder het mechanisme van cellulaire 
opname en de mate van ‘weefsel’ penetratie. We hebben een binding-site 
barrière waargenomen, die kon worden doordrongen door het variëren 
van zowel de concentratie van ELP deeltjes als ook de graad van 
functionalisatie met CPPs op het oppervlak van de deeltjes. 
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 In Hoofdstuk 3 hebben we laten zien dat we ELP nanodeeltjes 
konden functionaliseren met enkel-domein antilichaam fragmenten, 
welke aan de epidermische groei factor receptor (EGFR) kunnen binnen. 
Deze receptor is in bepaalde kankerweefsels in hoge mate aanwezig. 
Antilichaam affiniteit en specificiteit was behouden na fusering aan ELPs. 
We hebben deze deeltjes gecombineerd met photosensitizers – moleculen 
die toxische singlet zuurstof creëren als ze worden belicht. We hebben 
laten zien dat tweevoudig gefunctionaliseerde micellen selectief 
kankercellen die EGFR tot expressie brengen, kunnen herkennen en 
doden, waarbij aanwezige gezonde cellen niet worden beïnvloed.  
 In Hoofdstuk 4 hebben we antioxidanten en brein-gerichte 
peptiden met ELP nanodeeltjes gecombineerd om deze geschikt te maken 
voor de behandeling van mitochondriële ziekten in het brein. Een van de 
oorzaken van deze ziektes is genetische mutaties in het systeem voor 
mitochondriële oxidatieve fosforylering. Dit kan leiden tot de verhoogde 
productie van reactieve zuurstofradicalen en daardoor tot oxidatieve 
stress. De eerste stap was het fuseren van een bekende antioxidant en 
redox regulator aan de ELP nanodeeltjes. De toediening van deze deeltjes 
heeft geholpen om de oxidatieve stress in patiënten cellen te verminderen. 
Door het gebruik van peptiden die cellen van de bloed-hersenen barrière 
(BBB) kunnen binden, hebben we laten zien dat ELP nanodeeltjes door 
een endotheel cel model van de BBB kunnen worden getransporteerd. In 
vivo hebben we laten zien dat de modificatie van ELP nanodeeltjes de 
stabiliteit in circulatie kan verbeteren, maar dat verdere modificaties 
nodig zijn om ze effectief naar het brein te kunnen sturen. 
 In Hoofdstuk 5 hebben we een nieuwe manier van co-assemblage 
mechanisme voor elastine-achtige peptide laten zien. Door het transitie 
proces kinetisch te overschrijven konden wij verschillende ELPs met 
elkaar laten assembleren. Hun grootte was controleerbaar over een 
vijfvoudige range en ze konden worden gebruikt om eiwitten met een hoge 
efficiëntie te encapsuleren. We hebben twee fluorescente eiwitten 
gebruikt om te laten zien dat ze met elkaar interacteren, in dit geval via 
Förster resonance energy transfer. We hebben ook laten zien dat geco-
assembleerde deeltjes konden worden gebruikt om functionele eiwitten 
naar intracellulaire compartimenten zoals de endosomen en lysosomen 
te brengen. De interactie van de macromoleculaire cargo was nog steeds 
intact na de cellulaire opname. 
 In Hoofdstuk 6 worden de verkregen resultaten samengevat. 
Verder worden mogelijke ontwikkelingen en onderzoeksrichtingen voor de 
ELP gebaseerde nanomedicijnen bediscussieerd. 
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